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CHAPTER 1 
GENERAL INTRODUCTION 
 
There is a continuing need for new antimicrobial agents as infectious microbes 
have proven to be incredibly adaptable in their fight for survival.  Microbes are 
mutating and evolving in their ways that make them resistant in commonly 
occurring microbial infections. Therefore, better drugs are needed for emerging 
diseases, such as those caused by invasive streptococci, as well as drug 
resistant enterococci and mycobacterium. 
 
To meet this challenge, research has focused on finding new analogues of the 
existing classes of antimicrobial agents. In addition, novel classes lacking cross 
resistance would also be a target. Recently, organic compounds have attracted 
attention of Medicinal chemists towards their search for anti-microbial potential. It 
can be then be utilized as a means of chemotherapy of several diseases. 
Organic compounds either from biological origin or made by synthetic chemical 
reactions are being proved excellent alternate to antibiotics of microbial origin.  
 
Many antibiotics from the days of Alexander Fleming were used for curing 
diseases. When microorganisms are exposed to antibiotics they adapt some 
alternative survival routes related to their metabolism, enzyme production and 
gene transfers. Microbes found adaptation to unfavorable environment and 
continuous dosages of antibiotic. This phenomenon is frequently found 
throughout the world where organisms come into contact with antibiotics in more 
than one patient being exposed to high doses of antibiotic, such as during 
hospitalization. This is called multi-drug resistance and the organisms are called 
resistant ones. Now, for curing the diseases produced by such resistant, ever 
surviving strains of micro-organisms, we definitely need some other remedy. So, 
in search of a better drug, we have focused our search on synthesized organic 
compounds. 
 
The strains of antibiotic resistant Escherichia coli pose a major health threat in 
Canada (Tom Blackwell, 2002). Similarly, multi-drug resistant commensal 
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Escherichia coli in children in Peru and Bolivia was reported (Bartoloni and 
Pallecchi.2006). Community associated Methicillin resistant Staphylococcus 
aureus causing various infections in children and adults were also reported 
(Rybak and LaPlante, 2005). 
 
In recent years, there has been a dramatic increase in the incidence of hospital 
associated nosocomial infections caused by strains of Staphylococcus aureus 
that are resistant to multiple antibiotics. 
 
Although medicinal chemistry has many triumphs to its credit, there are many 
challenges to be faced in the future. The fight against cancer goes on and there 
is also a need for effective drugs against a large number of viral infections, 
including influenza, the common cold and the AIDS virus. With an increase in life 
expectancy, the diseases of old age have become more significant, and 
research into novel drugs that can be used to treat Alzheimer‟s disease, arthritis 
and senility are of increasing importance. Autoimmune diseases such as multiple 
sclerosis and Huntingdon‟s cholera still require effective treatments. 
 
Diseases that have been eliminated should not be ignored either. In resent 
years, scientists have come to appreciate just how fragile the victory over 
bacterial infections has been. Bacteria are mass at evolving to cope with 
different environmental pressures, and their ability to acquire resistance to 
antibiotics is no exception. The threat of „super bug‟ evolving which might be 
resistant to all known antibacterial drugs is a frightening but realistic prospect, so 
it is crucial that medicinal chemistry  is on search  for new strategies to defeat 
these adversaries. 
   
Antimicrobial substances and preparations are classified as disinfectants, 
antiseptic or chemotherapeutic agents. A chemotherapeutic agent is an 
antibacterial substance administered systematically for the treatment of an 
infection. It may be either bacteriostatic or bactericidal. Its main function is to 
prevent the multiplication of infective organisms and so allow the body functions 
to deal more effectively with the infection. 
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Organic compounds with antimicrobial potential are being synthesized in 
laboratory and referred as “Novel Compounds”. The synthetic organic 
compounds are synthesized and purified through analytical techniques to get the 
fine powder. Biological organic compounds are extracted from the original 
sources and then can be used for evaluating their anti-microbial activities. 
 
New organic synthetic compounds synthesized in laboratory are likely to be new 
on this earth and hence, their characteristics and activities are never evaluated 
and analyzed. However, they must be investigated properly before used as an 
alternative medicine for in vitro and in vivo anti-microbial activity. 
 
Several series are analyzed for various activities except Anti-microbial activity for 
bacteria and fungi and proved promising. In the present study, we have selected 
a number of series of compounds based on their varied chemical classes and 
possible chemotherapeutic values. For, biological organic compounds, we have 
investigated several algal compounds from Red algae. A few varieties of Red 
algae were used to get organic compounds from it through extraction 
procedures, i.e. mixtures of sterols, fatty acids and lipids.  
 
The action depends on the concentration of the agent employed. Some are 
acknowledged to be mainly bacteriostatic while others have slow and/or 
exclusive bactericidal activities. Bacteriostasis is a theoretical concept which 
applied to the action of a chemical antagonist on an organism under conditions 
where growth can normally occur. It means in effect, that each cell in a bacterial 
population is prevented from growing. However, the individual cell in such 
populations are far from uniform, each is in a different state of growth and 
development and so each will respond differently to an adverse situation. In 
practice, then, the state of Bacteriostasis means that the most resistant cells are 
inhibited, and so by inference, the action on the less resistant ones is more than 
that of simple inhibitions. 
 
 
 
 4 
In present study, we have explored antimicrobial potential of synthetic and 
biological organic compounds, with the view of finding novel anti-microbial 
agents. The objectives of the research are as follows: 
 Synthesis of organic compounds. 
 Screening of series of synthetic organic compounds. 
 Screening of natural organic compounds for their antimicrobial activities. 
 Screening and selection of microorganisms. 
 Standardization of Agar Dilution Method.  
 Primary and secondary screening of organic compounds. 
 Further investigation for the determination of MIC in final screening of Bio 
active compounds. 
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CHAPTER 2 
 
REVIEW OF LITERATUTE 
  
The interactions between host, microbial pathogen and antimicrobial agent 
can be considered as a triangle, and any alteration in one side will inevitably 
affect the other two sides.   
 
DISCOVERY AND DESIGN OF ANTIMICROBIAL AGENTS 
There are many antimicrobial agents already obtained from synthesis or from 
biological materials. Antibiotics are natural products of fungi, actinomycetes 
and bacteria which kill or inhibit the growth of micro-organisms. They are well 
studied for their mode of action on microbes. Antibiotic production is 
associated particularly with soil microorganisms and in the natural 
environment is thought to provide a selective advantage for organisms in the 
competition for space and nutrients.  Although the majority of antibacterial and 
antifungal agents in clinical use today are derived from natural products of 
fermentation, most are then chemically modified to improve their antibacterial 
or pharmacological properties. However, some agents are totally synthetic, 
e.g. sulphonamides, quinolones.  
The discovery of new antimicrobial agents was generally considered as a 
matter of chance. Pharmaceutical companies undertook massive screening 
programmes searching for new soil microorganisms which produced 
antibiotic.  In the light of our greater understanding of the mechanisms of 
action either for new natural products by target-site-directed screening or 
synthesizing molecules predicted to interact with a microbial target. The 
following is the generalized route for the discovery of antimicrobial agents:  
Select an appropriate target  identify a chemical lead (i.e. a new molecule 
with inhibitory activity on the target)  modify the lead compound to enhance 
potency  evaluate in vitro activity  evaluate in vivo activity and toxicity  
test in clinical trials and develop. The discovery of an antimicrobial agent 
results in marketing after years of rational design programmes. 
 6 
ANTIBACTERIAL AGENTS 
Bacteriostatic action, target site and chemical structure. 
Bactericidal versus bacteriostatic 
Some antibacterial agents kill bacteria (bactericidal), while others only inhibit 
their growth (bacteriostatic). Bacteriostatic agents are successful in the 
treatment of infections because they prevent the bacterial population from 
increasing and host defense mechanisms can cope with the static population.  
In immunocompromised patients, bacteriostatic drugs may be less efficacious. 
As a means of classification, the distinction between bactericidal and 
bacteriostatic agents has become blurred because some agents are capable 
of killing some species but are only bacteriostatic for others, e.g. 
chloromphenicol inhibits growth of Escherichia coli but kills Haemophilus 
influenzae. 
Target site 
A convenient way of classifying antibacterial is on the basis of their site of 
action.  This classification does not allow an accurate prediction of which 
antibacterial will be active against which bacterial species, but molecular basis 
of antibacterial action. There are four main target sites for antibacterial action: 
Cell wall synthesis, Protein synthesis, Nucleic acid synthesis and Cell 
membrane function. 
These targets differ to a greater or lesser degree from those in the host cells 
and so allow inhibition of the bacterial cell without concomitant inhibition of the 
equivalent mammalian cell targets (selective toxicity).Each target site 
encompasses a series of synthetic reactions, each of which may be 
specifically inhibited by an antibacterial agent.  A range of chemically diverse 
molecules may inhibit different reactions at the same target site (e.g. protein 
synthesis inhibitors).   
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Chemical structure 
Antibacterial agents are very diverse chemical structures so classification on 
this basis alone is not of practical use.  However, a combination of target site 
and chemical structure provides a useful working classification. Each target 
site will be considered in turn and the antibacterial agents grouped in families 
according to their chemical structure.                                     
CLASSES OF ANTIBACTERAL AGENTS  
CELL WALL SYNTHESIS 
Peptidoglycan, a vital component of the bacterial cell wall is a compound 
unique to bacteria and thus provides an optimum target for selective toxicity. 
Synthesis of peptidoglycan precursors begins in the cytoplasm; wall subunits 
are transported across the cytoplasmic membrane and finally inserted into the 
growing peptidoglycan molecule. Thus there are several different stages 
which are potential targets for inhibition. The antibacterial which inhibit cell 
wall synthesis is varied in chemical structure. The important groups are the 
beta-lactams and the glycopeptides; bacitracin and cycloserine.  
Beta-lactams 
This is a large family of different groups of compounds all containing the beta-
lactam ring. The different groups within the family are distinguished by the 
structure of the ring attached to the beta-lactam ring; in penicillins this is a 
five-membered ring, in cephalosporins a six-membered ring, and by the side 
chains attached to these rings Beta-lactams inhibit cell wall synthesis by 
binding to enzymes known as 'penicillin binding proteins' (PBPs).These 
proteins are carboxypeptidases and transpeptidases responsible for the final 
stages of cross-linking of the bacterial cell wall structure.  Inhibition of one or 
more of these essential enzymes results in an accumulation of precursor cell 
wall units causing the cell lysis. There are more than 40 different beta-lactam 
antibiotics currently registered for clinical use.  Some, such as penicillin, are 
active mainly against Gram Positive organisms. Whereas others have 
developed their activity against Gram Negative rods like Enterobacteria 
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(Kadurina, 2003). Only the more recent beta-lactams are active against 
resistant organisms such as Pseudomonas aeruginosa (Martin, 2004).   
Glycopeptides 
This group includes vancomycin and teicoplanin.  Both are large molecules. 
Teicoplanin is a complex of five different but closely related molecules. 
Glycopeptides interfere with cell wall synthesis by binding to terminal D-ala-D-
ala at the end of pentapeptide chains that are part of the growing bacterial cell 
was structure this binding inhibits the transglycosylation reaction and prevents 
incorporation of new subunits into the growing cell wall. Glycopeptides act at 
an earlier stage than beta-lactams, and thus it is not useful to administer them 
in combination in the treatment of infections. Both vancomycin and teicoplanin 
are active only against Gram Positive organisms. They are used mainly for 
the treatment of infections caused by Gram Positive cocci and Gram Positive 
rods that are resistant to beta-lactam drugs, or in patients who are allergic to 
beta-lactams.  Oral administration is used for the treatment of Clostridium 
difficile in antibiotic-associated colitis (Bauza, 2006). 
INHIBITORS OF PROTEIN SYNTHESIS 
Although protein synthesis proceeds in an essentially similar manner in 
prokaryotic and eukaryotic cells, it is possible to exploit the differences to 
achieve selective toxicity.  The process of translation of the mRNA chain into 
its corresponding peptide chain is complex and still incompletely understood.  
A range of antibacterial agents act as inhibitors of protein synthesis although 
the details of their mechanism of action are not yet all known. 
Amino glycoside 
This is a family of related molecules containing either streptidine 
(streptomycin) or 2-deoxystreptamine (e.g. gentamicin).The original structures 
have been modified chemically by changing the side chains to produce 
molecules (e.g. Amikacin, netilmicin) which are active against organisms that 
have developed resistance to earlier aminoglycosides. Amino glycosides 
inhibit and kill organism by interfering with the binding of formylmethionyl-
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tRNA (fmet-tRNA) to the ribosome and thereby preventing the formation of 
initiation complexes from which protein synthesis proceeds.  Streptomycin 
also causes misreading of mRNA codons. Gentamicin and the newer 
aminoglycosides; tobramycin, Amikacin and netilmicin are important for the 
treatment of serious Gram Negative infections including those caused by 
Pseudomonas aeruginosa. They are not active against streptococci, but do 
act against staphylococci. They are not active against anaerobes.  
Tobramycin is slightly more active than gentamicin against Pseudomonas 
aeruginosa.  Amikacin and netilmicin are both less active but may be active 
against strains resistant to gentamicin and tobramycin. Streptomycin is now 
reserved almost entirely for the treatment of mycobacterial infections.  
Neomycin is not used for systemic treatment, but can be used orally in gut 
decontamination regimens in neutropenic patients.  Spectinomycin is used to 
treat beta-lactam resistant, Neisseria gonorrhoeae. 
Tetracycline 
Tetracyclines are a family of large cyclic structures which have several sites 
for possible chemical substitutions. The members of the family differ mainly in 
their pharmacological properties rather than in their antibacterial spectra. 
Tetracyclines inhibit protein synthesis by preventing aminoacyl transfer RNA 
from entering the acceptor sites on the ribosome.  However, this action is not 
selectively toxic for prokaryotes.  They are used for treatment of infections 
caused by Mycomplasmas, Chlamydiae and Rickettsiae.  Tetracyclines are 
active against a wide variety of different bacterial species, but their use is now 
restricted due to widespread resistance (Tsanskov, 2003). 
Chloromphenicol 
Chloromphenicol is a relatively simple molecule containing a nitrobenzene 
nucleus which is responsible for some of the toxic problems associated with 
the drug.  Other derivatives have been produced but none is in widespread 
clinical use. Chloromphenicol blocks the action of peptidyl transferase thereby 
preventing peptide bond synthesis. It inhibits bacterial protein synthesis 
selectively because it has a much higher affinity for the transferase in the 50S 
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subunit of the bacterial ribosome than it has for the transferase in the 60S 
subunit of the mammalian ribosomes. However it does have some inhibitors 
activity on human mitochondrial ribosomes and this may account for some of 
the dose-dependent toxicity to bone marrow. Chloromphenicol is active 
against a wide variety of bacterial species- Gram Positive and Gram Negative, 
aerobes and anaerobes, including intracellular organisms such as Salmonella 
typhi, Chlamydiae and Rickettsiae.  It achieves satisfactory concentrations in 
the CSF and is valuable in the treatment of bacterial meningitis. Topical 
preparations are used for eye infections. 
Lincosamides 
The two important molecules in this group are lincomycin and clindamycin.  
The latter (which is a chlorinated derivative of the former) is more active and 
has almost completely superseded lincomycin. Lincosamides bind to the 50S 
ribosomal subunit and inhibit protein synthesis by inhibiting peptide bond 
formation, but the mechanism is incompletely understood. The selectively 
toxic action results from failure to bind to the equivalent mammalian ribosomal 
subunit. Clindamycin has a spectrum of activity similar to erythromycin but it is 
much more active against anaerobes, both Gram Positive e.g. Clostridium 
species, and Gram Negative e.g. Bacteroides.  However, Clostridium difficile 
is resistant and may be selected in the gut, causing pseudomembranous 
colitis. The activity of clindamycin against Staphylococcus aureus and its 
penetration into bone make it a valuable drug in the treatment of 
osteomyelitis. 
Fusidic acid  
This is a steroid compound which inhibits protein synthesis by forming a 
stable complex with elongation factor EF-G (the bacterial equivalent of the 
human EF-2), guanosine diphosphate and the ribosome. Fusidic acid is active 
against Gram Positive cocci and its most important use is in the treatment of 
staphylococcal infections which are resistant to beta-lactams, or in patients 
who are allergic to alternative staphylococcal agents.  Fusidic acid should be 
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given in combination with another anti-staphylococcal agent (e.g. rifampicin or 
erythromycin) to prevent the emergence of resistant mutants. 
INHIBITORS OF NUCLEIC ACID SYNTHESIS 
This category includes inhibitors of synthesis of precursors (sulphonamides 
and trimethoprim), inhibitors of DNA replication (quinolones) and inhibitors of 
RNA polymerase (rifampicin). 
INHIBITORS OF CYTOPLASMIC MEMBRANE FUNCTION 
The cytoplasmic membranes which encompass all kinds of living cells perform 
a number of vital functions. The structure of these membranes in bacterial 
cells differs from that in mammalian cells and allows the application of some 
selectively toxic molecules but these are few in number compared with those 
acting at other target sites.  The most important are the polymyxins which act 
on the membranes of Gram Negative bacteria.  The polyene antifungal agents 
(amphotercin B, nystatin) also act by inhibiting membrane function.  
Polymyxins 
These are cyclic polypeptides. The free amino groups act as a cationic 
detergent which disrupts the phospholipids structure of the cell membrane.  
Colistin (polymyxin E) is the most common member of the family in clinical 
applications. Colistin is active against Gram Negative organisms except 
Proteus species. As an oral agent it is used in some gut decontamination 
regimens for neutropenic patients.  Other topical uses include wound irrigants 
and bladder washouts (Falagas, 2006). 
URINARY TRACT ANTISEPTICS 
Nitrofurantoin and methenamine are both synthetic compounds which when 
taken orally are absorbed and excreted in the urine in concentrations high 
enough to inhibit urinary pathogens. Nitrofurantoin has activity only in acid 
urine.  Methenamine is hydrolyzed at acid pH to produce ammonia and 
formaldehyde; it is the latter which has antibacterial activity. Nitrofurantoin is 
used to treat uncomplicated urinary tract infection and both agents are used to 
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prevent recurrent UTIs. They have the advantage that resistance rarely 
develops. 
ANTI-TUBERCULOUS AGENTS 
The treatment of infections caused by Mycobacterium tuberculosis and other 
Mycobacteria presents an enormous challenge to medicine and the 
pharmaceutical industry. The emergence of resistance among the 
Mycobacteria and toxicity in the patient are more likely than with the 'short 
sharp shock' treatment more often administered for bacterial infections. A 
number of anti-tuberlculous agents are now available. Most are restricted to 
this use to prevent resistance emerging in other species and potentially being 
transferred to mycobacterium, or because the toxicity of the drugs makes 
them unattractive for general use (O’Donnell, 2004). 
First line therapy 
Treatment regimens may vary between countries but in general first-line 
therapy is a combination of isoniazid, ethambutol and rifampicin for 6 to 9 
months. Streptomycin may be added in treatment of tuberculous meningitis.   
Second-line therapy 
Despite the use of antibiotics in combination, the incidence of resistance 
among Mycobacteria is increasing and a cure may not be achieved by the 
first-line drugs.Infections with Mycobacteria other than Mycobacterium 
tuberculosis are on the increase as opportunist infections in AIDS patients 
and these organisms tend to be innately more resistant than Mycobacterium 
tuberculosis. Second-line therapy for drug resistant Mycobacterium 
tuberculosis includes drugs such as paraminosalicylate, pyrazinamide and 
thiacetazone.   
ANTIFUNGAL AGENTS 
In contrast to the antibacterial drugs, the number of antifungal drugs suitable 
for treatment of infections is very limited.  Selective toxicity is much more 
difficult to achieve in the eucaryotic fungal cells than in the prokaryotic 
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bacteria and although the available antifungals have greater activity against 
fungal cells than they do against human cells the difference is not as marked 
as it is for most antibacterial agents (Stratton,2006). Treatment of fungal 
infections is further hampered by problems of solubility, stability and 
absorption of the existing drugs. 
Development of new antifungal agents  
 Superficial fungal infections are extremely common but usually mild.  Although 
there are several effective preparations available, some conditions e.g. 
ringworm infection of the nails or recurrent vaginal candidiasis are frequently 
intractable to treatment (Auger et al, 1979) of infections in immuno 
compromised people.  However, the incidence of such patients and their 
improved survival is due to effective antibacterial therapy.  The number of 
agents available is severely limited and their adverse effects are considerable.  
Thus, there is an urgent need for safer, more efficacious antifungal agents, 
and considerable resources are being channeled into the search for new 
agents. 
ANTIVIRAL THERAPY 
For most viral infections there is no specific treatment.  Effective antiviral 
drugs are few in number in contrast to the great range of successful 
antibiotics available for bacterial infections. The shortage of antivirals is partly 
due to the difficulty of interfering with viral activity in the cell without adversely 
affecting the host. However, the advent of AIDS has stimulated intensive 
research, and new antiviral drugs will undoubtedly appear.  
 Multiple drug Resistance  
The spread of microbial drug resistance is a global public health challenge 
(Bax and Mullan, 1999) which impairs the efficacy of antimicrobial agents and 
results in substantially increased illness, death rates and healthcare-
associated costs. There are many different mechanisms by which microbes 
might exhibit resistance to drugs (Handwerger, 1985), (Davis, 1979). 
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Clinical Implications of Drug Resistance 
In 1936, when sulphonemides were first employed for the treatment of 
gonorrhea, practically all strains of Gonococci were susceptible, and most 
cases were cured by these drugs. Six years later, the majority of strains were 
resistant, and most cases failed to respond to sulphonemide therapy but were 
still highly susceptible to sulphonemides. Subsequently, sulphonemides-
resistant meningococci spread widely. Sulphonemides have now lost their 
usefulness in the prevention and treatment of meningococcal infections. 
In 1944, the vast majority of strains of staphylococci isolated from hospitalized 
patients or members of hospital staffs were sensitive to penicillins. By 1948, 
65-85 % of staphylococci in hospitals were emerged similarly. Thus, a 
majority of “hospital staphylococci” are resistant to both penicillin G and 
tetracycline, and treatment requires beta-lactamase resistant penicillins. 
Tetracycline resistant pneumococci and group A streptococci have also 
appeared. In 1979, staphylococci, in the community are 60-80 % resistant to 
lactamase-susceptible penicillins are often also to tetracyclines. 
Pneumococci were once uniformly susceptible to penicillin G in 1963; 
relatively resistant pneumococci appeared in New Guinea. In 1977, outbreaks 
of disease due to pneumococci that were resistant to penicillin as well as 
tetracyclines and other drugs occurred in South Africa, with wide 
dissemination of such organisms among hospital personnel. 
A similar situation has developed with respect to Gram Negative enteric 
organisms, especially in hospitals. The excessive use of drugs leads to 
suppression of drug-susceptible microbes and favors the survival of drug-
resistant ones. This “selection pressure” of drugs in the hospital environment 
gradually brings about prevalence of drug-resistant bacteria-especially, 
Enterobacter, Proteus, Pseudomonas, Serratia and fungi (Finland, 1979).To a 
limited extent drug resistant mutants have arisen in tuberculosis. They may 
complicate the treatment of individual patients in whom they arise and may be 
transmitted to contacts, giving rise to primary drug resistance (Gill, 1984). In 
fact, high resistance rates have often been reported in surveillance studies 
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dealing with clinical isolates and in prevalence studies of commensal bacteria 
taken as indicators to estimate spread of acquired resistance.  Moreover, in 
low resource countries, the impact of antimicrobial drug resistance on illness 
and death rates tends to be greater because of the high prevalence of 
bacterial infections and the major role of antimicrobial agents in combating 
infectious diseases (National Academy of Science, 1992). 
Methicillin-resistant Staphylococcus aureus (MRSA) is a common bacterial 
pathogen responsible for a variety of infections in both children and adults.  
Treatment of infections caused by these organisms is problematic due to its 
resistance to many drugs. Recent reports of community-associated MRSA 
(CA-MRSA) infections in patients with no known risk factors have serious 
public health implications (Rybok and Laplante, 2005). Likewise for 
vancomycin-resistant Enterococci, Multidrug resistant Mycobacterium 
tuberculosis and penicillin-resistant Streptococcus pneumoniae create clinical 
failures due to resistance (Volturo and Low, 2006). 
Virulence threat by Bacteria: 
The production of disease requires the expression of a series of important 
genes that allows the pathogen to adapt to hostile environment in the host 
(Richards, 1978). The expression of these genes contributes to the virulence 
of pathogens and such genes encode products frequently termed virulence 
factors.  In an ecological sense, virulence contributes to how an organism 
propagates in a mammalian host. 
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TABLE 2: Crisis organisms and Resistance problems (Barrett and 
Isaacson, 1995) 
 
 
 Organism Infection Problem 
1 Staphylococcus aureus 
(MRSA) 
systemic  Multidrug resistant 
2 Enterococci systemic Vancomycin,teicoplanin 
3 Streptococcus pneumoniae Respiratory Penicillin, 
Cephalosporin 
4 Mycobacterium tuberculosis Respiratory Multidrug resistant 
5 Pseudomonas aeruginosa Respiratory, Multidrug resistant 
  skin  
6 Enterobacteriaceae abdominal Multidrug resistant 
7 Bactericides abdominal cefotetan, cefoxitin, 
metronidazole 
8 Acinetobacter abdominal β-lactams 
9 Streptococci Respiratory, β-lactams 
  skin  
 
 
As per Dr. John Barrett (2006), now MRSA has become a serious nosocomial 
pathogen.  More recent reports in the scientific literature under-score the 
potential issues with emerging community MRSA.  It is reported to be involved 
in 75 % of the hospital staphylococcus aureus infections, more in ICU than 
non ICU. Together with its broad based β-lactam resistance, MRSA often 
possess a Multidrug resistance genotype, including 20 antimicrobial 
compounds (also antiseptics and disinfectants).  MRSA has now emerged as 
a predominant nosocomial Gram Positive pathogen with high rate of morbidity 
and mortality (Tambic, 2002). 
The (Bayram and Balci, 2006) data from National Nosocomial Infections 
surveillance (NNIS) shows that from 1988 to 1995, the number of patients 
receiving care in ICUS at high risk  for nosocomial infections are increasing 
because of the emergence of antimicrobial resistant pathogens. Recently, 
viridians group of streptococci are reported to be relatively resistant to 
traditional treatment of penicillin. They are the cause of community-acquired 
native value endocarditis in the patients who are not intravenous drug users.  
Species like Streptococcus pneumoniae, Streptococcus pyogenes group B, C 
and G of streptococci. They are also reported to be resistant against 
cephalosporins, macrolides, floroquinolones, carbopenems and vancomycin 
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(Kolenti and Respoina, 2005), (Zuckerman, 2004), (Sinner and Tunkel, 2004). 
Similar to pathogenic bacteria commensals have acquired some resistance 
genes. 
In a study made on commensal  Escherichia coli in low resource countries 
showed a high prevalence 70% to 95% resistance to many older 
antimicrobials like ampicillin, tetracycline, trimethoprim, sulfa-methoxazole, 
chloromphenicol and streptomycin.  There is a significant increase in the 
resistance rates for gentamycin, nalidixic acid and ciprofloxacin (Nightingale, 
2000).  In   Escherichia coli, commensal micro biota multiple resistance traits 
are found to prevail (Blackwell, 2002), (Bartoloni and Pallecchi, 2006). Atun 
and Colleagues studied multi-drug resistant tuberculosis (MDRTB) and found 
policy implications for control programmes in Eastern Europe and Central 
Asia. 
Both the Centers for Disease Control and Prevention (CDC) and the World 
Health Organization (WHO) have identified drug resistance as an important 
public health danger. In 1999, the CDC collaborated with National Institutes of 
Health and other federal agencies to form the Interagency Task Force on 
Antimicrobial Resistance. A public Health Action Plan to Combat Antimicrobial 
Resistance was released in 2000 to provide a blue print for actions against 
this emerging threat.  In 1961, reports from the United Kingdom indicated that 
Staphylococcus aureus isolates that had acquired resistance to Methicillin.  
Soon MRSA was discovered in other countries and was identified as a 
nosocomial infection or health care-associated MRSA (HA-MRSA). 
Gram Negative bacteria found in ICU like Pseudomonas aeruginosa, Serratia, 
Klebshiela pneumoniae and proteus are studied for their resistance.  It has 
shown high resistance and significant ESBL (extended-spectrum beta-
lactamase producing strains), (Bassetti and Cruciani, 2006). 
Keith Klugman (2007) recently observed increasing resistance of 
Streptococcus pneumoniae, the most common causative pathogen of 
community acquired respiratory tract infection, for antimicrobial agents 
including macrolides. High level telithromycin resistance is also studied in 
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Streptococcus pneumoniae (Wolfer, 2007). A multicenter study of CAP 
(Community acquired pneumonia) caused by Streptococcus pneumoniae was 
performed in Japan from 2003 to 2005 and resulted in erythromycin 
resistance. 
New strains of antibiotic resistant Escherichia coli raised a major health threat, 
when it migrates from stomach to bladder, blood or wounds. This ESBL- 
mediated resistant Escherichia coli and also Klebshiella cause pneumonia 
and other infections. This is published in communicable Disease Report, a 
Health Canada Publication (Gualco, 2007), (Pullukcu, 2007), (Yuksel, 2006), 
(Muratani, 2006), (Stratchounski, 2006), (Zhanel, 2006).  
Helicobacter Pylori is an important human pathogen that colonizes the 
stomach of about half of the World's population. Antibiotic resistance in 
Helicobacter pylori is widespread, and shows regional variation per antibiotic. 
It is a gastric pathogen, often leads to gastric ulcer development and deeply 
investigated (Gerrits, 2006). 
The emergence of β-lactam-resistant pneumococci and MDR Gram Negative 
bacilli in nosocomial bacterial meningitis created difficult situation in treating 
the disease (Wagenlehner, 2004A and 2004B).  
Fluconazole resistant Candida albicans was detected in patients with 
recurrent oropharyngeal Candidiosis and human Immunodeficiency virus 
infection (Ruhnke, 1994), (Bassetti, 2007), (Bassetti and Cruciani, 2006). 
Resistance is most commonly mediated substitution of ergo sterol by other 
sterols in fungal cell membranes. Resistance for polyenes to be species 
dependent and emerges uncommonly and slowly in isolates from patients 
treated with amphotercin B (Canadace and Taylor, 2003). These include 
Candida and Fuserium species. Trichosporon beigelli, Pseudallescheria 
boydii and Scedosporium prolificans.  Some other species of Candida may 
develop lesser degrees of resistance (Goldway, 1995). Azole resistance in 
0ropharyngeal Candida albicans strains isolated from patients infected with 
human immunodeficiency virus is reported (He, 1994), (Hood, 1995) have 
isolated itraconazole resistant Candida species. 
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New Antimicrobial Agents emerging from the horizon: 
As the fight against resistant, deadly microbes is not over, continuously new 
chemical entities are being discovered and investigated. They may be 
completely newly synthesized, modified forms of existing Antimicrobials or a 
small part of combination therapy (Williams, 1999).   
It is claimed by Pawan Sharma (2000) that a new, broad spectrum anti-
tubercular drug-3-substituted nitroimidazopyran (NAP) called PA-825 was 
very effective bactericidal agent for several Mycobacteria like Mycobacterium 
tuberculosis, Mycobacterium microti, Mycobacterium fortuitum.  Stover et al 
(2000) pointed out that as a small, orally active molecule amenable to large 
scale synthesis and with demonstratable activity against MDR strains as well 
as non-replicating static forms of Mtb, PA-824 offers a powerful new tool to be 
developed for use in the antitubercular therapy  (Mdluli,2006). Quinupristin is 
a streptogramin B whereas dalfopristin is a streptogramin A; combination of 
these two is used for treatment of adults with complicated skin and skin 
structure infection with Staphylococcus Pyogenes and vancomycin resistant 
Enterococcus faecium associated with bacteremia (Feizabadi and Asadi, 
2004),(Eliopoulous, 2004).   
The Food and Drug Administration-approved linezolid for its applications in 
skin infections caused by MRSA or oxycillin susceptible Staphylococcus 
aureus or group A or B streptococci, Staphylococcus aureus nosocomial 
pneumonia and infections caused by vancomycin-resistant Enterococci. A 
cyclic lipopetide-Daptomycin was effective against staphylococci including 
MRSA, vancomycin intermediate Staphylococcus aureus, coagulase negative 
staphylococci and many other Gram Negative bacteria (Hancock, 2005). 
The newest of the β-lactams to be approved for use in the United States 
includes ertapenem, the third carbopenem now available; another is 
cefdilotoren, one of the newest oral third-generation cephalosporins, 
moreover a newly approved high dose formulation is of amoxicillin- 
clavulanate; and now only forth-generation cephalosporin available for use is, 
cefopime (Matsumoto and Muratani, 2004). 
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Ertapenem is effective in infections of Gram Positive and Gram Negative 
aerobic and anaerobic pathogens like slow growing Mycobacteria, 
Enterococcus faecium, MRSA, Stenotrophomonas mattophila. Recently, FDA 
has approved Cefditoren for use in treating pharyngitis and tonsillitis, acute 
chronic bronchitis and uncomplicated skin and soft tissue infections (Martin 
and Kaye, 2004). Amoxycillin-clavulanate has been shown as effective in the 
treatment of otitis media, sinusitis, bronchitis, urinary tract infections, skin and 
soft tissue infections (Wagenlehner and Naber, 2004). Cefopime in approved 
to treat uncomplicated and complicated urinary tract infections, respiratory 
tract infections, skin and soft tissue infections, intra-abdominal infections, 
gynecologic infections, febrile neutropenia, meningitis in kids (Del Rosso, 
2004). 
Newer fluoroquinolones have excellent activity against the aerobic Gram-
Negative bacilli, MRSA, coagulase-negative staphylococci, such as 
Streptococcus epidermis, Streptococcus saprophyticus, Streptococcus 
haemolyticus (O’Donnell and Gelone, 2004). 
For treating the infections caused by PRSP (penicillin Resistant 
Streptococcus pneumoniae), new antimicrobial combination Amoxicillin-
Clavulanate Potassium is effectively used in the recent chemotherapeutic 
practice (Craig, 2004). Now a days, a type of ketolide-Telithromycin is 
effective against Multidrug resistant Streptococcus pneumoniae, chronic 
bronchitis, acute bacterial sinusitis, typical (Streptococcus pneumoniae, 
Haemophilus. influenzae, Mycobacterium. catarrhalis, Staphylococcus. 
aureus) and atypical (Chlamydophila pneumoniae, Mycoplasma pneumoniae) 
causative pathogens that are most frequently identified in CARTI (Community 
acquired respiratory tract infection) (File, 2004). 
Acyclovir is the gold standard for the treatment and prophylaxis of herpes 
zoster opthalmicus and herpes simplex epithelial keratitis.  Volganciclovir was 
approved by FDA in 2001 has supplanted ganciclovir in the oral treatment of 
CMV cytomegalovirus retinitis (Levinson and Rutzen, 2005). Voriconazole 
was approved in 2002 for the treatment of Aspergillosis and infections from 
Scedosporium apiospermum and fuserium species. Posaconazole is used 
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(analogue of itraconazole) for infections caused by Asperigillus, Candida, 
Cryptococcus neoformans, Trichosporon, Zygomycetes and dermatophytes.  
Caspefungin is an antifungal of the echinocondin class, cleared in 2001, 
effectively administered against Aspergillus, Candida albicans, Candida 
tropicalis, and Candida glabrata forming keratitis or fungal endopthalmitis. 
Tigecycline and Ramoplanin are being used for MRSA infections.  Tigecycline 
is also effective on penicillin-resistant Streptococcus pneumoniae. 
Ramoplanin shows potent activity against VREF (Vancomycin resistant 
Enterococci) and other strains resistant to ampicillin and erythromycin. New 
drugs are under consideration, including DO870 (Zeneca, UK), UK109, 496 
(Pfizer, UK) and new triazoles produced by Uriach (Spain) and Schering (NJ, 
USA).  All of the new triazoles are much more lipid soluble than fluconazole, 
have an increased fungal spectrum against fluconazole-resistant Candida 
albicans and other Candida species (Palacin and Tarrago, 2001).  
In addition to rifamycin derivatives and fluoroquinolones, others like 
diarylquinoline, a nitroimidazopyran, a nitro-dihydroimidazoxazole, a pyrole, 
macrolides, oxazolidinones and a diamine are being investigated in the flush 
of drug pipeline (O’Brien and spigelman, 2005). Other antifungal targets are 
being explored which include elongation factor 3, chitin syntheses, 
topoisomerse, translation and myristoylation steps specific to certain fungi, 
such as phenyl oxidase and capsule synthesis for Cryptococcus neoformans.  
Agents aimed at these new targets have not yet reached clinical trials. There 
are numerous in vivo animal studies examining combined antifungal drugs 
and immune modulators, such as phagocyte colony-stimulating factors, 
Interferons and interleukins (Rex , 1993), (Uchida , 1991).  
Colistin is used in treating infections caused by Klebshiella pneumoniae, 
Escherichia coli, Acinetobacter boumannii, Salmonella enterica (Li and 
Nation, 2006). Dalbavancin is a novel semi synthetic glycopeptide which is 
highly effective against Gram Positive pathogen including MRSA and VRSA. 
Entecavir is a novel deoxyguanosine analog with activity against hepatitis B-
virus with inhibition of viral polymerase (Chen and Zervos, 2007).  
 22 
Newly synthesized pyrazole-thiocyanates are found highly active to irradiate 
Epidermophyton floccosum and Trichophyton rubrum (Romagnoli and Mares, 
2002). Inherently resistant species that are not Candida albicans, such as 
Candida glabrata and Candida krusei, may emerge as potent target 
(Goodman, 1992).   
However, long courses and low dose exposure to fluconazole are associated 
with emergence of resistance to Candida albicans (Vazgnez, 2001). 
Synthetic compounds investigated for their Antimicrobial Activity: 
The biological importance of Coumarin derivatives has led to considerable 
study in the field of synthetic coumarins with 3, 4-carboxylic and 3, 4-
fusedheterocyclic ring systems (Murray, 1992). Quinolines are an important 
class of heterocyclic therapeutic agents. Many different Quinolinones revealed 
anti HIV, bacteriocidal, fungicidal activity (Kawase, 2001). Pyrroles are 
important heterocycles broadly used in material science and found as 
naturally occurring and biologically important molecules have shown anti-
inflammatory, antitumor and immunosuppressant activities (Craig, 1991). 
Azoles and Azines are well known for their anti-inflammatory, antiviral and 
antibacterial biological activities (Upadhyay, 1992). A few naturally occurring 
members are isolated from streptomyces. Their derivatives show antiviral, as 
well as antibacterial activity   1, 3, 4-oxodiazole, a thermally stable aromatic 
heterocycle, exhibit antimicrobial and fungicidal activity together with their 
derivatives. 4-hydroxy 2-quinolones are important compounds as their 
derivatives exhibit variety of interesting pharmacological properties like 
antibacterial, anti HIV, antitumor and anti viral (Abdul-Latif and Shaker, 1989). 
Pyrano fused heterocycles are very important for pharmacology as well as 
industries. Yosiuki Kawase et al (1989) have studied benzofuro quinolones for 
their remarkable activity as mutagens, carcinogens and antitumor agents. 
Coumarin and its derivatives are reported to possess bactericidal, fungicidal, 
antiviral and anti-inflammatory properties (Naveen and Laxmi, 2007). 
Coumarins, naturally produced by streptomyces, are inhibitors of bacterial 
DNA gyrase, an essential enzyme for cell viability.  They are found to be 
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active against MRSA. Some of coumarins derivatives have proved to be 
antimicrobial (Chavda and Shah, 2003B). Fluroquinolones are excellent 
antimicrobials found effective on normal microbial strains. The resistant 
microbes, however, show variation in responses (Judith and Steven, 2004). 
Biological Organic Compounds Utilized : 
Herbal medicines in developing countries are commonly used for the 
traditional treatment of health problems (Bedir and Khan, 2002). For the good 
purpose of investigating Antimicrobial activity of biological organic 
compounds, several extracts of red algae were investigated and reported in 
literature (Scott and Entwisle, 1997). Marine algae are used extensively for 
pharmaceutical products.  In historical pages algae has proved medicine 
against goiter, nephritis and producing many antibiotics too. Numerous algal 
extracts are active usually against Gram Positive bacteria reported 
antibacterial substance (moiety) from red algae Polysiphonia lanosa. 
Antifungal activity of several algae is also well reported. Zamardinia 
prototypes and Cystoseira oalearica possess the strongest antiviral activity 
and proved that several lipid extracts are effective against tobacco mosaic 
virus. In the wide group of Red algae available from costal region are Scinaia 
indica, Ceramium rubrum and Gracillaria corticata and are reported to be 
active antimicrobials (Bapodara, 1992). 
AGAR DILUTION METHOD FOR DETECTING ANTIMICROBIAL ACTIITIES 
No branch of therapeutics depends so heavily on the laboratory as 
antimicrobial and particularly antibacterial chemotherapy. Test of microbial 
sensitivity is, therefore, the most important of all. For testing a single 
antimicrobial compound some form of incorporation of diluted antimicrobials 
into solid media is preferred (Barry, 1970). For the convenience, in 1975 
British Society of Chemotherapy agreed to a general standardization of 
sensitivity testing (Garrod, 1981). 
Dilution testing by Agar Dilution Method is a well standardized, reliable 
antimicrobial susceptibility testing technique (approved NCCL, 2003). This 
newly revised standard provides updated reference methods for the MICs of 
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Aerobic bacteria by broth dilution and agar dilution. Agar Dilution Method is 
reported to be successful and reproducible for bacteria as well as fungi 
(Lorian, 1991). This method is well interpreted by several researchers for 
perfect predictions (Krasemann, 1986). 
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CHAPTER 3 
INTRODUCTION AND CHARACTERISTICS OF 
ORGANIC COMPOUNDS 
 
Introduction, Criteria of Selection and characteristics of 
organic compounds: An outline  
The coumarin molecules and N-methyl quinoline derivatives have been shown 
to possess unique antiadema and anti-inflammatory activities and it make 
particular by effective in the treatment of all high protein edemas (Kawase, 
2001), (Upadhyay, 1992). Several natural and synthetic compounds were 
found to inhibit lipid per oxidation and to scavenge hydroxyl radicals, 
superoxide radicals and hydrochlorous acid. Further more, furocoumarins, 
pyranocoumarins, greparvarin analogues and newly synthesized coumarins 
have been found as anti-inflammatory, antioxidant, cytostatic and antiviral 
(Chavda, 2003A). 
Several series of organic compounds with special pharmacophoric feature are 
used for determining their MICs for various microbes (Williums and Deecher, 
1995). The literature cited and references quoted have stimulated the thought 
of synthesizing them for MIC measures which may result in a discovery of 
novel drugs. 
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Substituted (3E)-3-benzylidene-2H-chromene-2,4(3H)-diones. 
 
O O
O
R
  
TABLE 3A : ANALYTICAL DATA OF CT SERIES 
 
Sr. 
No. 
 
Compound 
code 
 
Substitution-R 
 
Molecular 
Formula 
Molecular 
Weight 
Gm / mol 
1 CT-1 H C16 H12 O3 252.28 
2 CT-2 2-C1 C16 H11 CIO3 286.70 
3 CT-3 3-CI C16 H11 CIO3 286.70 
4 CT-4 2-NO2 C16 H11 NO5 297.26 
5 CT-5 3-NO2 C16 H11 N O5 297.26 
6 CT-6 4-NO2 C16 H11 NO5 297.26 
7 CT-7 3-OH C16 H12 O4 268.26 
8 CT-8 3-OCH3 C17 H14 O4 282.91 
9 CT-9 4-F C16 H11F O3 270.25 
10 CT-10 4-N, N, Di-CH3 C18 H17 N O3 295.33 
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Substituted (3E) benzylidene-1-methylquinoline-2,4(1H,3H)-dione 
N O
O
CH3
R
 
TABLE 3B : ANALYTICAL DATA OF QT SERIES 
 
Sr. 
No. 
 
Compound 
code 
 
Substitution-
R 
 
Molecular 
Formula 
Molecular 
Weight 
gm / mol 
1 QT-1 H C17H15NO2 265.30 
2 QT-2 2-CI C17H14CINO2 299.751 
3 QT-3 3-CI C17H14CINO2 299.751 
4 QT-4 2-NO2 C17H14N2O4 310.304 
5 QT-5 3-NO2 C17H14N2O4 310.304 
6 QT-6 4-NO2 C17H14NO4 310.30 
7 QT-7 3-OH C17H15NO3 281.30 
8 QT-8 3-OCH3 C18H17NO3 295.33 
9 QT-9 4-CI C17H14 CINO2 299.75 
10 QT-10 4-OH C17H15NO4 381.30 
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Etyl-2-amino-6-methyl-5-oxo-4-substitutedphenyl-5, 6-dihydro-4H-pyrano 
[3,2-c]quinoline -3- carboxylates 
Pyranoquinoline derivatives are known to possess various important biological 
properties such as antiallergic, anti-inflammatory and estrogenic activities 
(Burtner, 1935). Several bioactive alkaloids contain a pyranoquinoline moiety. 
Pyronoquinoline alkaloids i.e. huajiaosimuline is toxic toward several human 
cultured cell lines, especially the estrogen receptor positive breast cancer 
cells ZR-75-1(Dholakia, 2005). 
N
O
NH2
COOEt
R
O
CH3  
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TABLE 3C: ANALYTICAL DATA OF CDQ SERIES 
 
 
Sr. 
No. 
 
Compound 
Code 
 
Substitution 
 
Molecular 
Formula 
Molecular 
Weight 
gm / mole 
1. CDQ-1 Phenyl C22H22N2O4 376.00 
2. CDQ-2 2-CIPhenyl C22H19CIN2O4 411.00 
3. CDQ-3 3-CIPhenyl C22H19CIN2O4 411.00 
4. CDQ-4 4-CIPhenyl C22H19CIN2O4 411.00 
5. CDQ-5 2-NO2 Phenyl C22H19N3O5 421.00 
6. CDQ-6 3-NO2 Phenyl C22H19N3O6 421.00 
7. CDQ-7 4-NO2 Phenyl C22H19N3O6 421.00 
8. CDQ-8 2-F Phenyl C22H19FN2O4 394.00 
9. CDQ-9 3-Br Phenyl C22H19BrN2O4 455.00 
10. CDQ-11 4-SCH3Phenyl C23H22N2O4S 422.00 
11. CDQ-12 2-OH Phenyl C22H20N2O5 392.00 
12. CDQ-13 3-OH Phenyl C22H20N2O5 392.00 
13. CDQ-14 4-HO Phenyl C22H20N2O5 392.00 
14. CDQ-15 N,N-diCH3 Phenyl C24H25N3O4 419.00 
15. CDQ-16 2-OCH3  Phenyl C22H22N2O5 406.00 
16. CDQ-17 4-OCH3 Phenyl C22H22N2O5 406.00 
17. CDQ-18 2,3,4-Tri OCH3 
Phenyl 
C25H25N2O7 466.00 
18. CDQ-19 3,4-di OCH3 Phenyl C24H24N2O8 436.00 
19. CDQ-21 3-Anthracenyl C30H26N2O4 478.00 
20. CDQ-22 Propyl Phenyl C25H24N2O4 416.00 
21. CDQ-23 3-OCH3, 4-OH 
Phenyl 
C23H22N2O6 422.00 
22. CDQ-24 3-OC2H3,4-OH 
Phenyl 
C24H24N2O6 436.00 
23. CDQ-25 2-Indolyl C24H21N3O4 415.00 
24. CDQ-26 3-OCH3  Phenyl C23H22N2O5 406.00 
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4-Acetyl-3,5-dimethyl-N’-[(1E)-(substitutedphenyl)methylene]-1H-pyrrole-
2- carbohydrazides 
Pyrroles are highly biologically active and proven to display antibacterial, 
antiviral, anti-HIV, anti-inflammatory and antioxidant activity and were 
reported to inhibit cytokine-mediated diseases (Talele, 2007). 
With the aspect to develop the molecules of pharmacological interest 
containing Pyrrole ring systems which is documented as significant 
pharmacophore for treatment of tuberculosis, HIV, schizophrenia, anxiety, 
depression, cardiac rhythm disorders, diabetes, impaired glucose tolerance, 
tumors, mitomoimmune diseases and many others. Pyrrole is an important II-
excessive aromatic heterocycle (Almerico, 1998).  
 
N
H
O
N
NH
CH3 COCH3
CH3
R
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TABLE 3D: ANALYTICAL DATA OF CDSB SERIES 
Sr. 
No. 
Compound 
code 
Substitution Molecular 
Formula 
Molecular 
Weight 
gm / mole 
1. CDSB-1 Phenyl C16H17N3O2 283.00 
2. CDSB-2 2-Cl Phenyl C16H16 CIN3O2 317.50 
3. CDSB-3 3-Cl Phenyl C16H16CIN3O2 317.50 
4. CDSB-4 4-Cl  Phenyl C16H16CIN3O2 317.50 
5. CDSB-5 4-F Phenyl C16H16FN3O2 301.00 
6. CDSB-6 2-NO2   Phenyl C16H16N4O4 328.00 
7. CDSB-7 3-NO2  Phenyl C16H16N4O4 328.00 
8. CDSB-8  4-NO2 Phenyl C16H16N4O4 328.00 
9. CDSB-9 2-OH Phenyl C16H17 N3O3 299.00 
10. CDSB-10 4-OCH2  Phenyl C17H19N3O3 313.00 
11. CDSB-11 4-N, N-di CH3  Phenyl C18H22N4O2 326.00 
12. CDSB-12 4-Br Phenyl C16H16BrN3O2 362.00 
13. CDSB-13 3,4-di OCH3  Phenyl C18H21N3O4 343.00 
14. CDSB-14 Anthracenyl C24H21N3O2 383.00 
15. CDSB-15  3-Indolyl C18H18N4O2 322.00 
16. CDSB-16 3-Phenyl propanal C18H19 N3O2 369.00 
17. CDSB-17 3,4,5- tri OCH3  Phenyl C19H23N3O5 373.00 
18. CDSB-18 4-SCH3  Phenyl C17H19N3O2S 328.00 
19. CDSB-19 4-CH3  Phenyl C17H19N3O2 297.00 
20. CDSB-20 3-OCH3  4-OH Phenyl C17H19N3O4 329.00 
21. CDSB-21 3-OC2H5, 4-OH Phenyl C18H21N3O4 343.00 
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1-Substitutedphenyl-10H-[1, 2, 4]triazolo[3', 4’: 3, 4] [1, 2, 4]triazino[5, 6,-
b] indoles 
N
N
NN
N
N
H
R
 
Azoles and azines are well known for their diverse biological activities.  It is 
also known that fusion of the heterocyclic nuclei enhances the 
pharmacological activities more than the parent nucleus.  The importance of 
the indole nucleus is well established in pharmaceutical chemistry (Holla, 
2002), (Babalola, 1998).  
A few naturally occurring members of this class of compounds, pyridindolol 
and the two antibiotics CV-1 and guatamicin have been isolated from different 
species of streptomyces. Triazolo trianzino indoles show antihypertensive, 
antiviral, blood platelets aggregation inhibitory, analgesic and antibacterial 
activities (Abdul-Latif, 1989). Several as – triazines fused with an indole 
nucleus have been considered as potential drugs for the treatment of common 
cold infections caused by several rhino virus strains.  These compounds were 
active in nitro not only against rhinovirus but also against Coxsockie, Echo, 
Herpes, polio, Pseudorabbies and vaccinia viruses (Scott and Baginski, 
2000).  
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TABLE 3E: ANALYTICAL DATA OF KUITT SERIES 
Sr.No. Code Substitution (R) Sr.No. Code Substitution (R) 
1 KUITT-1 3,4-diOCH3 10 KUITT-12 3-OC6H5 
2 KUITT-2 4-OCH3 11 KUITT-14 3-OCH3 
3 KUITT-3 4-SCH3 12 KUITT-16 3-CI 
4 KUITT-4 3-Br 13 KUITT-17 2-OH 
5 KUITT-7 4-CI 14 KUITT-18 4-OH 
6 KUITT-8 3-NO2 15 KUITT-19 3-OH 
7 KUITT-9 4-NO2 16 KUITT-20 3-OCH3,4-OH 
8 KUITT-10 H 17 KUITT-21 4-CH3 
9 KUITT-11 2-NO2 18 KUITT-22 9-Anthracyl 
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1-{2,4-Dimethyl-5-[(5-substitutedphenyl-1,3,4-oxadiazol-2-yl)carbonyl]-
1H-pyrrol-3-yl} ethanones 
Bactericidal and fungicidal activities were reported for exazolidane, amino 
oxazodiozole, and oxadiazoline thiones (Desai, 2007).The tin derivatives in an 
effective fungicide and antimicrobial are shown by thiones. The oxazdidones 
have shown herbicidal and insecticidal activity (Upadhyay, 2006). 
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TABLE 3F: ANALYTICAL DATA OF KUPO SERIES 
 
Sr.No. Code Substituents 
Molecular 
Formula 
Molecular 
weight 
1 KUPO-1 Phenyl C16 H15N3O2 281.3 
2 KUPO-2 2-Cl Phenyl C16 H14  CIN3O2 315.8 
3 KUPO-3 4-Cl Phenyl C16 H14CIN3O2 315.7 
4 KUPO-4 4-NO2 Phenyl C16 H14N4O4 326.3 
5 KUPO-5 2-OH Phenyl C16 H15N3O3 297.3 
6 KUPO-6 4-OCH3 Phenyl C17 H17N3O3 311.3 
7 KUPO-9 3-NO2 Phenyl C16 H14 N4 O4 326.3 
8 KUPO-10 2-CH3 Phenyl C17 H17 N3 O2 295.3 
9 KUPO-11 4-CH3 Phenyl C17H17 N2O12 295.3 
10 KUPO-12 2-OH Napthyl C20 H17 N3O3 347.3 
11 KUPO-13 2-Indolyl C18 H16N4O2 320.3 
12 KUPO-14 2-OCOCH3 Phenyl C18H17N3O4 339.3 
13 KUPO-15 4-Br Phenyl C16H14 BrN3O2 360.2 
14 KUPO-16 2-C6H5NH Phenyl C22 H2 N4O2 372.4 
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2-Amino-6-alkylaryl-5-oxo-4-substitutedphenyl-5,6-dihydro-4H-
pyrano[3,2-C]quinoline-3-carbonitriles.    
4-hydroxyquinolones and pyranofused heterocycles are reported to have 
antimicrobial as well as antivital activity. Quinolone alkaloids are known to 
possess antimicrobial activity and cytotoxicity against animal and plant tumors 
(Dodia, 2000). 
2-propyl quinolone is reported to be proposed as a new oral treatment for 
visceral leishmaniosis (Murray and Baron, 1992). 
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TABLE 3G: ANALYTICAL DATA OF KUQP SERIES 
Sr. 
No. 
 
code 
 
Substituent 
Molecular 
Formula 
Molecular 
Weight 
1. KUQP-1 4-OCH2 Phenyl C27H21N3O3 435.4 
2. KUQP-2 4-F Phenyl C26H18FN3O2 423.4 
3. KUQP-3 4-CIPhnyl C26H18CIN3O2 439.8 
4. KUQP-4 4-NO2Phnyl C26H18N4O4 450.4 
5. KUQP-5 3,-DIOCH3 Phenyl C27H21N3O3 465.6 
6. KUQP-6 3,4,5-Tri’ OCH3 C28H23N3O5 495.5 
7. KUQP-7 2,5-DIOCH3 C28H23N3O4 465.5 
8. KUQP-8 2-NO2  Phenyl C26H18N4O4 450.4 
9. KUQP-9 3-NO2 Phenyl C26H18N4O4 450.4 
10. KUQP-10 2-OH C26H18CIN3O3 421.4 
11. KUQP-11 3,4-Di OH C26H18N3O4 437.4 
12. KUQP-12 2-OCH3 C27H21N3O3 435.4 
13. KUQP-13 3-OCH3 C27H21N3O3 435.4 
14. KUQP-14 3-Br C26H18BrN3O2 484.3 
15. KUQP-15 4-CH3 C27H21N3O2 419.4 
16. KUQP-16 4-SCH3 C27H21N3O2S 451.5 
 37 
 Ethyl-4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-2'-oxo-6-substitutedphenyl-
cyclohex-3-ene-1-carboxylates. 
The coumarins are a large group of naturally occurring oxygen heteroxycles. 
(Kakadiya and Bariwal, 2007).  Coumarins and its annulated derivatives are 
reported to possess bacteriocidal and fungicidal, coronary dilatory, 
hypothermal, anticoagulant, antiviral anti-inflammatory activities (Ng and Ling, 
1996), (Chavda and Shah, 2003). 
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TABLE 3H: ANALYTICAL DATA OF ASM (i) SERIES 
 
 
Sr.No. Code Substitution-R1 Substitution-R Mol. Weight 
1. ASM-5 CH3 H 434.45 
2. ASM-6 CH3 2- OCH3 434.45 
3. ASM-7 CH3 3- 0CH3 434.45 
4. ASM-8 CH3 4,5,6-Tri-OCH3 494.49 
5. ASM-9 CH3 4-NO2 449.41 
6. ASM-10 CH3 3-NO3 449.41 
7. ASM-11 CH3 2-OH 420.41 
8. ASM-12 CH3 3-OH 420.41 
9. ASM-13 CH3 H 443.44 
10. ASM-14 CH3 2-NO2 449.41 
11. ASM-15 CH3 4-OH 420.41 
12. ASM-16 CH3 4,5-OCH3 468.46 
13 ASM-17 CH3 4-Cl 438.85 
14 ASM-18 CH3 N,N-di-CH3 447.48 
15 ASM-19 CH3 3-Cl 438.85 
16 ASM-20 CH3 4-F 407.36 
17 ASM-21 CH3 2- Cl 438.85 
18 ASM-22 CH3 2-OH,4-OCH3 450.43 
19 ASM-23 CH3 3-Br-phenyl 483.30 
20 ASM-24 CH3 9-Anthraldehyde 504 
21 ASM-25 CH3 H 404.41 
22 ASM-26 CH3 3-Phenoxy 496.50 
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4-Anilino-6-ethyl-2H-pyrano[3, 2-C]quinoline-2,5(6H)-diones. 
Pyronofused heterocycles are commercially important as antimicrobials, 
antihistomines, antibacterials, enzyme substrates and alkaloids (Wolf, 1996). 
Several polysubstituted pyronoquinolines are bacteriocidal for Gram Positive 
and Gram Negative bacteria. Pyronoquinolines and fluroquinoline derivatives 
are effective for MRSA. Pyrano quinoline diones are good antifungal and anti 
HIV agents (Mishra, 2005), (Modi, 2007). 
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TABLE 3I: ANALYTICAL DATA OF ASM (ii) SERIES 
 
Sr. 
No. 
code Substitution. 
. R 
Molecular 
Weight 
Molecular 
Formula 
1. ASM-30 4-(C)C6H4 412.84 C20 H13 ClN2O4S 
2. ASM-31 - 332.35 C20 H16 N2O3 
3. ASM-32 3,6-Di Cl 401.24 C20 H14 Cl2N2O3 
4. ASM-33 3-Cl, 1,4-F 384.78 C20 H14 ClFN2O3 
5. ASM-34 4-F 352.35 C20 H17 FN2O3 
6. ASM-35 4-OH 420.41 C20 H16 N2O3 
7. ASM-36 2-Cl 368.41 C20 H17 ClN2O3 
8. ASM-37 4-OCH3 364.39 C21 H20 N2O4 
9. ASM-38  2-OCH3 364.39 C21 H20 N2O4 
10. ASM-39 3-NO2 379.36 C20 H17 N3O5 
11. ASM-40 2- CH3  348.39 C21 H20 N2O3 
12. ASM-41 2-NO2 377.37 C20 H15 N3O5 
13. ASM-42 4-NO2 377.37 C20 H15 N3O5 
14 ASM-43 2, 4-CH3 360.40 C22 H20 N2O3 
15. ASM-44 2,3 - CH3 360.40 C22H20N2O3 
16. ASM-45 2, 5 - CH3 360.40 C22H20N2O3 
17. ASM-46 4 - CH3 348.39 C21H20N2O3 
18. ASM-47 4 – CI 366.79 C22H18N2O3 
19. ASM-48 3, 5 - CH3 360.40 C22H20N2O3 
20. ASM-49 2- COOH 376.36 C22H18N2O5 
21. ASM-50 4-(CH3)C6H4 390.45 C22 H18 N2O3S 
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 N-Benzylidine-6-methyl[-2-oxo-2H-chromene-4-carbohydrazides. 
Caumarin containing antibiotics such as Novobiosin, amino caumarin core 
produced by streptomyces have gained renewed interest since the discovery 
that they are potent inhibitors of bacterial DNA gyrase, which is essential for 
cell viability.  In addition, these coumarin antibiotics are potent against MRSA.  
Effective reversal of breast cancer resistant protein mediated Drug resistance 
by Novobiosin is well studied (Yu and Suzuki, 2003). 
Schiff bases are important intermediates for the synthesis of some bioactive 
compounds such as β-lactams. They are antibacterial, antifungal, anti 
hepatitis virus, anti herpes simplex virus, anti adeno virus, anticancer and 
herbicidal (Manvar and Malde, 2008), (Kostova, 2006). 
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TABLE 3J: ANALYTICAL DATA OF MSB SERIES 
 
Sr. 
No. 
Code     Substitution-R Substitution-R1 
Molecular  
formula 
Molecular 
Weight 
1. MSB-1 6-CH3 C6H5 C18H14N2O3 306.31 
2. MSB-2 6-CH3 4-OCH3-C6H4 C19H16N2O4 336.34 
3. MSB-3 6-CH3 4-F-C6H4 C18H13FN2O3 324.30 
4. MSB-4 6-CH3 2-OH-C6H4 C18H14N2O4 322.31 
5. MSB-5 6-CH3 C6H5-CH-=CH- C21H16N2O4 360.36 
6. MSB-6 6-CH3 3,4,5-Tri-OCH3-C6H2 C21H20N2O6 396.33 
7. MSB-7 6-CH3 3,4-Di-OCH3-C6H3 C20H18N2O5 366.36 
8. MSB-8 6-CH3 3-OCH3-C6H4 C19H16N2O4 336.34 
9. MSB-9 6-CH3 C18H13CIN2O3 C18H13CIN2O3 340.76 
10. MSB-10 6-CH3 C18H13CIN2O3 C18H13CIN2O3 340.76 
11. MSB-11 6-CH3 C18H13CIN2O3 C18H13CIN2O3 340.76 
12 MSB-12 6-CH3 C18H13N2O5 C18H13N2O5 351.31 
13 MSB-13 6-CH3 C18H18N2O4 C18H18N2O4 336.34 
14 MSB-14 6-CH3 C18H13N2O5 C18H13N2O5 351.31 
15 MSB-15 6-CH3 C18H13N2O3 C18H13N2O3 385.21 
16 MSB-16 6-CH3 C18H14N2O8S C18H14N2O8S 386.38 
17 MSB-17 6-CH3 C20H15N3O3 C20H15N3O3 345.35 
18 MSB-18 6-CH3 C18H14N2O4 C18H14N2O4 322.31 
19 MSB-19 6-CH3 C18H14N2O4 C18H14N2O4 322.31 
20 MSB-20 6-CH3 C28H18N2O3 C28H18N2O3 406 
21 MSB-21 6-CH3 C18H16N2O5 C18H16N2O5 352.34 
22 MSB-22 6-CH3 C19H18N2O C19H18N2O 349.38 
23 MSB-23 6-CH3 C18H13N3O5 C18H13N3O5 351.31 
24 MSB-24 6-CH3 C24H18N2O4 C24H18N2O4 398.41 
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Fluroquinolone Derivatives (Floxacin series) 
First generation quinolones were active against bacteria causing urinary tract 
infections.  Second generation quinolones (Norfloxacin) are found to be active 
against Gram Positive and Gram Negative bacteria. Liprofloxacin, ofloxacin, 
levofloxacin are broad spectrum antimicrobials used in many community 
acquired diseases like respiratory, gastrointestinal, STDs, skin, bone and soft 
tissue infections (Wolfson and Hooper, 1985). Third generation 
fluxoquinolones gatifloxacin and moxifloxacin have enhanced activity against 
Gram Positive bacteria including anaerobes and MRSA (Blondeau, 1999), 
(Nightingale, 2000). 
Following novel quinolone structures were synthesized by Prof. Ulrich Jordis 
group at Vienna. They were studied for their Antimicrobial Activity at out 
laboratory. 
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Biological Organic Compounds 
As a raw biological material to get lipid extract, sterol extract and fatty acid 
extract several Red Algae are selected, for producing Antimicrobial profile. 
1)   Scinaia indica: - They are large red algae, turgid and firmly structured. Its 
height is 17 cms or more. It has thalli having repeatedly and regularly 
forked with deep constrictions more or less at regular intervals. It is 
dichotomously branched more than 7-8 times; greater part is red in 
color, tending to be darker red towards the lower portion and paler 
towards the tip portions. 
  2)    Ceramium rubrum :- They are the red algae forming large bushes, rising 
from dish like bases tall up to 1-4 cms, red in color, obscurely banded, 
dichotomous branching, tapering to the upper divisions, branch tips 
forcipate to eract,nodes little swollen and below indeed more contracted, 
nodal rings almost contiguous from the apex.  This alga is found in 
shallow waters but not stagnant or brackish. 
  3)    Gracillaria corticata: - It occurs in tropical waters, generally at midlittoral 
region, but extends up to fringe of subtidal level.  It is usually attached to 
rocks or corals.  The mature plant grows up to 10 cms. It has 
dichotomous and fastigiate thallus. The thallus is rigid and cartilaginous.  
The thallus is di or tri-partite. The apices of the segments are acute, with 
proliferations given out from the edge of the thallus. It is usually found in 
tide-pools at midlittoral region.  
Antifungal activity of several medicinal plants and marine algae is reported in 
literature (Yamamoto, 1984), (Martinez, 1996). Antibacterial principle was 
isolated from red algae Gracillaria corticata which was antibacterial to several 
microbes (Biard, 1980). Lipid extracts of the three red algae:   Scinaia indica, 
Ceramium rubrum and Gracillaria corticata were investigated and proved 
antibacterial as well as antifungal agent.  
The sterol and fatty acid content found from Scinaia indica, Gracillaria 
corticata and Ceramium rubrum showed antimicrobial activity against several 
bacterial and fungal strains (Bapodara, 1992). 
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CHAPTER 4 
 
Antimicrobial Activities of Organic Compounds 
4.1 Introduction 
In-vitro Antimicrobial susceptibility tests are well established by NCCL.The 
subcommittee of NCCL develops standards that promote accurate antimicrobial 
susceptibility testing and appropriate reporting. The standards and guidelines of 
NCCL are comprehensive and include all antimicrobial agents for which the 
data meet established NCCL guidelines. Either broth or agar dilution methods 
may be useful to measure quantitatively the in-vitro activity of an antimicrobial 
agent against a given isolate (NCCL Guidelines, 2003). 
 
Susceptibility tests are most often indicated when the causative belong to a 
species capable of exhibiting resistance to commonly used antimicrobial agents 
(Turnidge, 2003), (CLSI, 2006).  The Agar Dilution Method is intended primarily 
for testing commonly isolated aerobic or facultative bacteria that grow well after 
overnight incubation.  
 
Test of microbial sensitivity is therefore, the most important of all for testing 
many microbes against a single antimicrobial agent – compound (Erricsson and 
Sherries, 1971).Some form of incorporation of diluted antibiotics into solid 
media is preferred for the convenience of all researchers in 1975. British 
society of Chemotherapy agreed to a general standard of sensitivity testing 
(Garrod, 1978). Agar Dilution Method is reported to be successful and 
reproducible for bacteria as well as fungi (Lorian, 1991). Agar Dilution Method 
is interpreted by several researchers (Krasemann, 1980).  
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4.2 Protocols for studying Antimicrobial Activity 
Agar Dilution Procedure 
 
The Agar Dilution Method for determining antimicrobial susceptibility is a well-
established technique (Koneman, 1992).The antimicrobial agent is incorporated 
into the agar medium with each plate containing a different concentration of the 
agent.  The inocula can be applied rapidly and simultaneously to the agar 
surfaces using inoculums replicating apparatus (Woods, 1995). 
 
Reagent and Materials:  
Microorganisms and Media: 
ATCC Bacterial cultures obtained from NCL, Pune were 
1. Escherichia coli  ATCC 25922 
2. Pseudomonas aeruginosa ATCC 27853 
3. Staphylococus aureus  ATCC 25923 
4. Bacillus subtilis ATCC 6633 
5. Candida albicans ATCC 10231 
Laboratory Bacterial cultures 
1. Escherichia coli 
2. Enterobacter aerogenes 
3. Proteus vulgaris 
4. Salmonella paratyphi B. 
5. Pseudomonas aeruginosa 
6. Staphylococcus citrus 
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Clinical isolates from Civil Hospital, Rajkot and Medical College, Jamnagar 
were: 
 
 
1. Escherichia coli* 
2. Proteus vulgaris* 
3. Staphylococcus albus*  
4. Staphylococcus citrus* 
5. Salmonella paratyphi B*   
6. Klebshiella pneumoniae*1 
7. Klebshiella pneumoniae*2 
8. Candida albicans* 
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Mueller Hinton Agar Medium 
Of the all media available, the subcommittee considers Mueller Hinton agar to 
be the best for routine susceptibility testing of nonfastidious bacteria due to its 
acceptable reproducibility, satisfactory growth of most pathogens and a good 
possibility of large bodies of data of susceptibility tests performed. (NCCL, 
1996), (Barry and Jones, 1998).  
Composition of Mueller Hinton Agar   G / liter 
Beef Infusion     300.00 
Casein acid hydrolysate        17.50 
Starch               1.50 
Agar           17.50 
Final pH (at 25°C) 7.3 + 0.2 
Preparing Agar Dilution plates 
(1) Appropriate dilutions i.e. 1 ml quantity of antimicrobial solution are added 
to Mueller Hinton agar (19 ml quantity) (Hi Media) that have been allowed 
to equilibrate in a water bath to 45 to 50 °C. One part of antimicrobial 
solution is added to nine parts of liquid agar.   
 
(2) The agar and antimicrobial solution were mixed thoroughly and the 
mixture is poured into Borocil glass Petri dishes having 9 cm diameter on 
a level surface to result in an agar depth of 3 to 4 mm. 
 
(3) The plates should be poured as quickly after mixing as possible to prevent 
cooling and partial solidification in the mixing container, avoiding bubbles. 
 
(4) The Agar was allowed to solidify at room temperature, and the plates 
were either used immediately or stored in sealed plastic bags at 2 to 8 °C 
for up to five days for reference work, or longer for routine tests. 
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(5) Plates stored at 2 - 8 °C were allowed to equilibrate at room temperature 
before use, assuring that the agar surface was dry before inoculating the 
plates. If necessary, plates were placed in an incubator or laminar flow 
hood for approximately 30 minutes with their lids. It helps agar to hasten 
drying of the agar surface. 
 
Source of Antimicrobial agent: 
 It was stored in air tight container or under desiccation at 4 °C if in powder form.  
All synthetic organic compounds were obtained from Chemistry Department, 
Saurashtra University. 
 
 Preparation of Biological organic compounds (Lipid, sterol and fatty acid 
extracts from Red Algae) 
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SCHEME 
100 gm ground material (Red Algae) 
Extract in 2 liters of chloroform: methanol (2:1) for 24 hrs. 
Filter through cotton 
Removal of solvent with rotary evaporator 
Residue (Lipids), saponified with 20ml of 20% methanolic KOH 
Addition of double amount of water  
Extracted with diethyl ether 
 
Combined diethyl ether fraction 
Washed with distilled water 
Dried over anhydrous sodium sulphate 
Unsaponifiable fraction 
(Sterols) 
Aqueous layer 
Acidified with 5 % H2SO4 
Liberated fatty acids, extracted in 
benzene 
 
Washed with distilled water 
Dried over anhydrous sodium sulphate 
(Fatty acids) 
 
Preparation of solutions of antimicrobial agents to be incorporated into 
the agar based medium: 
10 mg of the antimicrobial agent was dissolved in 5 ml of DMSO to prepare the 
main stock of the compound to be tested. 1 ml of this main stock was added to 
19 ml of Mueller Hinton Agar medium to take the final concentration of 1000 µg 
/ ml in the agar medium. The main stock solution was further diluted in 
demineralized water by two fold dilution procedure to obtain the desired 
concentration in the agar medium, i.e. 1000 µg / ml, 500 µg / ml, 250 µg/ml, 125 
µg /ml, 62.5 µg / ml, 31.2 µg / ml, 15.6 µg / ml, 7.8 µg / ml, 3.9 µg / ml, 1.9 µg / 
ml, 0.9 µg / ml, 0.4 µg / ml and 0.2 µg / ml. 
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 Control plates: 
(1) Drug-free plates prepared from the Mueller Hinton Agar medium were 
used as growth controls. These plates were free from Antimicrobial agent 
as well as solvent. 
(2) Control plates prepared from the base medium with the addition of only 1 
ml solvent DMSO (free of antimicrobial agent), were called as solvent 
control plate. 
The control plates were inoculated in the same manner with the inoculum 
before incubation. 
 
Preparation of inoculum of the test cultures: 
One loopful of culture from the slant was inoculated into 5 ml Mueller Hinton 
broth (HiMedia) in a test tube. The tube was incubated at 32 °C for 4 to 6 hours 
till the absorbance at 625 nm, equals that of 0.5 Mac Farland standards. 
(Section 5, NCCL Guidelines). The absorbance readings were taken against a 
sterile Mueller Hinton broth Media blank. The density of the suspension was 
adjusted to 10
8
 colony forming units (CFU) per milliliter by comparing its 
turbidity to a MacFarland 0.5 BaSO4 standard. 
 
The bacterial cultures were then transferred at 2-8 °C and maintained at the 
same temperature till further use.  Appropriate dilutions of the bacterial cultures 
were made based on the viable count of the bacterial cultures previously done 
to establish the relationship between absorbance at 625 nm and viable count 
before inoculating the plates with the antimicrobial test agents. 2µl of this 
diluted culture was used to spot inoculate the plates with antimicrobial agents 
using micropipette. 
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Preparation of 0.5 Mac Farland standard: 
It was used as a reference for turbidity measurement for bacterial cultures 
before they were used as inoculum for spot inoculate the Mueller Hinton Agar 
media containing antimicrobial agents. 
 
Briefly, 0.5 ml of 1.175% w/v BaCl2 solution was added to 99.5 ml of 1 % v/v 
H2SO4 solution with constant stirring, the absorbance of the solution was 
measured 625nm against demineralized water blank by UV spectrophotometer. 
The absorbance was in the range of 0.08 to 0.1 optical densities. 
 
Incubation:  All plates were kept at 37 °C for 24 hours in an ambient air 
incubator before taking the results of MIC.  
 
Antifungal Activity Determination: 
For fungal cultures the fungal media Yeast Nitrogen base agar plate (YNBG) 
(Difco Make) 6.7 g and Glucose 10 g, dissolved in 100 ml of distilled water and 
filter sterilized was used. The inoculum was prepared from 3-4 days old 
sabouraud’s Dextrose agar slants.The growth was uniformly mixed with 
Distilled water. The Size of inoculum prepared for inoculating YNBG agar plates 
was 102 –103 cfu/ml, adjusted with McFarland solution. After inoculation of 
properly diluted fungal solution, the plates were incubated at 37 °C for 48 
hours. 
 
Determination of type of Antimicrobial Activity: 
Organic compounds may be bacteriostatic or bacteriocidal for microbial 
cultures. To check this, from the Mueller Hinton Agar plates (showing no visible 
growth of bacteria), sub culturing was carried out on Nutrient Agar plates 
(Collins, 1967).  After streaking, Nutrient Agar plates were incubated for 24 h at 
37°C.  Then after observation was made to see the colonies formed.  If 
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colonies were found, the dilution was considered as bacteriostatic and if no 
colonies observed, it was considered as bactericidal. Bacteriocidal dilutions of 
the organic compounds were considered as exact Minimum inhibitory 
concentration (MIC) for a particular organic compound. 
 
 Interpretation of Results: 
 
1. In case of positive control, plate due to complete absence of 
antimicrobial agent and its solvent bacterial / fungal cultures gave 
luxuriant growth.  
2. In the solvent control plate inhibition of growth of microbes due to 
presence of organic solvent DMSO. 
3. The microbial cultures, if shown 1-5 colonies per spot inoculated instead 
of confluent growth as in the control plate, it was considered to be 
inhibited by test antimicrobial compounds. 
4. The microorganisms that were sensitive to the concentration of 
antimicrobial in Mueller Hinton agar plate did not produce a circle of 
growth at the inoculum site. 
5. The microbes that were resistant to it appeared as circular colonies. The 
agar plates were marked with a grid so that each microorganism could 
be identified by a number. 
 
It is suggested by the authors of ICS Report that satisfactory, reproducible MIC 
will be only be obtained if all the factors influencing the activity of the 
antimicrobial drugs are consistently controlled (Ratan,2000),(Charles,2006). 
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Quantitative Measurement of bacterial growth: 
Enumeration of bacteria was carried out using viable count technique and 
Direct Microscopic count (Cappucino, 2004), (Johnson, 1998). Determination of 
grown and survived bacteria was done by consideration of results of both the 
techniques. 
 
First of all Mueller Hinton Agar plates with  bacterial growth, solvent control 
plate and Growth control plate ( no compound added) were used to carry out 
enumeration method. Mueller Hinton Agar plates showing visible bacterial 
growth were used to carry out viable count and Microscopic count. 
 
1.  Mueller Hinton agar plates with luxuriant to poor growth were used for 
suspending entire growth in 10 ml of Distilled water blank tube.  Further 
serial dilutions were prepared from the suspension tube; viable count 
was carried out by pouring the molten top agar in Base Agar plates. 
 
2. For microscopic count from the same suspension tube bacterial cells 
were counted using Haemocytometer chamber. 
 
Finally, the results of both the techniques were put together to take average of 
colony forming unit / ml (cfu/ml) for each plate. For all bacterial cultures, cfu/ml 
was calculated and the results were plotted in the graph of 
cfu/ml→Concentration of compound. 
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Quality Control: 
The control procedures: 
(1) Growth control was performed to check viability of the organisms. 
(2) Purity control by sample inoculum streaked on a suitable agar plate. 
(3) Inoculum control by plate counts was performed on representative 
inoculum periodically. 
(4) End point interpretation control was independently read for all dilution 
plates. 
 
Rigorous quality control was maintained through the experimentation by 
checking large numbers of variables that may affect the results. Physical and 
chemical characteristics of Mueller Hinton agar media were monitored, such as 
pH and depth of agar. The final control was provided by a series of reference 
strains including Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 27853, Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC 
6633, Candida albicans ATCC 10231.The reference strains were stored at 
temp below -20 °C. 
 
Factors influencing MIC Results: 
1.  Ingredients of Culture Media : 
Many substances are present in culture media that affect growth of 
microorganisms; such as peptone, tryptone, yeast extract and agar 
(Waterworth, 1983). Unless Mueller  Hinton broth has the correct 
concentrations of the divalent cations, Ca++ and Mg++ (20 to 25 mg of Ca++ / L 
and 10 to 12.5 mg of Mg++/L), MICs of aminoglycosides for Pseudomonas 
aeruginosa and MICs of tetracycline for all bacteria will be different from those 
obtained on Mueller Hinton agar. 
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2. Choice of Medium : 
Any changes in type of media, quality of ingredients, company providing the 
medium or any change in pH of the media may lead to unsatisfactory results 
(Woods, 1995). The activity of amino glycosides is enhanced in alkaline 
medium and reduced in acidic medium and the reverse is shown in case of 
tetracyclines.  The pH of each preparation of Mueller Hinton broth was 
checked; the pH should be between 7.2 and 7.4 at room temperature (25 °C) 
(Jones, 2005).  Moreover, the media plates not poured with even depth or very 
thin plates may give wrong conclusions. 
 
   3. Effect of Inoculum size: 
Dilution methods are less affected by this variable (Waterworth, 1978).  It is 
observed that all the tests with sulfonamides are invalidated if the inoculum is 
too heavy and even relatively small differences may affect the results.  The ICS 
Report recommends that the inoculums for dilution tests should be taken from 
broth cultures in the logarithmic or early stationary phase of growth and diluted 
in broth to contain 105 to 106 viable organisms per ml. Routine checking of 
stability of barium sulfate turbidity standard should also be done (Washington, 
1973). 
 
4.3 Criteria for selection of Microbes: 
[1] For performing in- vitro testing of organic compounds and to get their effect 
on ATCC cultures, first of all several ATCC microbial cultures were selected 
and brought from NCl, Pune. 
[2] After getting moderate to good activity on these species, we tried some of 
the routine laboratory cultures to check the differences in their response to 
antimicrobial compounds and their normal sensitivity compared to resistant 
strains of same type. 
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[3] In the third spell of the experiment, we collected some of clinical isolates 
from Civil Hospital Rajkot and Medical College, Jamnagar which are already 
resistant to current antibiotics and more or less resistance was found among 
them. As they were collected from patients of CAD, Immunosuppressant and 
HIV infection, they exhibited high resistance towards Antibiotics (Broth Dilution 
Method), (TABLE 4A and 4B). 
 
[4] The objective of the experimentation was to search for proper sensitivity 
profile of the microbes which are difficult to treat by conventional antibiotics 
specially when related with CAD. 
 
Thus, using three categories of microorganisms, comparative effects of 
antimicrobial activity of organic compounds were studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
TABLE 4A: CLINICAL DATA OF SELECTED CLINICAL ISOLATES 
MICROBIAL 
CULTURE 
PATHOLOGICAL 
SAMPLE 
DISEASE 
PRODUCED 
CHARACTERS 
Escherichia. Coli. Urine Urinary tract infection Gram Negative short rods 
Proteus valgaris Urine Urinary tract infection Gram Negative short rods 
Salmonella 
paratyphi B 
Blood Septicemia Gram Negative short rods 
Staphylococcus 
albus 
Sinus secretion Sinitis Gram Positive cocci 
Staphylococcus 
citrus 
Wound swab Wound infection Gram Positive cocci 
Klebshiella 
pneumoniae 1 
Lung secretion Pneumonia Gram Negative short rods 
Klebshiella 
pneumoniae 2 
Lung secretion Pneumonia Gram Negative short rods 
Candida albicans Cerebral fluid Cerebral Candidosis Gram Positive, Unicellular fungi, 
oval shaped cells 
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TABLE 4B: CHARACTERIZATION DATA OF SELECTED CLINICAL ISOLATES 
 
ABRIVIATIONS: COChemoorganotrophic nutrition 
                            CADCommunity acquired disease 
                            FAnFacultative Anaerobe 
                            IS Immunosuppression condition 
MICROBIAL 
CULTURE 
NUTRITION RELATED 
DISEASE 
MORPHOLOGY 
µM   
ARRANGEMENT TEMP 
0 C 
COLONY 
CHARACTERS 
SPECIAL 
FORMS 
O2 
NEED 
Escherichia. Coli. CO CAD 1.1-1.5 to 2-6  Single cells 37 Smooth,round, 
small 
semitransparent 
Mucoid 
colony 
FAn 
Proteus vulgaris CO CAD 0.4-0.8 to 1-3  Single cells 37 Smooth,round, 
small 
semitransparent 
Swarming 
colony 
FAn 
Salmonella paratyphi B CO CAD 0.7-1.5 to 2-5  Single cells 37 Smooth,round, 
small 
semitransparent 
S-R 
mutants 
FAn 
Staphylococcus albus CO IS 0.5 to 1 clusters 37 Smooth,round, 
big, opaque 
R variants FAn 
Staphylococcus citrus CO IS 0.5 to 1 clusters 37 Smooth,round, 
big, opaque 
Yellow color 
variants 
FAn 
Klebshiella pneumoniae 
1 
CO CAD 1.1-1.5 to 2-6  Single cells 37 Smooth,round, 
small 
semitransparent 
capsules FAn 
Klebshiella pneumoniae 
2  
CO AIDS 1.1-1.5 to 2-6  Single cells 37 Smooth,round, 
small 
semitransparent 
capsules FAn 
Candida albicans  CO AIDS 4 to 6 Clusters, chains 30 Smooth, big, 
round, opaque 
pseudo 
mycelia 
FAn 
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4.4 Results of antimicrobial activity of organic compounds 
Antibacterial activity of synthetic organic compounds 
Antibacterial action of CT  
Ten compounds, CT 1- CT 10, were screened for their antibacterial activity. 
Several Gram Negative and Gram Positive bacteria were used to check their 
sensitivity for above compounds. Out of the ten CT compounds, four CT 
compounds, i.e. CT 5, CT 7, CT 8, CT 9 and CT 10 were not satisfactory to inhibit 
bacterial growth at 1000 µg/ml concentration. The effect of solvent DMSO was 
studied and presented in graphical manner (Graph No.1).  
 
Surprisingly, four bacterial cultures; Enterobacter aerogenes laboratory culture, 
Proteus vulgaris laboratory culture, Salmonella paratyphi B clinical isolate, 
Pseudomonas aeruginosa laboratory culture were not able to grow in the 
presence of compound CT1 at 1000 µg/ml concentration. As the dilutions 
increased from 500 µg/ml or 250 µg/ml dilutions, the inhibitory effects vanished. 
 
Escherichia coli laboratory culture, Salmonella paratyphi B clinical isolate and 
Pseudomonas aeruginosa ATCC 27853 were highly sensitive against CT1. 
Whereas, Staphylococcus aureus ATCC 25923 was inhibited at 125 µg/ml 
concentration, but grew at 62.5 µg/ml (Graph No.2). 
 
The bacterial count of Escherichia coli ATCC 25922 was increased as the 
concentration of CT 1 decreased. In case of Escherichia coli Clinical isolate, the 
count was increased in higher dilutions. The growth of Proteus vulgaris gradually 
increased with lower to higher dilutions (Graph 2A). The effect of solvent DMSO 
was studied to check any inhibitory effect on test organisms (Graph: 1A, 1B, 1C). 
Maximum bacterial count was found in case of Salmonella paratyphi B lab culture 
even at 1000 µg/ml concentration. Pseudomonas aeruginosa lab culture gave 
decrease in count, as the concentration of compound increased (Graph 2B). 
Being more resistant, Staphylococcus albus clinical isolate showed bacterial 
count in all dilutions. As the dilution became low, Bacillus subtilis ATCC 6633 did 
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not grow. General pattern of decrease in bacterial count (cfu/ml) was found in 
most of bacteria as the dilution decreased (Graph 2C). 
 
CT 2 was poor in affecting the bacteria growth. Out of all 12 bacterial cultures, six 
were grown even at 1000 µg/ml concentration of the compound.  Moreover, 
almost all microbes have shown resistance against action of this organic 
compound. (Graph No. 3). CT 3 was effective for only specific types of microbes 
(Graph No. 4). Most of the Gram Negative organisms have not responded to CT 
3 except Salmonella paratyphi B clinical isolate and Pseudomonas aeruginosa 
ATCC 27853, whereas, in case of Gram Positive organisms, a little antimicrobial 
effect was evident.  All cultures gave bacterial count (cfu/ml) in almost all dilutions 
of CT3 (Graph 3A), only one single culture, Salmonella paratyphi B lab culture 
could grow (Graph 3B). Staphylococcus aureus clinical isolate yielded cell 
numbers in all dilutions. Whereas, only in last two dilutions; 31.2 and 15.6 µg/ml, 
Bacillus subtilis ATCC 6633 produced only limited growth (Graph 3C). 
  
Pseudomonas aeruginosa ATCC 27853 was sensitive against CT 3, as it was 
inhibited at highest dilution of secondary screening procedure i.e. 15.2 µg/ml. CT 
4 was very poor in affecting bacterial growth even at lowest dilution. Similarly, for 
CT 5, all cultures have shown resistance. Interestingly, eight bacterial cultures 
were inhibited at 1000 µg/ml and only two cultures; Salmonella paratyphi B and 
Staphylococcus citrus clinical isolate, exhibited sensitivity at 500 µg/ml. Rest of 
the cultures have shown resistance when grown in higher dilution plates. 
 
Very poor inhibition was obtained for last four CTs i.e. CT 7, CT 8 (Graph No.5), 
CT 9 and CT 10.  Except culture Staphylococcus citrus clinical isolate, CT 7 could 
not inhibit organisms at 1000 µg/ml, as rest of all cultures observed to be none 
responding to antimicrobial action.  All cultures were, however resistant to CT 8, 
CT 9 and CT 10 (Table 4A).   
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Graph No.3-Effect of  CT 2 on Growth of 
Micro organisms
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Graph No.4-Effect of CT 3 on Growth of 
Micro organisms
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Graph No. 5-Effect of CT8 on Growth of 
Micro organisms
0
1
2
3
4
5
6
1000
μg/mL
500
μg/mL
250
μg/mL
125
μg/mL
62.5
μg/mL
31.2
μg/mL
15.6
μg/mL
Concentration of Organic Compound 
(ug/mL)
D
e
g
re
e
 o
f 
In
h
ib
iti
o
n
 
o
f 
M
ic
ro
b
ia
l G
ro
w
th
Graph No.1-Effect of DMSO on Growth of 
Micro organisms
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Graph No. 1B : Effect of DMSO on growth of organisms
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Graph No. 1C : Effect of DMSO on growth of 
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Graph No. 2A : Effect of CT 1 on growth of tested bacterial 
cultures
0
2
4
6
8
0 15.1 31.2 62.5 125 250 500 1000
Concentration of CT 1 (ug/ml)
N
o
.
 
o
f
 
c
f
u
 
X
 
1
0
5
E.coli ATCC 25922 Escherichia coli*
Escherichia coli Enterobacter aerogenes
Proteus vulgaris* Proteus vulgaris 
Graph No. 2B : Effect of CT1  on growth of 
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Graph No. 2C : Effect of CT1 on growth of organisms
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Graph No. 3A : Effect of CT3 on growth of tested bacterial 
cultures
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Graph No. 3C : Effect of CT3 on growth of organisms
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Antibacterial action of QT SERIES  
 Total numbers of 15 QT compounds were analyzed for their antimicrobial 
activity, starting from QT 1 to QT 15.  QT compounds, such as QT 2 (Graph 
No.6) QT 5, QT 6 and QT 9 could not show any effect on Escherichia coli ATCC 
25922 and Escherichia coli laboratory culture.QT 13 showed MIC of 500 µg/ml. 
Enterobacter aerogenes lab culture could grow in the presence of QT 2, QT 5, 
QT 6, QT 7, QT 9 (Graph No. 9) and QT 11.  This organism was sensitive for QT 
1, QT 3 (Graph No.7), QT 4, QT 8 (Graph No. 8), QT 10, QT 12 (Graph No.10), 
QT 14 and QT 15 at 1000 µg/ml. Similarly, QT 13 exhibited MIC of 500 µg/ml. 
Several compounds like QT 2, QT 4, QT 7, QT 8, QT 10, QT 11 and QT 12 had 
antimicrobial effect on Proteus vulgaris laboratory culture at 1000 µg/ml.  
However in case of QT 1, QT 3, QT 5, QT 6, QT 9, QT 13, QT 14 and QT 15, 
Proteus vulgaris remained unaffected. Salmonella paratyphi B clinical isolate 
showed resistance for QT 1 and QT 5 compounds. Pseudomonas aeruginosa 
ATCC 27583 displayed sensitivity towards QT 2, QT 12 and QT 5. QT 2 and QT 
12 showed MIC of 125 µg/ml.  In case of QT 5, MIC obtained was 250 µg/ml.  
Pseudomonas aeruginosa laboratory culture was found to be resistant for QT 8 
and QT 12. Whereas QT 9, QT 10, QT 11, QT 14 and QT 15 gave inhibition of 
organisms only at 1000 µg/ml. QT 13 showed bactericidal effect at the 
concentration 500 µg/ml.  
Staphylococcus albus clinical isolate could not show any sign of sensitivity for QT 
6. Staphylococcus aureus ATCC 25923 showed sensitivity for QT 5 and QT 12 at 
250 µg/ml. A  MIC at dilution 500 µg/ml of QT 1 for Staphylococcus aureus was 
evident.  However, for QT 3, QT 4, QT 6 and QT 8, no effect was recorded.  
 
Staphylococcus citrus clinical isolate was highly sensitive to QT 12 as it gave MIC 
of dilution 62.5 µg/ml.  In case of QT 9, it has exhibited antimicrobial action at 125 
µg/ml. Whereas, Staphylococcus citrus stopped growing at 250 µg/ml in the 
presence of QT 5 and QT 7.  QT 1 and QT 8 could affect Staphylococcus citrus 
clinical isolate at 500 µg/ml.  However; QT 3, QT 4 and QT 6 had no effect on 
their growth.  MIC for QT 2, QT 10, QT 11, QT 13, QT 14 and QT 15 was 1000 
µg/ml for Staphylococcus citrus clinical isolate. Klebshiella pneumoniae clinical 
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isolate 1 and 2 were inhibited by QT 7, QT 8, QT 12 at 250 µg/ml, 500 or 250 
µg/ml. The organisms were resistant for QT 1, QT 2, QT 3, QT 6, QT 10 and QT 
13.  In QT 9 and QT 11, Klebshiella pneumoniae isolate 1 was grown at 500 
µg/ml and Klebshiella pneumoniae isolate 2 showed sensitivity up to 125 µg/ml 
for QT 9; for QT 11, MIC was 62.5 µg/ml. For QT 12, isolate 1 was inhibited at 
250 µg/ml and isolate 2 at125 µg/ml. Both isolates showed resistance for QT 1, 
QT 2, QT 3, QT 6, QT 10 and QT 13. While QT 4, QT 9, QT 11, QT 14 and QT 
15 could stop their growth only at 1000 µg/ml (Table 4B). 
 
Bacillus subtilis ATCC 6633 was not at all inhibited by QT 1, QT 2, QT 3, QT 4, 
QT 5, QT 6, QT 7, QT 9, QT 10, and QT 11. For QT 2, there were various 
responses of Escherichia coli ATCC 25922 and Escherichia coli lab culture. The 
bacterial count (cfu/ml) decreased with the increasing concentrations of QT 2 
(Graph 4A).  Klebshiella pneumoniae cultures gave bacterial count in all dilutions. 
Pseudomonas aeruginosa ATCC 27853 was poor in growth, where as 
Salmonella paratyphi B Cultures and Pseudomonas aeruginosa lab culture 
showed similar growth (Graph 4B). Bacillus subtilis ATCC 6633 was able to grow 
in all dilutions; Staphylococcus aureus ATCC 25923 and Staphylococcus citrus 
clinical isolate were resistant in dilutions higher than 500 µg/ml (Graph 4C). 
 
QT12 had resulted similar kind of growth of Gram Negative short rods except in 
1000 µg/ml plate. The number of cells (cfu/ml) marginally varied (Graph 5A). 
However, much variation was found among these Gram Negative short rods in 
producing growth in various dilutions of QT 12 (Graph 5B). Being most resistant 
of all, Staphylococcus citrus clinical isolate produced cell count in higher two 
dilutions. Bacillus subtilis ATCC 6633 gave moderate growth in dilutions more 
then 1000 µg/ml (Graph 5C).  
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Graph No.8-Effect of QT8 on Growth of Micro 
organisms
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Graph No.9-Effect of QT 9 on Growth of 
Micro organisms
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Graph No.10-Effect of QT12 on Growth of 
Micro organisms
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Graph No.6-Effect of QT 2 on Growth of Micro 
organisms
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Graph No.7-Effect of QT 3 on Growth of Micro 
organisms
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Antibacterial action of CDQ SERIES 
A total ten compounds were analyzed from CDQ series. They were CDQ 1, CDQ 
3, CDQ 5, CDQ 8, CDQ 11, CDQ 14, CDQ 18, CDQ 19, CDQ 21, and CDQ 23. 
500 µg/ml of CDQ 1 was MIC for Proteus vulgaris cultures, Klebshiella 
pneumoniae cultures and Bacillus subtilis ATCC 6633. Whereas Gram Positive 
cocci were inhibited at 62.5 µg/ml (Graph No. 11), Escherichia coli ATCC 25922 
and Proteus vulgaris lab culture have increased growth at 250 µg/ml, while others 
have the same tendency of growth at 500 µg/ml (Graph 6A). Salmonella 
paratyphi B and, Pseudomonas aeruginosa laboratory culture were grown at 500 
µg/ml; less growth (cfu/ml) with Klebshiella pneumoniae clinical isolate 1 at 250 
µg/ml and  Pseudomonas aeruginosa ATCC 27853 with more cells (cfu/ml) at 
62.5 µg/ml  was found (Graph 6B). All Gram positive cocci at 62.5 µg/ml had high 
cfu/ml. However, Bacillus subtilis ATCC 6633 gave low cell count at 250/ml 
(Graph 6C). 
 
Escherichia coli lab culture, Escherichia coli clinical isolate, Salmonella paratyphi 
B cultures, Pseudomonas aeruginosa laboratory culture were inhibited at 1000 
µg/ml. Antimicrobial action of CDQ 3 on Escherichia coli ATCC 25922, 
Enterobacter aerogenes, Proteus vulgaris cultures, Klebshiella pneumoniae 
clinical isolate 2 and Bacillus subtilis ATCC 6633 was estimated at 500 µg/ml 
(Graph No.12). Staphylococcus albus clinical isolate was inhibited at 250 µg/ml. 
Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 25923 
and Staphylococcus citrus cultures were inhibited at 125 µg/ml. 
 
CDQ 5 was more effective on Escherichia coli ATCC 25922 Enterobacter 
aerogenes lab culture, Proteus vulgaris cultures, Staphylococcus albus clinical 
isolate and Staphylococcus aureus ATCC 25923 as they were inhibited at 125 
µg/ml (Graph No.13). Bacillus subtilis ATCC 6633 showed sensitivity at 250 
µg/ml.  MIC of CDQ 5 for Escherichia coli clinical isolate, Salmonella paratyphi B 
clinical isolate, Pseudomonas aeruginosa lab culture, Staphylococcus citrus 
cultures, Klebshiella pneumoniae cultures and Bacillus subtilis ATCC 6633 was 
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500 µg/ml.Escherichia coli lab culture, Salmonella paratyphi B lab culture, 
Pseudomonas aeruginosa ATCC 27853, was inhibited at 1000 µg/ml only. 
 
 Moderate type of inhibition up to 250 µg/ml as a MIC was found in case of CDQ 
8.  Cultures of Staphylococcus citrus were affected at 250 µg/ml. Escherichia coli 
ATCC 25922, Proteus vulgaris lab culture, Pseudomonas aeruginosa lab culture, 
Staphylococcus albus clinical isolate, Staphylococcus aureus ATCC 25923, 
Klebshiella Pneumoniae cultures and Bacillus subtilis ATCC 6633 exhibited 
sensitivity at 500 µg/ml (Table 4C). 
.  
CDQ 11 expressed its antimicrobial action on cultures either at concentrations of 
62.5 µg/ml or 125 µg/ml (Graph No.14).   All Gram Negative bacteria were able to 
grow from 62.5 µg/ml (Graph No. 7A). Salmonella paratyphi B cultures and 
Pseudomonas aeruginosa lab culture had moderate cell count at 500 
µg/ml.Gradual increase in bacterial numbers in case of Pseudomonas aeruginosa 
ATCC 27853 from second dilution and for Klebshiella pneumoniae clinical isolate 
1 from third dilution was recorded (Graph No.7B). Staphylococcus aureus ATCC 
25923 and Staphylococcus citrus cultures showed high bacterial count at 31.2 
µg/ml. With 62.5 µg/ml, Staphylococcus albus clinical isolate gave significant cell 
count, while Bacillus subtilis ATCC 6633 from 62.5 µg/ml, low cell numbers were 
apparent (Graph No. 7C). 
 
CDQ 14 could not inhibit Escherichia coli laboratory culture, Escherichia coli 
clinical isolate, Enterobacter aerogenes lab culture, Salmonella paratyphi B 
cultures.  Whereas, at 500 µg/ml, Escherichia coli ATCC 25922 and Proteus 
vulgaris cultures did not grow (Graph No.15). A concentration at 250 µg/ml was 
inhibitory to Bacillus subtilis ATCC 6633 and Pseudomonas aeruginosa ATCC 
27853. The maximum concentration of CDQ 14 which had antibacterial effect on 
organisms like Staphylococcus aureus ATCC 25923, Staphylococcus citrus 
cultures was 62.5 µg/ml.  
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 CDQ 18 and CDQ 19 could not inhibit microbial cultures at the concentration at 
500 µg/ml. In case of all Gram Positive cocci, Salmonella paratyphi B cultures 
and Pseudomonas aeruginosa cultures showed their sensitivity at 500 µg/ml. 
CDQ 21 was effective against a Gram Positive cocci acting at 62.5 µg/ml.  
Pseudomonas aeruginosa ATCC 27853 was inhibited at 250 µg/ml. For 
Escherichia coli ATCC 25922, Salmonella paratyphi B clinical isolate, 
Staphylococcus albus clinical isolate and Klebshiella pneumoniae clinical isolate 
1, MIC of 500 µg/ml was observed for CDQ 2 (Graph No.16). The effect of CDQ 
23 was very similar to CDQ 19 on microbes. General scenario of CDQ series 
compounds revealed that they were more active on Gram Positive bacteria. 
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Graph No.11-Effect of CDQ 1 on Growth of 
Micro organisms
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Graph No.12-Effect of CDQ 3 on Growth of 
Micro organisms
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Graph No.13-Effect of CDQ 5 on Growth of 
Micro organisms
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Graph No.14-Effect of CDQ 11 on Growth of 
Micro organisms
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Graph No.15-Effect of CDQ 14 on Growth of 
Micro organisms
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Graph No.16-Effect of CDQ 21 on Growth of 
Micro organisms
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Graph No. 6A : Effect of CDQ 1 on growth of tested 
bacterial cultures
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Graph No. 7A : Effect of CDQ 11 on growth of tested bacterial 
cultures
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Graph No. 6B : Effect of CDQ 1 on growth of organisms
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Graph No. 7B : Effect of CDQ 11 on growth of organisms
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Antibacterial action of CDSB SERIES  
 In CDSB series, total number of compounds screened was eleven. Out of two 
compounds, CDSB 15 and CDSB 19 (Graph No.20) expressed considerable 
antimicrobial effects on some cultures.  CDSB 15 inhibited Pseudomonas 
aeruginosa ATCC 27853 at 125 µg/ml and for Staphylococcus citrus, the MIC 
was 125 µg/ml. CDSB 19 exhibited its effect on Staphylococcus aureus ATCC 
25923 and Staphylococcus citrus lab culture at 15.6 µg/ml (Graph No.19). For 
Proteus vulgaris clinical isolate and Staphylococcus citrus clinical isolate, MIC of 
125 µg/ml was observed.  Rests of all cultures were sensitive up to 500 or 1000 
µg/ml.  
 
CDSB 10 and CDSB 20 also  inhibited up to higher dilutions i.e. 250 µg/ml. CDSB 
10 for Pseudomonas aeruginosa cultures, Staphylococcus aureus ATCC 25923 
had MIC of 250 µg/ml (Graph No.18). CDSB 20 worked on Salmonella paratyphi 
B clinical isolate, Pseudomonas aeruginosa ATCC 27853 and all Gram positive 
cocci displayed MIC of 250 µg/ml (Graph No.21). Rest of the cultures for CDSB 
10 were inhibited at 500 µg/ml where as for CDSB 20, it varied, giving 1000 µg/ml 
as MIC. 
 For all Escherichia coli cultures, CDSB 1, 3, 4, 6, 7, 11, and 15 showed MIC of 
1000 µg/ml. The MIC for Proteus vulgaris lab culture was 500 µg/ml; CDSB 15 
gave MIC at 500 µg/ml for Proteus vulgaris clinical isolate (Graph No.17). CDSB 
21 inhibited Gram positive bacteria at 250 µg/ml, whereas Escherichia coli ATCC 
25922, Enterobacter aerogenes laboratory culture, Proteus vulgaris laboratory 
culture and Salmonella paratyphi B Clinical isolate were inhibited at 250 µg/ml 
(Graph No. 22). 
 
In case of CDSB 15, increased cells of Escherichia coli ATCC 25922, 
Enterobacter aerogenes lab culture and Proteus vulgaris clinical isolate from 250 
µg/ml was observed. Proteus vulgaris lab culture, Escherichia coli lab culture, 
Escherichia coli clinical isolate grew in moderate bacterial count at 500 µg/ml, 
with an increase in numbers at high dilutions (Graph 8A). Salmonella paratyphi B 
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clinical isolate, Pseudomonas aeruginosa culture and Klebshiella pneumoniae 
clinical isolate 1 had moderate cell numbers (cfu/ml) at 250 µg/ml (Graph 8B). 
Increase in growth of Staphylococcus aureus ATCC 25923 and Staphylococcus 
albus clinical isolate at 125 µg/ml was recorded. For Staphylococcus citrus 
cultures growth occurred at 62.5 µg/ml. For Bacillus subtilis ATCC 6633 growth 
increased with 250 µg/ml (Graph 8C). 
 
For CDSB 19, bacterial count of Proteus vulgaris clinical isolate was observed at 
62.5 µg/ml, Escherichia coli lab culture, Escherichia coli clinical isolate gave 
increase in cell numbers from 250 µg/ml and in case of Escherichia coli ATCC 
25922, Enterobacter aerogenes lab culture, Proteus vulgaris lab culture it was 
from 500 µg/ml (Graph No. 9A). Salmonella paratyphi B clinical isolate and 
Pseudomonas aeruginosa cultures showed growth at 250 µg/ml. Salmonella 
paratyphi B lab culture and Klebshiella pneumoniae clinical isolate recorded cell 
numbers from 500 µg/ml (Graph No. 9B). Variability in producing growth was 
found in CDSB 19. Formation of bacterial colonies with Staphylococcus albus 
clinical isolate at 250 µg/ml, in  Staphylococcus citrus clinical isolate at 62.5 µg/ml 
was observed. Low count in case of Bacillus subtilis ATCC 6633 at  500 µg/ml 
was evident (Graph No. 9C).In case of CDSB 21 Gram Negative bacteria were 
inhibited more than Gram Negative bacteria. Figure-3 (C)). 
 
Overall picture of CDSB series revealed that they could inhibit the bacteria at 
least at the exact concentration of primary screening i.e. 1000 µg/ml. This series 
was less active against bacteria (Table 4D). 
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Graph No.17-Effect of CDSB 3 on Growth of 
Micro organisms
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Graph No.18-Effect of CDSB 10 on Growth of 
Micro organisms
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Graph No.19-Effect of CDSB 15 on Growth of 
Micro organisms
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Graph No.20-Effect of CDSB 19 on Growth of 
Micro organisms
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Graph No.21-Effect of CDSB 20 on Growth of 
Micro organisms
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Graph No.22-Effect of CDSB 21 on Growth of 
Micro organisms
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Graph No. 8A : Effect of CDSB15 on growth of tested 
bacterial cultures
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Graph No. 9A : Effect of CDSB19 on growth of tested 
bacterial cultures
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Graph No. 8B : Effect of CD5B 15 on growth of organisms
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Graph No. 9B : Effect of CD5B 19 on growth of organisms
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Graph No. 8C : Effect of CD5B 15 on growth of organisms
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Antibacterial action of KUITT SERIES    
In KUITT series, 1 to 22 KUITT compounds for primary and secondary screening 
were taken.  They generally gave considerable inhibition of microbes even in 
higher dilutions.  (Figure -1(A). Figure-1(B), Figure- 1(C)) 
 
Escherichia coli ATCC 25922 showed resistance to KUITT 4 at 500 µg/ml. 
Whereas, KUITT 2 (Graph No.24), KUITT 3 (Graph No.25), KUITT 5, KUITT 10, 
KUITT 13 (Graph No.32) and KUITT 18 gave MIC at 500 µg/ml. However, KUITT 
1(Graph No.23), KUITT 8 (Graph No.20), KUITT 9 exhibited inhibition of 
organisms up to 250 µg/ml. KUITT 6 (Graph No.26), KUITT 7 (Graph No.27), 
KUITT 15 showed activity up to 125 µg/ml concentrations (Graph No.34). KUITT 
12, KUITT 17, KUITT 19, KUITT 20 and KUITT 22 could give MIC of 62.5 µg/ml.  
However, except a few cases, like KUITT 12 and KUITT 15, Escherichia coli 
Laboratory culture also gave the same type of response to all these compounds. 
KUITT 12 (Graph No.31) and KUITT 15 gave MIC at 500 µg/ml for Escherichia 
coli laboratory culture. In case of Escherichia coli, clinical isolate similar type of 
response was found except in few cases.  KUITT 1 and KUITT 2 had MIC at 125 
µg/ml. KUITT 19 gave MIC at 500 µg/ml. Enterobacter aerogenes laboratory 
isolate was inhibited maximally by KUITT 15, KUITT 20, KUITT 13, KUITT 21 
(Graph No. 12) and KUITT 22 at the dilution 62.5 µg/ml. At 125 µg/ml, 
compounds such as KUITT 3, KUITT 6, KUITT 7, KUITT 15 inhibited organisms. 
KUITT 8 (Graph No.28), KUITT 9, KUITT 11 (Graph No.30) exhibited 
antimicrobial activity at 250 µg/ml.  While, KUITT 4, KUITT 5, KUITT 10(Graph 
No.29), KUITT 12, KUITT 18 and KUITT 19 inhibited at 500 µg/ml. 
 
Proteus vulgaris laboratory culture was sensitive to action of KUITT 1, KUITT 2, 
KUITT 13, KUITT 14(Graph No.33), KUITT 16 (Graph No.35), KUITT 17(Graph 
No.36), KUITT 19, KUITT 20, KUITT 21, KUITT 22, as they showed MIC of 62.5 
µg/ml. KUITT 6, KUITT 7 exhibited antimicrobial activity at 125 µg/ml. KUITT 3, 
and KUITT 15 could act as bactericidal at 250 µg/ml.  Whereas, other compounds 
being poor in antimicrobial activity like KUITT 4, KUITT 5, KUITT 8, KUITT 9, 
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KUITT 10, KUITT 12, KUITT 17, KUITT 18, exhibited MIC at 500 µg/ml. Proteus 
vulgaris clinical isolate had more or less similar type of sensitivity like lab culture 
for KUITT series. MIC was noted at 125 µg/ml in KUITT 3; 250 µg/ml in KUITT 8 
,KUITT 9 and KUITT 11 and 125 µg/ml in KUITT 15.  Salmonella paratyphi B 
laboratory culture appeared to be resistant to majority of KUITT compounds. At 
500 µg/ml, some compounds showed bacteriocidal effects i.e. KUITT 4, KUITT 5, 
KUITT 8, KUITT 9, KUITT 10, KUITT 18, and KUITT 17 had 250 µg/ml as its MIC. 
The MIC for KUITT 1, KUITT 2, KUITT 16, KUITT 19, KUITT 20(Graph No.37), 
KUITT 21(Graph No.38), and KUITT 22(Graph No.39) was 62.5 µg/ml. 
Comparatively, Salmonella paratyphi B clinical isolate proved to be more 
sensitive to the action of this series.  KUITT 3, KUITT 4, KUITT 5, KUITT 10, 
KUITT 13, KUITT 14, KUITT 18 showed MIC at 500 µg/ml. In case of KUITT 7, 
KUITT 8, KUITT 9, 250 µg/ml is inhibitory concentration for the organisms. KUITT 
1, KUITT 2, KUITT 10, KUITT 12, KUITT 15 KUITT 16, KUITT 17, KUITT 20, 
KUITT 21, KUITT 22 gave antimicrobial activity at 62.5 µg/ml whereas, KUITT 6 
inhibited organisms at 125 µg/ml. 
 
Mixed type of response was observed in case of Pseudomonas aeruginosa 
ATCC 27853. Whereas KUITT 4, KUITT 5, KUITT 8 KUITT 9, KUITT 19, KUITT 
1, KUITT 12, KUITT 14, KUITT 18 have bactericidal effect at 500 µg/ml and then 
after organisms remained unaffected. KUITT 13 gave MIC of 250 µg/ml.For 
KUITT 1, KUITT 2, KUITT 3, KUITT 6, KUITT 15, MIC was 125 µg/ml. 
Compounds inhibited organisms at 125 µg/ml for KUITT 1, KUITT 2, KUITT 3, 
KUITT 6, and KUITT 15. However, for KUITT 10, KUITT 17, KUITT 19, KUITT 22 
MIC was 62.5 µg/ml.  Remarkable inhibition of Pseudomonas aeruginosa ATCC 
27853 was observed in case of KUITT 20 and KUITT 21 i.e. at 31.2 µg/ml. 
 
Slight variation was observed in case of Pseudomonas aeruginosa laboratory 
culture for responses to KUITT series.  It was more resistant than Pseudomonas 
aeruginosa ATCC 27853 i.e. 1000 µg/ml for KUITT 4, 500 µg/ml in KUITT 10, 
1000 µg/ml for  KUITT 13, 500 µg/ml for KUITT 15, 250 µg/ml for KUITT 17 and 
KUITT 19. Staphylococcus albus clinical isolate was inhibited by KUITT 3, 
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KUITT 4, KUITT 6, KUITT 7, KUITT 14, and KUITT 17 at 1000 µg/ml. The 
compounds like KUITT 5, KUITT 8, KUITT 9, KUITT 11, KUITT 18 exhibited MIC 
at 500 µg/ml. KUITT 15 showed bactericidal effect at 250 µg/ml. KUITT 12 and 
KUITT 19 were antimicrobial at 125 µg/ml. KUITT 1, KUITT 2, KUITT 10, KUITT 
12 inhibited at 62.5 µg/ml. KUITT 16, KUITT 20, KUITT 21 and KUITT 22 were 
very effective as they displayed MIC at 31.2 µg/ml. 
 
Similar type of sensitivity was seen in Staphylococcus aureus ATCC 25923 for 
KUITT series, KUITT 18, KUITT 8, KUITT 9. It was more resistant than 
Pseudomonas aeruginosa ATCC 27853 with an MIC of 250 µg/ml. Different 
pattern of sensitivity was seen in case of KUITT 11; MIC was 62.5 µg/ml, for 
KUITT 15 MIC was 125 µg/ml for KUITT 17, while MIC was 62.5 µg/ml, for KUITT 
19 MIC, 62.5 µg/ml, KUITT 20; MIC 62.5 µg/ml, KUITT 21; MIC 62.5 µg/ml. 
 
Similar pattern of sensitivity for KUITT series as observed in Gram Positive cocci. 
Klebshiella pneumoniae clinical isolate 1 was not at all inhibited by KUITT 12 at 
500 µg/ml.  KUITT 1, KUITT 8, KUITT 9 inhibited organisms at 250 µg/ml. In case 
of KUITT 3, KUITT 15, KUITT 16, the MIC was 500 µg/ml. KUITT 6, KUITT 12, 
KUITT 16 gave MIC at 250 µg/ml only. KUITT 10, KUITT 11, KUITT 13, KUITT 
14, KUITT 17, KUITT 19, KUITT 20, KUITT 21, KUITT 22 exhibited their effect on 
organisms up to 62.5 µg/ml. 
 
Bacillus subtilis ATCC 6633   did not give any sign of sensitivity for KUITT 1 and 
KUITT 15.  In case of KUITT 5, KUITT 7, KUITT 9, KUITT 17, KUITT 18, KUITT 
19, the MIC was 500 µg/ml. KUITT 6, KUITT 12, KUITT 16 could give bactericidal 
effect at 250 µg/ml.  KUITT14, KUITT21, KUITT 22 exhibited their effect on 
organisms up to 62.5 µg/ml. Only one compound, KUITT 20 gave antimicrobial 
action in higher dilution i.e. 31.2 µg/ml. Several compounds like KUITT 3, KUITT 
11, KUITT 13, KUITT 14, KUITT 20, KUITT 21 and KUITT 22 exhibited 
antimicrobial action on Klebshiella pneumoniae clinical isolate 2  at high dilution 
i.e. 62.5 µg/ml. 
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Enumeration of bacteria for KUITT 16 showed that except a few cultures, all 
could grow at 15.6 µg/ml. Salmonella paratyphi B lab culture and Pseudomonas 
aeruginosa ATCC 27853 have increase in bacterial numbers from 62.5 µg/ml 
dilutions (Graphs 16A, 16B and 16C). In case of KUITT 21, almost all cultures, 
appeared to produce cfu/ml from 31.2 µg/ml. However, Proteus vulgaris clinical 
isolate Pseudomonas aeruginosa ATCC 27853 and Staphylococcus albus clinical 
isolate could not grow in 31.2 µg/ml (Graphs 17A, 17B and 17C).  
 
Overall, antimicrobial action in KUITT series revealed that Staphylococcus albus 
clinical isolate and Bacillus subtilis ATCC 6633 were sensitive for several 
compounds of the series as they showed sensitivity up to 31.2 µg/ml 
concentrations (Table 4E (a) and 4E (b)). 
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Graph No.23-Effect of KUITT 1 on Growth of 
Micro organisms
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Graph No.24-Effect of KUITT 2 on Growth of 
Micro organisms
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Graph No.25-Effect of KUITT 3 on Growth of 
Micro organisms
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Graph No.26-Effect of KUITT 6 on Growth of 
Micro organisms
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Graph No. 27-Effect of KUITT 7 on Growth of 
Micro organisms
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Graph No.28-Effect of KUI TT 8 on Growth of 
Micro organisms
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Graph No.29-Effect of KUITT 10 on Growth of 
Micro organisms
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Graph No.30-Effect of KUITT 11 on Growth of 
Micro organisms
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Graph No.31-Effect of KUITT 12 on Growth of 
Micro organisms
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Graph No.32-Effect of KUITT 13 on Growth of 
Micro organisms
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Graph No.33-Effect of KUITT 14 on Growth of 
Micro organisms
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Graph No.34-Effect of KUITT 15 on Growth of 
Micro organisms
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Graph No.35-Effect of KUITT 16 on Growth of 
Micro organisms
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Graph No.36-Effect of KU1TT 17 on Growth 
of Micro organisms
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Graph No. 37-Effect of KUI TT 20 on Growth 
of Micro organisms
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Graph No.38-Effect of KUITT 21 on Growth of 
Micro organisms
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Graph No.39-Effect of KUI TT 22 on Growth of 
Micro organisms
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Graph No. 16B : Effect of KUITT16 on growth of organisms
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Graph No. 16A : Effect of KUITT 16 on growth of tested 
bacterial cultures
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Graph No. 16C : Effect of KUITT16 on growth of 
organisms
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Graph No. 17B : Effect of KUITT 21 on growth of organisms
0
2
4
6
8
0 15.1 31.2 62.5 125 250 500 1000
Concentration of KUITT 21 (ug/ml)N
o
.
 
o
f
 
c
e
l
l
s
 
X
 
1
0
5
Salmonella paratyphi B
Salmonella paratyphi B*
Pseudomonas aeruginosa ATCC 27853
Pseudomonas aeruginosa
Klebshilla pneumoniae*1
Klebshilla pneumoniae*2
Graph No. 17C : Effect of KUITT21 on growth of organisms
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Graph No. 17A : Effect of KUITT 21 on growth of 
tested bacterial cultures
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Figure1 (A) Stock solutions of KUITT 
series 
 
 
 
 
 
 
Figure1 (B) Final screening of 
KUITT 9  
 
 
 
 
 
 Figure1 (C) Primary and secondary 
screening of KUITT 9 
 
 
 
 
 
 
Primary & secondary 
Screening 
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Antibacterial action of KUPO SERIES  
Total number of compounds investigated in KUPO series was 16. Out of which 
several compounds exhibited similar pattern of inhibition for all bacteria. KUPO 2 
showed MIC of 500 µg/ml. KUPO 4 showed MIC of 500 μg/ml; while for KUPO 8 
the MIC was 250 μg/ml for all organisms. In case of KUPO 7, all organisms were 
inhibited at 31.2 µg/ml.  Whereas, for in case of KUPO 14 almost all organisms 
showed sensitivity at a single dilution 62.5 µg/ml. 
 
KUPO 1 inhibited organisms like Salmonella paratyphi B, Pseudomonas 
aeruginosa cultures, Staphylococcus albus clinical isolate, Staphylococcus 
aureus ATCC 25922, Staphylococcus citrus laboratory culture, Enterobacter 
aerogenes lab culture Proteus vulgaris lab culture (Graph No.40). At 250 µg/ml 
Escherichia coli ATCC 25922, Escherichia coli clinical isolate Klebshiella 
Pneumoniae cultures and Bacillus subtilis ATCC 6633.  However, some cultures 
like Escherichia coli lab culture, Proteus vulgaris clinical isolate, Staphylococcus 
citrus clinical isolate were inhibited at 500 µg/ml (Table 4F). 
 
Enumeration from KUPO 1 plates indicated that there was a great variability in 
growth among Gram Negative bacteria. Escherichia coli ATCC 25922 and 
Escherichia coli clinical isolate have low cell count at 125 µg/ml, which gradually 
increased with higher dilutions. Whereas, Escherichia coli lab culture and Proteus 
vulgaris clinical isolate grew at 500 µg/ml. Enterobacter aerogenes lab culture 
and Proteus valgaris Clinical isolate had enhanced growth at 62.5 µg/ml (Graph 
No. 18A). Except Klebshiella pneumoniae cultures, all Gram Negative cultures 
resulted in growth at 62.5 µg/ml (Graph No. 18B). For Staphylococci similar result 
was found except Staphylococcus citrus with cell count observed at 250 µg/ml. In 
Bacillus subtilis ATCC 6633 less bacterial count at 125 µg/ml was observed 
(Graph No.18C). 
 
KUPO 3 inhibited most of the Gram Negative rods; Escherichia coli cultures, 
Enterobacter aerogenes lab culture, Proteus vulgaris cultures and Salmonella 
paratyphi B cultures at 15.6 µg/ml. Pseudomonas aeruginosa, all staphylococci, 
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Klebshiella pneumoniae and Bacillus subtilis ATCC 6633  were inhibited at 500 
µg/ml (Graph No.41).  
 
 KUPO 5 expressed its antimicrobial activity at 500 µg/ml. Escherichia coli lab 
culture, Escherichia coli clinical isolate, Enterobacter aerogenes, cultures of 
Salmonella paratyphi B, Pseudomonas aeruginosa lab culture, Staphylococcus 
albus clinical isolate, Staphylococcus aureus ATCC 25923, Staphylococcus citrus 
lab culture were inhibited at 250 µg/ml. Most of the Gram Negative rods were 
inhibited at 250 µg/ml of KUPO 6 except Pseudomonas aeruginosa lab culture. 
Klebshiella pneumoniae clinical isolate 2 and Bacillus subtilis ATCC 6633 
showed sensitivity at 250 µg/ml, whereas, all Gram Positive cocci, Pseudomonas 
aeruginosa lab culture were inhibited at 125 µg/ml (Graph No.42). KUPO 7 
exhibited MICs for all cultures at 31.2 µg/ml (Graph No.43). 
 
 KUPO 9 gave inhibition of all Gram Negative rods at 250 µg/ml, whereas all 
Gram Positive cocci were killed at 125 µg/ml (Graph No.44). 
 
 With KUPO 10, except a few, all cultures were inhibited at 500 µg/ml. 
Escherichia coli cultures, Enterobacter aerogenes lab culture, Proteus vulgaris 
lab culture were inhibited at 15.6 µg/ml  or 31.2 µg/ml (Graph No.45).  Moderate 
increase in growth at 15.2 µg/ml in Escherichia coli lab culture, Enterobacter 
aerogenes lab culture and others did not grow. Proteus vulgaris clinical isolate 
gave low bacterial count with 250 µg/ml (Graph No. 19A). All the cultures grew at 
250 µg/ml (Graph No. 19B). Similar pattern of growth was found in all Gram 
Positive ones bacteria (Graph No.19C). 
 
KUPO 11 inhibited Salmonella paratyphi B clinical isolate, cultures of 
Pseudomonas aeruginosa, Gram Positive cocci, Klebshiella pneumoniae cultures 
and Bacillus subtilis ATCC 6633 at 125 µg/ml. Whereas all Escherichia coli 
cultures, Enterobacter aerogenes lab culture, cultures of Proteus vulgaris, 
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Salmonella paratyphi B lab culture were sensitive up to 15.6 µg/ml. (Graph 
No.46). 
 
Over all picture of KUPO 12 says that it has affected actively Gram Negative 
bacteria except Salmonella paratyphi B clinical isolate at 15.6 µg/ml .Other 
cultures were found to be inhibited at of 125 µg/ml   (Graph No.47). 
  
In case of KUPO 13, Escherichia coli (Graph No.48) cultures showed high 
sensitivity, expressing by complete inhibition at 15.6 µg/ml. Rest of the bacteria 
were affected at 250 µg/ml. Most of the cultures were inhibited at MIC of 62.5 
µg/ml by KUPO 14 (Graph No.49). KUPO 15 gave MIC for cultures either at 62.5 
µg/ml or 125 µg/ml (Graph No.50). All Gram Negative rods were sensitive at MIC 
of 62.5 µg/ml by KUPO 16.  Whereas Gram Positive cocci and rods were 
inhibited at 125 µg/ml (Graph No.51).  
 
 At 250 µg/ml Escherichia coli ATCC 25922, Escherichia coli clinical isolate 
Klebshiella Pneumoniae cultures and Bacillus subtilis ATCC 6633.  However, 
some cultures like Escherichia coli lab culture, Proteus vulgaris clinical isolate, 
Staphylococcus citrus clinical isolate were inhibited at 500 µg/ml.These 
compounds were more active for Gram Negative bacteria. 
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Graph No.40-Effect of KUPO 1 on Growth of 
Micro organisms
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Graph No.41-Effect of KUPO 3 on Growth of 
Micro organisms
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Graph No.42-Effect of KUPO 6 on Growth of 
Micro organisms
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Graph No.43-Effect of KUPO 7 on Growth of 
Micro organisms
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Graph No.44-Effect of KUPO 9 on Growth of 
Micro organisms
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Graph No.45-Effect of KUPO 10 on Growth of 
Micro organisms
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Graph No.46-Effect of KUPO 11 on Growth of 
Micro organisms
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Graph No.47-Effect of KUPO 12 on Growth of 
Micro organisms
0
1
2
3
4
5
6
1000
μg/mL
500
μg/mL
250
μg/mL
125
μg/mL
75
μg/mL
37.5
μg/mL
18.75
μg/mL
Concentration of Organic Compound 
(ug/mL)
D
e
g
re
e
 o
f 
In
h
ib
iti
o
n
 
o
f 
M
ic
ro
b
ia
l G
ro
w
th
Graph No.48-Effect of KUPO 13 on Growth of 
Micro organisms
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Graph No.49-Effect of KUPO 14 on Growth of 
Micro organisms
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Graph No.50-Effect of KUPO 15 on Growth of 
Micro organisms
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Graph No.51-Effect of KUPO 16 on Growth of 
Micro organisms
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Graph No.18A : Effect of KUPO 1 on growth of tested 
bacterial cultures
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Graph No. 18B : Effect of KUPO 1 on growth of 
organisms
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Graph No. 18C : Effect of KUPO 1 on growth of 
organisms
0
5
10
15
20
0 15.1 31.2 62.5 125 250 500 1000
Concentration of KUPO1(ug/ml)
N
o
. 
o
f 
c
e
ll
s
 X
 
1
0
5
Staphylococcus albus*
Staphylococcus aureus ATCC 25923
Staphylococcus citrus
Staphylococcus citrus*
Bacillus sublitis ATCC 6633
Graph No. 19A : Effect of KUPO 10 on growth of tested 
bacterial cultures
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Graph No. 19B : Effect of KUPO 10 on growth of 
organisms
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Graph No. 19C : Effect of KUP10 on growth of 
organisms
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Antibacterial action of KUQP SERIES 
Total 15 compounds were analyzed in this category. They were KUQP 1-9 
(Graph No. 55), 10, 11,12,13,15, and 16.  The effective minimum dilution of 
antimicrobial action of all compounds on cultures was 500 µg/ml and maximum 
level of inhibition was observed at 31.2 µg/ml. 
 
 KUQP 1 expressed antimicrobial activity giving MIC for all bacteria at 500 µg/ml 
except Staphylococcus albus clinical isolate and Klebshiella pneumoniae clinical 
isolate 2 .All Escherichia coli cultures, Enterobacter aerogenes lab culture and 
Proteus vulgaris lab culture were inhibited at 250 µg/ml, whereas rest of all 
cultures stopped growing at 500 µg/ml only. For Salmonella paratyphi B cultures 
and Pseudomonas aeruginosa ATCC 27853, KUQP 3 expressed bactericidal 
effect at 250 µg/ml, whereas all other cultures were affected at 500 µg/ml. Gram 
Positive cocci except Staphylococcus citrus clinical isolate were inhibited by 
KUQP 4 at MIC of 125 µg/ml. However all other cultures showed no growth at 
500 µg/ml (Graph No. 52). KUQP 5 exhibited bactericidal effect on all cultures at 
250 µg/ml only. 
 
Pseudomonas aeruginosa cultures were inhibited at high dilution of secondary 
screening by KUQP 6, i.e. 31.2 µg/ml, while other organisms were inhibited with 
MIC at 500 or 250 µg/ml (Graph No. 53). Similar growth at 250 µg/ml was 
observed in all Gram Negative bacteria except, Enterobacter aerogenes 
laboratory culture (Graph No.  20A). Salmonella paratyphi B cultures inhibited the 
growth at 250 µg/ml, cultures of Pseudomonas aeruginosa from 15.2 µg/ml. 
Klebshiella pneumoniae clinical isolates were inhibited by 62.5 µg/ml (Graph No.  
20B) and Staphylococcus albus clinical isolate and Bacillus subtilis ATCC 6633 
produced cells from 125 µg/ml. The rest of the three cultures yielded colonies 
from 250 µg/ml (Graph No.  20C).  
 
KUQP 7 had two types of effects; for certain cultures, the MIC was 250 µg/ml, 
while for others it was 125 µg/ml (Graph No. 54). KUQP 8 displayed MIC at 250 
µg/ml or 500 µg/ml or all cultures. KUQP 11 had MIC at 250 µg/ml for Salmonella 
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paratyphi B clinical isolate, cultures of Pseudomonas aeruginosa and 
Staphylococcus albus clinical isolate. For other organisms, KUQP 11 displayed 
MIC at 500 µg/ml. 
 
All Escherichia coli cultures, Enterobacter aerogenes lab culture, Proteus vulgaris 
lab culture were found sensitive at 62.5 µg/ml of KUQP 12 (Graph No. 56). For 
KUQP 12, first four cultures had bacterial counts from 31.2 µg/ml and Proteus 
vulgaris clinical isolate displayed the same effect from 250 µg/ml (Graph No. 
21A). All cultures expressed growth from 250 µg/ml (Graph No.21B).Similar 
response was found in all Gram Positive ones (Graph No.  21C). 
 
Escherichia coli ATCC 25922, Proteus vulgaris clinical isolate, Salmonella 
paratyphi B clinical isolate and Pseudomonas aeruginosa ATCC 27853 were 
inhibited by KUQP 13 at 125 µg/ml. Rest of all cultures were inhibited at MIC of 
250 µg/ml (Graph No. 57). KUQP 15 expressed MIC at 125 µg/ml (Graph No. 
58).KUQP 16 inhibited all cultures at 250 µg/ml. The over all impact of this series 
on bacteria is summarized (Table 4G). 
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Graph No.52-Effect of KUQP 4 on Growth of 
Micro organisms
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Graph No.53-Effect of KUQP 6 on Growth of 
Micro organisms
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Graph No.54-Effect of KUQP 7 on Growth of 
Micro organisms
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Graph No.55-Effect of KUQP 9 on Growth of 
Micro organisms
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Graph No.56-Effect of KUQP 12 on Growth of 
Micro organisms
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Graph No.57-Effect of KUQP 13 on Growth of 
Micro organisms
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Graph No.58-Effect of KUQP 15 on 
Growth of Micro organisms
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Graph No. 20A : Effect of KUQP 6 on growth of tested 
bacterial cultures
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Graph No. 21A : Effect of KUQP 12 on growth of tested 
bacterial cultures
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Graph No. 20B : Effect of KUQP 6 on growth of organisms
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Graph No. 21B : Effect of KUQP 12 on growth of 
organisms
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Graph No. 20C : Effect of KUQP 6 on growth of 
organisms
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Graph No. 21C : Effect of KUQP 12 on growth of 
organisms
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Antibacterial action of ASM SERIES (i) 
The number of compounds studied among ASM series was twenty two;  ASM 5, 
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26. ASM 5, 
ASM 6, ASM 7 gave inhibition at 500 µg/ml for all microbes. Other compounds 
exhibited variety of antimicrobial action on microbes.  
  
ASM 8 has inhibited Proteus vulgaris laboratory culture, Staphylococcus aureus 
ATCC 25923, Staphylococcus albus clinical isolate, Staphylococcus citrus 
laboratory culture and Bacillus subtilis ATCC 6633 at highest dilution of 
secondary screening i.e. 15.6 µg/ml. However, for Escherichia coli ATCC 25922, 
Escherichia coli laboratory culture, Salmonella paratyphi B clinical isolate ASM 8 
showed MIC at 500 µg/ml (Graph No. 59),(Table 4H(a)). 
 
For ASM 8, Escherichia coli ATCC 25922, and Escherichia coli laboratory culture 
were able to grow with 250 µg/ml. Cultures of Proteus vulgaris were poor in 
growth. Escherichia coli clinical isolate and Enterobacter aerogenes laboratory 
culture gave moderate increase in cfu/ml from 500 µg/ml (Graph No.10A). Being 
sensitive, Salmonella paratyphi B clinical isolate exhibited cell numbers from 250 
µg/ml (Graph No. 10B). Only one single culture, Klebshiella pneumoniae clinical 
isolate 1 could grow, but with decreased cell counts as the dilution increased. 
Rest of the bacteria were inhibited to grow (Graph No. 10C). 
 
For ASM 9 several organisms responded only at 1000 μg/ml i.e. Escherichia coli 
ATCC 25922, Escherichia coli laboratory culture, Escherichia coli clinical isolate, 
Proteus vulgaris laboratory culture, Salmonella paratyphi B clinical isolate, 
Pseudomonas aeruginosa ATCC 27853, Pseudomonas aeruginosa laboratory 
culture, Staphylococcus albus clinical isolate. The concentration at 125 µg/ml was 
inhibitory for Proteus vulgaris clinical isolate. Enterobacter aerogenes laboratory 
culture, Staphylococcus aureus ATCC 25923, Staphylococcus citrus laboratory 
culture, Staphylococcus citrus clinical isolate, Klebshiella pneumoniae clinical 
isolates 1 and 2, Bacillus subtilis ATCC 6633 were sensitive up to the 62.5 µg/ml 
of ASM 9 (Graph No. 60). However, ASM 10 inhibited all organisms with a single 
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dilution plate of 125 µg/ml (Graph No. 61). ASM 11 has less effect on Gram 
Negative bacteria with MIC at 500 µg/ml. For Klebshiella pneumoniae clinical 
isolate 1 and 2, the inhibitory concentration was 500 µg/ml, whereas for Bacillus 
subtilis, it was 1000 µg/ml (Graph No. 62). 
 
ASM 13 had less effect on growth of Gram Positive as well as Gram Negative 
bacteria. Escherichia coli, Enterobacter aerogenes, Salmonella paratyphi B and 
Pseudomonas aeruginosa, Klebshiella pneumoniae clinical isolate 1 and 2 
exhibited sensitivity at 500 μg/ml only. Whereas in case of Proteus vulgaris and 
all Gram Positive cocci, they were inhibited at 250 μg/ml. 
 
Quite surprising results were obtained in case of ASM 14, as it could not inhibit 
the organisms at even 1000 µg/ml, especially Gram Negative bacteria, except 
cultures of Proteus vulgaris which could be inhibited at 1000 µg/ml.  
Staphylococcus albus clinical isolate, Staphylococcus aureus ATCC 25923, 
Bacillus subtilis ATCC 6633, and Klebshiella pneumoniae clinical isolate 1 and 2 
exhibited no growth at 500 µg/ml. In case of Staphylococcus citrus laboratory 
culture, Staphylococcus citrus clinical isolate ASM 14 gave MIC at 250 µg/ml. 
 
Escherichia coli ATCC 25922, Escherichia coli Lab culture, Escherichia coli 
clinical isolate and Enterobacter aerogenes being less sensitive towards action of 
ASM 15, could be inhibited only at 1000 µg/ml. Proteus vulgaris, Salmonella 
paratyphi B, Pseudomonas aeruginosa and Klebshiella pneumoniae ASM 15 
exhibited 250 µg/ml as MIC. For Gram Positive cocci like Staphylococcus albus 
clinical isolate, Staphylococcus aureus ATCC 25923 and Staphylococcus citrus 
cultures, ASM 15 proved to be inhibitory at 62.5 µg/ml (Graph No. 63). 
 
ASM 16 showed inhibition of all Gram Negative bacteria at 62.5 µg/ml, whereas 
for Gram Negative bacteria, the MIC of 125 µg/ml was evident. For clinical 
isolates 1 and 2 of Klebshiella pneumoniae, the inhibitory concentration was 250 
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µg/ml   and most resistant bacteria for ASM 16 was Bacillus subtilis ATCC 6633. 
At higher dilutions it remained unaffected (Graph No. 64). 
 
 ASM 18 being the most effective antimicrobial compound among the ASM series 
gave remarkable inhibitions of microbes even at higher dilutions. The MIC was 
15.6 µg/ml for Escherichia coli clinical isolate, Proteus vulgaris clinical isolate, 
Pseudomonas aeruginosa lab culture, Staphylococcus citrus clinical isolate and  
Bacillus subtilis ATCC 6633 (Graph No. 65). Responses to ASM 18 vary greatly 
among all used cultures. Minimum amount of bacterial numbers was found in 
Escherichia coli ATCC 25922 from second dilution variable amount of cfu/ml 
were found from 62.5 µg/ml in Escherichia coli laboratory culture, Enterobacter 
aerogenes laboratory culture, Proteus vulgaris laboratory culture. Proteus 
vulgaris clinical isolate and Escherichia coli clinical isolate did not show any 
growth (Graph No. 11A).Salmonella paratyphi B clinical isolate, Pseudomonas 
aeruginosa ATCC 27853 and Klebshiella pneumoniae clinical isolate 1 yielded 
growth from 62.5 µg/ml. whereas Pseudomonas aeruginosa laboratory culture did 
not grow at all (Graph No. 11B). 
 
For Gram Positive rods and cocci, the effect of ASM 18 was different. 
Staphylococcus albus clinical isolate, Staphylococcus aureus ATCC 25923 grew 
at 62.5 µg/ml. Much difference in Staphylococcus citrus laboratory culture and 
Staphylococcus albus clinical isolate was observed, the latter could not grow at 
all (Graph No. 11C). 
 
For Escherichia coli ATCC  25922, Salmonella paratyphi B laboratory culture, 
Staphylococcus citrus laboratory culture, Klebshiella pneumoniae clinical isolate 
2 were inhibited by 31.2 µg/ml. Whereas, Escherichia coli laboratory culture, 
Enterobacter aerogenes laboratory culture, Proteus vulgaris laboratory culture, 
Salmonella paratyphi B clinical isolate, Pseudomonas aeruginosa ATCC 27853, 
Staphylococcus albus clinical isolate, Staphylococcus aureus ATCC 25923, 
Klebshiella pneumoniae clinical isolate 1  were inhibited at 125 µg/ml  
concentration of ASM 18. 
 109 
 
ASM 19 gave MIC of 1000 µg/ml for Escherichia coli ATCC 25922, Escherichia 
coli laboratory culture, Bacillus subtilis ATCC 6633. For all Gram Positive cocci 
and Gram Negative rods like Pseudomonas aeruginosa and Klebshiella 
pneumoniae cultures ASM 19 has shown 500 µg/ml as its MIC.For several Gram 
Negative rods like Escherichia coli clinical isolate, Enterobacter aerogenes lab 
culture, cultures of Proteus vulgaris and Salmonella paratyphi B were sensitive at 
concentration of 250 µg/ml (Graph No. 66). 
 
 ASM 20 seemed to be effective for Gram Positive cocci and rods, 62.5 µg/ml 
concentration was observed as MIC for Escherichia coli ATCC 25922, Proteus 
vulgaris clinical isolate, Pseudomonas aeruginosa laboratory culture 
Staphylococcus albus clinical isolate, Staphylococcus aureus ATCC 25923, 
Staphylococcus citrus clinical isolate, Klebshiella pneumoniae clinical isolate 1 
and Bacillus subtilis ATCC 6633. The third high dilution (250 µg/ml) was 
observed to be detrimental for the growth of Enterobacter aerogenes laboratory 
culture and Pseudomonas aeruginosa ATCC 27853.Escherichia coli laboratory 
culture could not show any sensitivity for ASM 20 (Graph No. 67). 
 
ASM 21 was relatively effective on Gram Positive cocci than Gram Negative rods.  
A MIC of 1000 µg/ml was observed for Proteus vulgaris laboratory culture, 
Proteus vulgaris clinical isolates, Salmonella Paratyphi B laboratory culture, 
Salmonella Paratyphi B clinical isolate, Bacillus subtilis ATCC 6633 and 
Klebshiella pneumoniae clinical isolate 2.  It was noted that 500 µg/ml was the 
concentration inhibiting Enterobacter aerogenes laboratory culture, 
Pseudomonas aeruginosa and Klebshiella pneumoniae clinical isolate 1 (Graph 
No. 68), (Table 4H (b)). 
 
Antimicrobial action was observed against cultures like Escherichia coli clinical 
isolate, Staphylococcus citrus laboratory culture and Staphylococcus citrus 
clinical isolate at 250 µg/ml. The concentration inhibitory to Staphylococcus albus 
clinical isolate and Staphylococcus aureus ATCC 25923 was 125 µg/ml. 
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ASM 22 displayed variable responses in all cultures. Pseudomonas and 
Salmonella cultures, Bacillus subtilis ATCC 6633 were affected at 1000 µg/ml. 
For Escherichia coli ATCC 25922, Proteus cultures and Klebshiella pneumoniae 
clinical isolate 2, the MIC was at 500 µg/ml. Escherichia coli clinical isolate, 
Escherichia coli laboratory culture and Staphylococcus citrus clinical isolate were 
inhibited at  250 µg/ml.Whereas Gram Positive bacteria like Staphylococcus 
aureus ATCC 25923 Staphylococcus albus clinical isolate and Staphylococcus 
citrus laboratory culture were killed at 125 µg/ml (Graph No. 69). 
 
ASM 22 also gave moderate inhibition of all microbial cultures (Table 4H(b)).  
Salmonella paratyphi B laboratory cultures Salmonella paratyphi B Clinical isolate 
and Pseudomonas aeruginosa, Klebshiella pneumoniae clinical isolate 1 and 
Bacillus subtilis ATCC 6633.  ASM 23 also had variable effect of inhibition on 
microorganisms. Gram Negative Rods and Positive Rods were inhibited at 1000 
µg/ml, for example Proteus vulgaris, Salmonella paratyphi B, Bacillus subtilis 
ATCC 6633.  At 250 µg/ml, Escherichia coli laboratory culture, Escherichia coli 
Clinical isolate, Pseudomonas aeruginosa laboratory culture, Staphylococcus 
citrus laboratory culture, Staphylococcus citrus clinical isolate were inhibited. 
Staphylococcus albus and Staphylococcus aureus ATCC 25923 were inhibited at 
125 µg/ml of ASM 23 (Graph No. 70). In primary screening, at 1000 µg/ml, a few 
cultures were sensitive, such as Escherichia coli laboratory culture, Escherichia 
coli Clinical isolate, Salmonella paratyphi B cultures, Cultures of Klebshiella 
pneumoniae and Bacillus subtilis ATCC 6633.  
 
At 1000 µg/ml, a few cultures were sensitive like Escherichia coli laboratory 
culture, Escherichia coli clinical isolate, Salmonella paratyphi B, Klebshiella 
pneumoniae and Bacillus subtilis ATCC 6633. Some cultures were inhibited at 
500 µg/ml. The highest dilution of ASM 24 as antibacterial for Staphylococcus 
citrus cultures was 250 µg/ml. ASM 25 was effective for microbes and in most of 
the cases it has inhibited organisms at 62.5 µg/ml.  The microbes have been 
Enterobacter aerogenes laboratory culture, Proteus vulgaris cultures, Salmonella 
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paratyphi B, all Staphylococci, Klebshiella pneumoniae and Bacillus subtilis 
ATCC 6633.  However, all Escherichia coli cultures, Pseudomonas aeruginosa 
and Staphylococcus albus clinical isolate were inhibited at MIC of 500 µg/ml 
(Graph No. 71). 
 
 ASM 26 is particularly effective on the growth of Gram Positive cocci as all the 
cultures of Staphylococci were killed at 62.5 µg/ml. Similar finding was evident in 
case of Proteus vulgaris clinical isolate also (Graph No. 72).Rest of all cultures 
had growth only in the first plate during primary screening at 1000 µg/ml.  These 
cultures were Escherichia coli cultures, Enterobacter aerogenes, Proteus vulgaris 
laboratory culture, Salmonella paratyphi B culture, Pseudomonas aeruginosa 
ATCC 27853 and Klebshiella pneumoniae. 
Antibacterial action of ASM SERIES (ii) 
Except ASM 48 and ASM 49, all the ASM compounds generally inhibited at least 
at 1000 µg/ml.  Total numbers of compounds screened through were fifteen, 
starting from ASM 36 to ASM 50. Certain compounds exhibited similar type of 
action on all microbes. ASM 38 and ASM 34 inhibited all microbial cultures at 250 
µg/ml.  Whereas, compound ASM 35 and ASM 49, showed inhibitory effect at 
500 µg/ml (Table 4I (a) and 4I (b)). 
 
In case of ASM 30, Escherichia coli laboratory culture and Salmonella paratyphi 
B laboratory culture, where sensitivity was at 1000 µg/ml only.  Escherichia coli 
clinical isolate was inhibited at 500 µg/ml. Salmonella paratyphi B clinical isolate 
and Klebshiella pneumoniae clinical isolate 1 were inhibited at 250 µg/ml.  In 
case of Enterobacter aerogenes laboratory culture, Proteus vulgaris clinical 
isolate, Pseudomonas aeruginosa laboratory culture, the inhibitory effect was at 
125µg/ml (Graph No. 73). The inhibitory concentration of ASM 30 for Proteus 
vulgaris laboratory ATCC 27853 and Bacillus subtilis ATCC 6633 was 62.5µg/ml.                                                                                                                                                                                                  
At the same concentration, Staphylococcus albus clinical isolate, Staphylococcus 
aureus ATCC 25923, Staphylococcus citrus cultures were also affected (Figure-3 
(D)). 
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ASM 31 could work only at lower concentrations, for Klebshiella pneumoniae and 
Bacillus subtilis it was ineffective. For Gram Positive cocci, it gave MIC of 1000 
µg/ml. Except one Gram Negative culture, Proteus vulgaris clinical isolate, 
exhibited sensitivity to 1000 µg/ml. Rest of all microbial cultures were sensitive to 
500 µg/ml. ASM 32 could show effect on organisms in 500 µg/ml as minimum 
inhibitory concentration i.e.  Escherichia coli laboratory culture, Escherichia coli 
clinical isolate were sensitive to 500 µg/ml. Proteus vulgaris clinical isolate, 
Pseudomonas aeruginosa ATCC 27853, Pseudomonas aeruginosa laboratory 
culture were inhibited at 250 µg/ml. Escherichia coli ATCC 25922, Proteus 
vulgaris lab culture, Salmonella paratyphi B showed sensitivity at 125 µg/ml. It 
was same observation for Staphylococcus albus clinical isolate and Klebshiella 
pneumoniae clinical isolate 1.Highest dilution which proved inhibitory for 
Staphylococcus aureus ATCC 25923, Staphylococcus citrus clinical isolate and 
Bacillus subtilis ATCC 6633 was 62.5 µg/ml (Graph No. 74). 
Bacillus subtilis ATCC 6633 was inhibited at 250 µg/ml.  However, Enterobacter 
aerogenes lab culture, Proteus vulgaris cultures and Escherichia coli ATCC 
25922 were sensitive to 125 µg/ml. For Gram Positive cocci and Klebshiella 
pneumoniae clinical isolate 1 MIC was 31.2 µg/ml (Graph No. 75).ASM 36 is 
more effective on Gram Positive cocci than Gram Negative rods.  Gram Positive 
cocci - all cultures of staphylococci were inhibited at 62.5 µg/ml. For Bacillus 
subtilis ATCC 6633 MIC was 31.2 µg/ml.  ASM 36 exhibited antimicrobial action 
in cultures like Enterobacter aerogenes lab culture, proteus vulgaris lab culture, 
Salmonella paratyphi B lab culture and Pseudomonas aeruginosa cultures at 500 
µg/ml (Graph No. 76). 
 
Most of the microbial cultures are sensitive to 1000 µg/ml i.e. except 
Staphylococcus citrus cultures for ASM 37. 
 
ASM 40 proved very effective for Gram Positive organisms like Staphylococcus 
aureus ATCC 25923, Staphylococcus citrus laboratory culture, Bacillus subtilis 
ATCC 6633 and Klebshiella pneumoniae. Whereas, for other microbes its MIC 
was either 1000 µg/ml or 500 µg/ml (Graph No. 77). Variable responses to ASM 
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40 in case of quantity of bacterial growth. Escherichia coli lab culture and Proteus 
vulgaris lab culture gave moderate increase in growth from 250 µg/ml. 
Enterobacter aerogenes laboratory culture has same count at 500 µg/ml. Only 
limited growth was observed in Escherichia coli ATCC 25922 at 125 µg/ml 
(Graph No.  12A). Three types of expression were observed. Moderate increase 
in growth of Salmonella paratyphi B lab culture and Pseudomonas aeruginosa lab 
culture was evident at 500 µg/ml. Pseudomonas aeruginosa ATCC 27853 had 
low cell count  at 250 µg/ml. Klebshiella pneumoniae clinical isolate 1 gave 
minimum increase in cell numbers from 31.2 µg/ml, Klebshiella pneumoniae 
clinical isolate 2 ( Graph No. 12B). There were no bacterial cells observed in any 
of the culture (Graph No.12C). 
 
ASM 41 inhibited microbial cultures at almost 250 µg/ml.  Except two cultures 
Escherichia coli clinical isolate, Escherichia coli ATCC 25922 all were sensitive at 
125 µg/ml (Graph No. 78). Certain cultures did not show any effect with ASM 42, 
such as Klebshiella pneumoniae and Bacillus subtilis ATCC 6633.However, Rest 
of the Gram Positive and Negative, pathogen or nonpathogen were inhibited at 
1000 µg/ml only. 
 
For Gram Positive cocci and Rods, Proteus vulgaris cultures, Escherichia coli 
ATCC 25922 ASM 43 gave MIC at 62.5 µg/ml. Salmonella paratyphi B clinical 
isolate, Pseudomonas aeruginosa ATCC 27853 were killed at 125 µg/ml (Graph 
No. 79). However, Enterobacter aerogenes laboratory culture and Salmonella 
paratyphi B laboratory culture were sensitive to 500 µg/ml of ASM 43.   Whereas, 
Escherichia coli lab culture and Escherichia coli clinical isolate exhibited their 
response at 1000 µg/ml and gave no growth. In case of Staphylococcus citrus lab 
culture and Klebshiella pneumoniae clinical isolate 1, ASM 44 did show MIC of 
31.5 μg/ml (Graph No. 80).  
 
Proteus vulgaris lab culture was inhibited up to 250 µg/ml and Escherichia coli lab 
culture at 500 µg/ml. Pseudomonas aeruginosa showed sensitivity only at 1000 
µg/ml. Escherichia coli ATCC 25922 and Enterobacter aerogenes and 
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Salmonella paratyphi B were not inhibited at all by ASM 44. ASM 47 was 
effective for Escherichia coli cultures as well as for Gram Positive cocci, Proteus 
vulgaris lab culture as it gave MIC of 15.6 µg/ml (Graph No. 81). One single 
culture out of these did grow, Enterobacter aerogenes lab culture has moderate 
increase in cfu/ml from 250 µg/ml, and rest of the cultures could not grow (Graph 
No. 13A). Pseudomonas aeruginosa cultures gave moderate increase in cfu/ml 
from 500 µg/ml. From 250 µg/ml Salmonella paratyphi B. lab culture had 
moderate increase in bacterial numbers. Klebshiella pneumoniae clinical isolate 1 
did not grow (Graph No. 13B). There was no cell count observed at all in any 
culture (Graph No. 13C). 
 
ASM 48 was less effective on growth of microbes. Staphylococcus aureus ATCC 
25929, Staphylococcus citrus laboratory culture were sensitive at 500 µg/ml. The 
concentration of ASM 50 to prove inhibitory for microbes was 500 µg/ml in most 
of the cultures except a few. Staphylococcus aureus ATCC 25923, and 
Staphylococcus citrus laboratory culture were inhibited at 250 µg/ml. It had no 
effect on cultures of Klebshiella pneumoniae. 
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Graph No.59-Effect of ASM-8 on Growth of 
Micro organisms
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Graph No. 60-Effect of ASM 9 on Growth of 
Micro organisms
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Graph No. 61-Effect of ASM 10 on Growth of 
Micro organisms
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Graph No. 62-Effect of ASM 11 on Growth of 
Micro organisms
0
1
2
3
4
5
6
1000
μg/mL
500
μg/mL
250
μg/mL
125
μg/mL
75
μg/mL
37.5
μg/mL
18.75
μg/mL
Concentration of Organic Compound (ug/mL)
D
e
g
re
e
 o
f 
In
h
ib
it
io
n
 o
f 
M
ic
ro
b
ia
l 
G
ro
w
th
Graph No.63-Effect of ASM 15 on Growth of 
Micro organisms
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Graph No. 64-Effect of ASM 16 on Growth of 
Micro organisms
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Graph No. 65-Effect of ASM 18 on Growth of 
Micro organisms
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Graph No. 66-Effect of ASM 19 on Growth of 
Micro organisms
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Graph No. 68-Effect of ASM 21 on Growth of 
Micro organisms
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Graph No.67-Effect of ASM 20 on Growth of 
Micro organisms
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Graph No. 69-Effect of ASM 22 on Growth of 
Micro organisms
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Graph No.70-Effect of ASM 23 on Growth of 
Micro organisms
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Graph No. 71-Effect of ASM 25 on Growth of 
Micro organisms
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Graph No.72-Effect of ASM 26 on Growth of 
Micro organisms
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Graph No.73-Effect of ASM 30 on Growth of 
Micro organisms
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Graph No.74-Effect of ASM 32 on Growth of 
Micro organisms
0
1
2
3
4
5
6
1000
μg/mL
500
μg/mL
250
μg/mL
125
μg/mL
75
μg/mL
37.5
μg/mL
18.75
μg/mL
Concentration of Organic Compound 
(ug/mL)
D
e
g
re
e
 o
f 
In
h
ib
it
io
n
 
o
f 
M
ic
ro
b
ia
l 
G
ro
w
th
Graph No.75-Effect of ASM 33 on Growth of 
Micro organisms
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Graph No.76-Effect of ASM 36 on Growth of 
Micro organisms
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Graph No.77-Effect of ASM 40 on Growth of 
Micro organisms
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Graph No. 78-Effect of ASM 41 on Growth of 
Micro organisms
0
1
2
3
4
5
6
1000
μg/mL
500
μg/mL
250
μg/mL
125
μg/mL
75
μg/mL
37.5
μg/mL
18.75
μg/mL
Concentration of Organic Compound (ug/mL)
D
e
g
re
e
 o
f 
In
h
ib
iti
o
n
 
o
f 
M
ic
ro
b
ia
l G
ro
w
th
Graph No.79-Effect of ASM 43 on Growth of 
Micro organisms
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Graph No.80-Effect of ASM 44 on Growth of 
Micro organisms
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Graph No.81-Effect of ASM 47 on Growth of 
Micro organisms
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Graph No. 10A : Effect of ASM 8 on growth of 
tested bacterial cultures
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Graph No. 10B : Effect of ASM 8 on growth of 
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Graph No. 10C : Effect of ASM 8 on growth of 
organisms
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Graph No. 11A : Effect of ASM 18 on growth of 
tested bacterial cultures
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Graph No. 11B : Effect of ASM18 on growth of 
organisms
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Graph No. 11C : Effect of ASM 18 on growth of 
organisms
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Graph No. 12C : Effect of ASM 40 on growth 
of organisms
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Graph No. 13C : Effect of ASM 47on growth of 
organisms
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Graph No. 12A : Effect of ASM 40 on growth of tested 
bacterial cultures
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Graph No. 12B : Effect of ASM40 on growth of 
organisms
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Graph No. 13A : Effect of ASM 47 on growth of tested 
bacterial cultures
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Graph No. 13B : Effect of ASM 47 on growth of 
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Antibacterial action of MSB SERIES  
In MSB series total number of compounds was 16.  Out of which the most 
effective antibacterial was MSB 3.  The MSB 3 has inhibited all cultures at 62.5 
µg/ml.  
 
MSB 1 was potent antibacterial for some cultures Staphylococcus aureus ATCC 
25923, Staphylococcus citrus laboratory culture i.e. 15.6 µg/ml (Graph No. 82)   It 
was similarly found in case of Escherichia coli laboratory culture as well as in 
Enterobacter aerogenes laboratory culture. Whereas, Pseudomonas aeruginosa 
ATCC 27853 was sensitive at 500 µg/ml. Escherichia coli lab culture and 
Enterobacter aerogenes lab culture did not grow in MSB 1(Graph No.  14A). 
Salmonella paratyphi B lab culture and Pseudomonas aeruginosa laboratory 
culture grown in 1000 µg/ml gave increased cfu/ml then after. Klebshiella 
pneumoniae clinical isolate 1 had linear increase in cfu/ml from 1000 µg/ml of 
MSB 1. Pseudomonas aeruginosa ATCC 27853 gave moderate increase in 
cfu/ml at 250 µg/ml (graph Graph No.  14B). There was no growth observed at all 
in any culture (graph Graph No. 14C). 
 
MSB 2 proved to be effective for Proteus vulgaris cultures, Staphylococcus citrus 
lab culture, Staphylococcus citrus clinical isolate and Klebshiella pneumoniae 
clinical isolate 1 as it resulted in MIC at 62.5 µg/ml.  Pseudomonas aeruginosa 
laboratory culture was sensitive up to 250 µg/ml. Others, such as Staphylococcus 
albus clinical isolate, Staphylococcus aureus ATCC 25923, Salmonella paratyphi 
B cultures and Pseudomonas aeruginosa ATCC 27853 were inhibited at 500 
µg/ml (Graph No. 83). In case of MSB 3, all cultures proved sensitive and were 
inhibited at 62.5 µg/ml. However, Staphylococcus aureus ATCC 25923 was 
inhibited at 31.2µg/ml (Graph No. 84).  
 
MSB 4 inhibited all bacterial cultures at 1000 µg/ml. MSB 5 inhibited strongly at 
250 µg/ml, except a few cases like Salmonella paratyphi B. lab culture, 
Pseudomonas aeruginosa ATCC 27853, Pseudomonas aeruginosa lab culture 
and Staphylococcus aureus ATCC 25923 showing MIC of 125 µg/ml . Bacillus 
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subtilis ATCC 6633 was resistant as it inhibited only at 1000 µg/ml (Graph No. 
85).All the bacterial cultures were inhibited in similar manner by MSB 6, with MIC 
at 125 µg/ml (Graph No. 86).Most of the Gram Negative Rods were not affected 
by MSB 7, except Proteus vulgaris cultures.  All Gram Positive cocci were 
inhibited at higher concentration of MSB 7 i.e. at 62.5 µg/ml, whereas Klebshiella 
pneumoniae cultures remained unaffected (Graph No. 87).  
   
MSB 8 was not effective on Enterobacter aerogenes lab culture, Proteus vulgaris 
cultures and Salmonella Paratyphi B clinical isolate, At 125 μg/ml concentration a 
few bacterial cultures could not grow, such as Escherichia coli lab culture, 
Salmonella paratyphi B lab culture, Staphylococcus aureus ATCC 25923 and 
Klebshiella pneumoniae clinical isolate 1.The most sensitive culture against 
action of MSB 8 was Staphylococcus citrus lab culture, which could not grow at 
62.5 µg/ml (Graph No. 88). Most of the Gram positive cocci and rods were 
inhibited by MSB 9 at 62.5 µg/ml. Some Gram Negative rods i.e. Escherichia coli 
ATCC, Salmonella paratyphi B clinical isolate, Pseudomonas aeruginosa cultures 
and Klebshiella Pneumoniae cultures were also inhibited at 62.5 µg/ml. Proteus 
vulgaris lab culture was sensitive up to 250 µg/ml. MIC for Escherichia coli clinical 
isolate was 500 µg/ml (Graph No. 89, Figure-3(B)). 
 
MSB 10 was effective on Gram Positive cocci with MIC at 62.5 µg/ml. For 
Proteus vulgaris lab culture and Pseudomonas aeruginosa ATCC 27853, the MIC 
was 250 µg/ml. Proteus vulgaris clinical isolate was inhibited at 125 µg/ml. 
Salmonella paratyphi B was sensitive up to 500 µg/ml.  All Escherichia coli 
cultures were inhibited at 1000 μg/ml. Some cultures, like Salmonella paratyphi B 
lab culture and cultures of Klebshiella Pneumoniae remained unaffected by the 
action of MSB 10. For Gram Negative bacteria, MSB 11 proved effective, with 
MIC at 31.5 µg/ml. For Gram Negative Rods, it has expressed antimicrobial 
action up to 500 µg/ml only (Graph No. 91).Whereas, in case of Klebshiella 
Pneumoniae clinical isolate 1, the MIC was 1000 µg/ml and for Klebshiella 
pneumoniae clinical isolate 2, it was 31.5 µg/ml (Graph No. 90).   Moderate cell 
count was obtained in Escherichia coli ATCC 25922, Escherichia coli clinical 
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isolate, Enterobacter aerogenes lab culture and Proteus vulgaris lab culture from 
250 µg/ml (Graph No. 15A). All Gram Negative short rods could grow from 500 
µg/ml, except Klebshiela pneumoniae clinical isolate 2, which was inhibited up to 
31.2 µg/ml (Graph No. 15B). In case of Gram Positive rods and cocci, similar 
pattern of cfu formation was observed; only in 15.6 µg/ml they grew luxuriantly 
(Graph No. 15C). 
 
Maximum MIC for MSB 12 was 31.5 µg/ml with respect to cultures; 
Staphylococcus citrus lab culture and Klebshiella pneumoniae clinical isolate 1.  
MIC of 125 µg/ml   for Escherichia coli lab culture, Salmonella paratyphi B lab 
culture, Pseudomonas aeruginosa ATCC 27853 was recorded. At the 
concentration of 1000 µg/ml; Enterobacter aerogenes lab culture, Proteus 
vulgaris cultures were inhibited.  Bacillus subtilis ATCC 6633 and Klebshiella 
pneumoniae were inhibited at 500 µg/ml. The unaffected cultures were 
Escherichia coli ATCC 25922, Pseudomonas aeruginosa lab culture and 
Staphylococcus aureus ATCC 25923 (Graph No. 92). 
   
For Gram Positive bacteria, effect of MSB 13 was more pronounced as compared 
to Gram Negative bacteria.  Staphylococcus citrus was most sensitive at 62.5 
µg/ml. Staphylococcus albus clinical isolate and Staphylococcus aureus ATCC 
25923 were inhibited upto125 µg /ml.  For Pseudomonas aeruginosa lab culture, 
MIC at 250 µg/ml was observed. MIC at 500 µg/ml was observed for Escherichia 
coli clinical isolate and Pseudomonas aeruginosa ATCC 27853 (Graph No. 93).  
MSB 14 was effective on Staphylococcus citrus lab culture and Klebshiella 
Pneumoniae clinical isolate.  At 250 µg/ml, some sensitive cultures were 
Escherichia coli lab culture, Salmonella paratyphi B lab culture, Pseudomonas 
aeruginosa ATCC 27853 (Graph No. 94).     
Organisms like Enterobacter aerogenes lab culture, Proteus vulgaris lab culture, 
Pseudomonas aeruginosa lab culture, Staphylococcus aureus ATCC 25923, 
Bacillus subtilis ATCC 6633, Klebshiella pneumoniae clinical isolate 2 were 
sensitive at 1000 µg/ml.  MSB 15 could inhibit Gram Positive cocci as well as 
Pseudomonas aeruginosa cultures, Proteus vulgaris lab culture and Salmonella 
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paratyphi B clinical isolate at concentration of 125 Escherichia coli clinical isolate 
was inhibited at 250 µg/ml (Graph No. 95),(Table 4J).  
  
MSB 15 had antimicrobial action on all Gram Positive cocci and some of Gram 
Negative orgs. Staphylococcus citrus cultures being most sensitive among all 
inhibited at 62.5 µg/ml.  Staphylococcus albus and Staphylococcus aureus ATCC 
25923 were inhibited at 125 µg/ml. Pseudomonas aeruginosa lab culture was 
inhibited at 250 µg/ml. MSB 16 was active on Gram Positive cocci; 
Staphylococcus albus clinical isolate, Staphylococcus aureus ATCC 25923 (MIC 
125 µg/ml) and Staphylococcus citrus cultures (MIC 62.5 µg/ml), (Graph No. 96).   
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Graph No.82-Effect of MSB 1 on Growth of 
Micro organisms
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Graph No.83-Effect of MSB 2 on Growth of 
Micro organisms
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Graph No.84-Effect of MSB 3 on Growth of 
Micro organisms
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Graph No.85-Effect of MSB 5 on Growth of 
Micro organisms
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Graph No.86-Effect of MSB 6 on Growth of 
Micro organisms
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Graph No.87-Effect of MSB 7 on Growth of 
Micro organisms
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Graph No.88-Effect of MSB 8 on Growth of 
Micro organisms
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Graph No.89-Effect of MSB 9 on Growth of 
Micro organisms
0
1
2
3
4
5
6
1000
μg/mL
500
μg/mL
250
μg/mL
125
μg/mL
75
μg/mL
37.5
μg/mL
18.75
μg/mL
Concentration of Organic Compound (ug/mL)
D
e
g
re
e
 o
f 
In
h
ib
iti
o
n
 
o
f 
M
ic
ro
b
ia
l G
ro
w
th
Graph No.90-Effect of MSB 10 on Growth of 
Micro organisms
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Graph No.91-Effect of MSB 11 on Growth of 
Micro organisms
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Graph No.92-Effect of MSB 12 on Growth of 
Micro organisms
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Graph No.93-Effect of MSB 13 on Growth of 
Micro organisms
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Graph No.94-Effect of MSB 14 on Growth of 
Micro organisms
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Graph No.95-Effect of MSB 15 on Growth of 
Micro organisms
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Graph No.96-Effect of MSB 16 on Growth of 
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Graph No. 14B : Effect of MSB1 on growth of 
organisms
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Graph No. 14C : Effect of MSB 1 on growth of 
organisms
0
10
20
0 15.1 31.2 62.5 125 250 500 1000
Concentration of MSB 1(ug/ml)
N
o
. 
o
f 
c
e
ll
s
 X
 
1
0
5
Staphylococcus albus*
Staphylococcus aureus ATCC 25923
Staphylococcus citrus
Staphylococcus citrus*
Bacillus sublitis ATCC 6633
Graph No. 15B : Effect of MSB 11 on growth of 
organisms
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Graph No. 14A : Effect of MSB 1 on growth of tested 
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Comparison of Growth pattern of Bacteria 
 
 
 
 
 
Figure 3(A) Growth control and solvent control of Bacteria 
 
 
 
 
Figure 3(B) Bacterial Growth in MSB 9 
 
 
 
 
Figure 3(C) Bacterial Growth in of CDSB 21 
 
 
 
 
Figure 3(D) Bacterial Growth in ASM 30 
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Antibacterial action of K SERIES  
All compounds were very potent in antibacterial activity. Total 11 compounds 
were analyzed. These compounds inhibited all 17 cultures in secondary 
screening up to dilution of 15.6 µg/ml. Therefore; they were again screened in the 
final screening to find exact concentration of their MICs.Their effect has been 
discussed in detail in the next chapter. 
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Antibacterial action of ALGAL EXTRACTS 
Gracillaria Corticata Sterol extract      
Escherichia coli ATCC 25922, Enterobacter aerogenes lab culture and 
Staphylococcus albus clinical isolate were inhibited by this biological extract up to 
250 µg/ml.  Whereas, in case of Pseudomonas aeruginosa lab culture and 
Klebshiela pneumoniae clinical isolate 1, it exhibited MIC at 500 µg/ml (TABLE 
4K). 
 
Gracillaria Corticata fatty acid Extract 
Perfect inhibition of any culture was not observed by this extract at 250 µg/ml.  
Whereas, for Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 
27853, Staphylococcus albus clinical isolate and Klebshiella pneumoniae clinical 
isolate 1 , the MIC was 500 µg/ml. The MIC of fatty acid extract for Escherichia 
coli lab culture, Proteus vulgaris lab culture, Salmonella paratyphi B lab culture, 
Staphylococcus albus clinical isolate, Staphylococcus aureus ATCC 25923, 
Staphylococcus citrus lab culture and Klebshiella pneumoniae clinical isolate 2 
was 1000 µg/ml.  However, some cultures which remained unaffected were 
Escherichia coli clinical isolate, Enterobacter aerogenes lab culture, Salmonella 
paratyphi B clinical isolate (Figure-2(A), Figure-2(B)). 
 
Gracillaria corticata lipid extract 
Only two out of seventeen cultures; Staphylococcus albus clinical isolate and 
Klebshiella pneumoniae clinical isolate 1, were inhibited at 250 µg/ml.  Whereas 
majority of the cultures were affected at only 1000 µg/ml and these cultures were 
Escherichia coli, Enterobacter aerogenes lab culture, Proteus vulgaris clinical 
isolate cultures of Salmonella paratyphi B, Pseudomonas aeruginosa lab culture, 
all the Gram Positive cocci, Bacillus subtilis ATCC 6633 and Klebshiella 
pneumoniae clinical isolate 2.  
 
 
 137 
TABLE 4K: ANTIBACTERIAL ACTIVITY OF BIOLOGICAL EXTRACTS 
MICROORGANISM Gc S Gc F Gc L Cr S Cr F Cr L Si S Si F Si L 
Escherichia coli ATCC 25922 250 500 1000 250 500 500 250 250 250 
Escherichia coli 1000 1000 1000 500 500 1000 1000 500 1000 
Escherichia coli* 1000 >1000 1000 1000 1000 >1000 1000 500 500 
Enterobacter aerogenes 250 >1000 1000 >1000 1000 500 1000 500 500 
Proteus valgaris 1000 1000 >1000 1000 500 500 1000 1000 1000 
Proteus valgaris* >1000 1000 1000 500 500 1000 >1000 1000 >1000 
Salmonella paratyphi B 1000 1000 1000 >1000 500 >1000 1000 >1000 1000 
Salmonella paratyphi B* >1000 >1000 1000 1000 500 1000 500 >1000 1000 
Pseudomonas aeruginosa ATCC 
27853 
>1000 500 1000 500 250 1000 250 250 500 
Pseudomonas aeruginosa 500 >1000 >1000 500 1000 1000 1000 500 500 
Staphylococcus albus* 250 500 250 250 500 250 500 250 1000 
Staphylococcus aureus ATCC 25923 >1000 1000 1000 1000 500 >1000 1000 500 1000 
Staphylococcus citrus >1000 1000 1000 >1000 1000 1000 1000 1000 500 
Staphylococcus citrus* >1000 >1000 1000 1000 1000 >1000 >1000 500 1000 
Klebshiella pneumoniae* 1 500 500 250 1000 250 250 500 250 250 
Bacillus subtilis ATCC 6633 1000 >1000 1000 1000 1000 1000 1000 500 500 
Klebshiella pneumoniae* 2 1000 1000 1000 1000 500 >1000 1000 1000 1000 
 
Abbreviations: 
Gc S: Gracillaria Corticata Sterol extract      
Gc F: Gracillaria Corticata fatty acid Extract 
Gc L: Gracillaria corticata lipid extract 
Cr S: Ceramium rubrum sterol extract 
Cr F: Ceramium rubrum fatty acid extract 
Cr L: Ceramium rubrum lipid Extract 
Si S: Scinaia indica sterol extract 
Si F: Scinaia indica fatty acid extract 
Si L: Scinaia indica lipid extract 
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Ceramium rubrum sterol extract 
For Escherichia coli ATCC 25922 and Staphylococcus albus clinical isolate, 
sterol extract had MIC at 250 µg/ml. Some cultures, such as Escherichia coli lab 
culture, Proteus vulgaris clinical isolate cultures of Pseudomonas aeruginosa, 
were inhibited at MIC of 500 µg/ml. Some cultures remained unaffected, such as 
Enterobacter aerogenes lab culture, Salmonella paratyphi B lab culture, and 
Staphylococcus citrus lab culture. Cultures inhibited at MIC of 1000 µg/ml were 
Escherichia coli clinical isolate, Proteus vulgaris lab culture, Proteus vulgaris 
clinical isolate, Salmonella paratyphi B clinical isolate, Staphylococcus aureus 
ATCC 25923, Staphylococcus citrus clinical isolate, cultures of Klebshiella 
pneumoniae and Bacillus subtilis ATCC 6633 (Figure- 2(A), Figure-2(C)). 
 
Ceramium rubrum fatty acid extract 
For Pseudomonas aeruginosa ATCC 27853 and Klebshiella pneumoniae clinical 
isolate 1, it showed MIC of 250 µg/ml.  Escherichia coli ATCC 25922, Escherichia 
coli lab culture, cultures of Proteus vulgaris, cultures of Salmonella paratyphi B, 
Staphylococcus albus, Staphylococcus aureus ATCC 25923 and Klebshiella 
pneumoniae clinical isolate 2 were inhibited at MIC of 500 µg/ml. 
 
Ceramium rubrum lipid Extract 
For Staphylococcus albus clinical isolate and Klebshiella pneumoniae clinical 
isolate 1, it has expressed antimicrobial action at 250 µg/ml. At 500 µg/ml, some 
cultures like Escherichia coli ATCC 25922, Enterobacter aerogenes lab culture, 
Proteus vulgaris lab culture were affected.  Bacillus subtilis ATCC 6633, 
Staphylococcus citrus lab culture, cultures of Pseudomonas aeruginosa, 
Salmonella paratyphi B  clinical isolate, Proteus vulgaris clinical isolate and 
Escherichia coli lab culture were inhibited at 1000 µg/ml. Clinical isolates of 
Escherichia coli; Staphylococcus citrus; Klebshiella pneumoniae and Salmonella 
paratyphi B lab culture were not inhibited.   
Scinaia indica sterol extract 
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For Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC; Scinaia 
indica sterol extract has showed MIC of 250 µg/ml.  For cultures like Salmonella 
paratyphi B clinical isolate, Pseudomonas aeruginosa lab culture, 
Staphylococcus aureus ATCC 25923, cultures of Staphylococcus citrus, Bacillus 
subtilis ATCC 6633 and Klebshiella pneumoniae clinical isolate 2 it has given 
MIC at 1000 µg/ml. For Salmonella paratyphi B clinical isolate, Staphylococcus 
albus clinical isolate and Klebshiella pneumoniae clinical isolate 1, it gave 500 
µg/ml.  Proteus vulgaris clinical isolate and Staphylococcus citrus clinical isolate 
were unaffected.  
 
Scinaia indica fatty acid extract 
 For Escherichia coli ATCC 25922, Staphylococcus albus clinical isolate and 
Klebshiella pneumoniae clinical isolate 1, this extract exhibited MIC at 250 µg/ml.  
For all Gram positive cocci, lab culture and clinical isolate of Escherichia coli, 
Enterobacter aerogenes lab culture, lab culture of Pseudomonas aeruginosa, 
Bacillus subtilis ATCC 6633, it had MIC at 500 µg/ml. For Proteus vulgaris and 
Klebshiella pneumoniae clinical isolate 2, MIC was 1000 µg/ml. Salmonella 
paratyphi B were unaffected by this extract. 
 
Scinaia indica lipid extract 
Escherichia coli ATCC 25922 and Klebshiella pneumoniae clinical isolate 1 were 
sensitive at MIC 250 µg/ml. For cultures of Pseudomonas aeruginosa, 
Staphylococcus aureus ATCC 25923, Enterobacter aerogenes lab culture, 
Bacillus subtilis ATCC 6633, it expressed antimicrobial action at 500 µg/ml. For 
cultures of Salmonella paratyphi B, Proteus vulgaris lab culture, Staphylococcus 
albus clinical isolate, Staphylococcus aureus, the MIC was 1000 µg/ml. Proteus 
vulgaris clinical isolate was unaffected. 
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Antimicrobial action of biological extract 
 
 
 
 
 
Figure 2(A) Growth control and solvent control of extracts of red Algae 
 
 
 
 
 
Figure 2(B) Inhibition in Gracillaria corticata fatty acid extract 
 
 
 
 
Figure 2(C) Inhibition in Ceramium rubrum sterol extract 
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TABLE 4L: Antifungal activity of Biological organic compounds (in     
µg/ml) 
RED ALGAE YEAST CULTURE 1000   500 250 
Gracillaria Corticata 
(1)Sterol Extract 
C.albicans# - - - 
C.albicans* - - + 
(2)Fatty acid Extract C.albicans# - + + 
C.albicans * + + + 
(3)Lipid Extract C. albicans# + + + 
C. albicans * - + + 
Ceramium rubrum 
(1)Sterol Extract 
C. albicans# - - + 
C.albicans * - + + 
(2)Fatty acid Extract C.albicans# - - + 
C.albicans * - + + 
(3)Lipid Extract C.albicans - - + 
C. albicans * - + + 
Scinaia indica 
(1)Sterol Extract 
C.albicans# - - - 
C. albicans * - - + 
(2)Fatty acid Extract C.albicans# - - - 
C.albicans * - - + 
(3)Lipid Extract C.albicans# - - - 
C.albicans * - - + 
 
Note *  Clinical isolate of Candida albicans;# 
            Candida albicans ATCC 10231 
 
Antifungal Action of CT series 
The compounds were analyzed for two fungal cultures, Candida albicans ATCC 
10231 and Candida albicans clinical isolate from HIV patient.  
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It was observed that among all the compounds, minimum concentration for 
inhibition was 31.5 µg/ml and maximum concentration was 1000 µg/ml. There 
was a remarkable difference in MIC of standard culture of Candida and the 
clinical isolate. Candida albicans ATCC 10231 was found to be more sensitive 
than Candida albicans clinical isolate.  Four compounds were truly active against 
Candida albicans ATCC 10231 giving MIC at high dilutions i.e. CTI with MIC of 
31.5 µg/ml, CT 3 at 62.5; CT 7 and CT 8 showed 62.5 µg/ml as MIC (Graph 
No.97) (Table 4L). 
Antifungal Action of QT series 
Inhibition by this series of compounds was not more than 62.5 µg/ml 
concentration. Some of the compounds have shown more effect on clinical 
isolate than ATCC Candida culture; QT 7, QT 14, QT 15, QT 3, QT 10 expressed 
higher antifungal action among all giving 62.5 µg/ml as MIC for Candida albicans 
ATCC 10231(Graph No.98). 
 
Antifungal Action of CDQ Series 
 CDQ 8 and CDQ 23 were more effective on Candida albicans ATCC 10231. 
CDQ 14 inhibited Candida albicans ATCC 10231 giving MIC of 62.5 µg/ml.  
Clinical isolate being more resistant for CDQ 3, CDQ 18, CDQ 19 were inhibited 
at 1000 µg/ml (Graph No.99). 
 
 Antifungal Action of CDSB   Series 
CDSB11 could inhibit Candida albicans ATCC 10231 at 62.5 µg/ml. Where as for 
CDSB 6 and CDSB 11, Clinical isolate was more resistant and was inhibited at 
500 µg/ml and 1000 µg/ml, respectively (Graph No.100). 
 
Antifungal Action of KUITT Series 
KUITT 3, KUITT 7, KUITT 16 and KUITT 20 exhibited antifungal action at MIC of 
62.5 µg/ml for either of the cultures. Except a few cases, Candida albicans 
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clinical isolate proved to be more resistant to KUITT series than Candida albicans 
ATCC 10231(Graph No.101). 
 
 Antifungal Action of KUPO series  
Most effective among all was KUPO 8; it gave MIC of 31.25 µg/ml for C. albicans 
ATCC 10231. 
 
KUPO 8 was effective on clinical isolate at 62.5 µg/ml. It was comparatively 
moderately effective series out of all (Graph No.102). 
 
Antifungal Action of KUQP series 
Many compounds from the KUQP series were effective for both the fungal 
cultures.  KUQP 3, KUQP 5, KUQP 6, KUQP 12, expressed their MIC at 62.5 
µg/ml for C. albicans ATCC 10231. In case of KUQP 14, MIC was 31.25 µg/ml 
which was the maximum higher concentration to inhibit fungi. KUQP 11 was the 
most effective on clinical isolate as it had MIC at 62.5 µg/ml. Comparatively 
KUQP 4 and KUQP12, KUQP7 KUQP 9 KUQP10, had effectively high dilutions 
as their MIC for clinical isolate (Graph No.103). 
 
Antifungal Action of ASM series (i) 
For ASM 10, C. albicans ATCC 10231 showed MIC at 62.5 µg/ml. ASM 9 proved 
more effective on clinical isolate as it had higher dilutions as MIC, 125 µg/ml 
(Graph No.104). 
 
Antifungal Action of ASM Series (ii) 
ASM 35 even at 1000 µg/ml concentration was not able to stop growth of Candia 
albicans ATCC 10231, whereas it was effective on clinical isolate as it’s MIC was 
at 500 µg/ml. ASM 32, ASM 34 and ASM 44 were comparatively more effective 
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for clinical isolate. Maximum resistance of clinical isolate was found for ASM 36 
and ASM 47 (Graph No.105). 
 
 Antifungal Action of MSB series 
In majority of MSB compounds, inhibition of clinical isolate was at lower dilution, 
as it was more resistant than Candida albicans ATCC 10231. For clinical isolate 
of Candida albicans, MSB 15 showed MIC at 250 µg/ml, whereas it gave MIC for 
C. albicans ATCC 10231 at 500 µg/ml. Otherwise, most of the clinical isolates 
behaved to be resistant to the action of MSB compounds (Graph No.106). 
 
Antifungal Action of K series 
The most effective series out of all analyzed was K series.  Effectively expressed 
MIC at very high dilutions in final screening was observed. Maximum higher 
concentration at which K 1 showed MIC for C. albicans ATCC 10231 was 3.9 
µg/ml,  whereas, K 4 and 6 had high dilution as MIC for clinical isolate at 7.8 
µg/ml. All compounds proved potential antimicrobial for Candida albicans (Graph 
No.107). 
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Graph No.104-MICs of ASM(i) series
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Graph No.103-MICs of KUQP series
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Graph No. 106-MICs of MSB series
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CHAPTER 5 
Advanced study on new promising antimicrobial 
Agents. 
 
Out of first initial findings of Primary screening of all organic compounds, 
secondary screening was performed using 500 µg/ml to 15.6 µg/ml 
concentrations of compounds. A few compounds successfully passed secondary 
screening inhibiting microorganisms at 15.6 µg/ml concentration. The 
compounds which gave inhibition of even a single bacterial culture were further 
investigated for their exact MIC findings by further diluting the compounds from 
7.8 µg/ml to 0.2 µg/ml. So, in final screening  20 compounds which proved active 
were used for the preparation of higher dilutions.  
 
Standard drug Ciprofloxacin was also used to investigate the MICs of bacterial 
ATCC cultures. These results were used to compare the results of MICs of 
organic compounds. In case of CT 1 it was active against Salmonella paratyphi 
B clinical isolate and showed MIC at 7.8 µg/ml.Pseudomonas aeruginosa 
laboratory culture was also inhibited at 7.8 µg/ml in final screening of CT 1.CT 1 
was comparatively less active than the compounds of ASM and KUPO series. 
 
In ASM (i) series, ASM 47 was more potent than other three compounds and 
inhibited Escherichia coli ATCC 25922 (MIC-15.6 µg/ml), Escherichia coli  lab 
culture (MIC-15.6 µg/ml), Proteus vulgaris laboratory  culture (MIC-15.6 µg/ml), 
Staphylococcus aureus ATCC 25923 (MIC-7.8 µg/ml), Staphylococcus citrus lab 
culture (MIC-7.8 µg/ml), Klebshiella pneumoniae clinical isolate 1 (MIC-15.6 
µg/ml), Bacillus subtilis ATCC 6633(MIC-7.8 µg/ml). ASM 47 inhibited 7 
microbial cultures out of total 17 cultures, active against seven cultures in the 
secondary screening. In the final screening, it affected Bacillus subtilis ATCC 
6633 at 7.8 µg/ml whereas, in case of ASM 8, it had antimicrobial effect on 
Staphylococcus aureus ATCC 25923 And Bacillus subtilis ATCC 6633. The 
same type of antimicrobial action was also detected in other compounds of this 
series. 
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ASM 8 proved active compound from ASM (i) series. It inhibited bacteria at 7.8 
µg/ml (Staphylococcus aureus ATCC 25923 and Bacillus subtilis ATCC 
6633).The cultures Proteus vulgaris laboratory culture, Staphylococcus albus 
clinical isolate and Staphylococcus citrus laboratory culture were inhibited at 
15.6 µg/ml. 
 
Other two compounds from ASM series were active.ASM 40 inhibited Bacillus 
subtilis ATCC 6633 and Staphylococcus aureus ATCC 25923 at 7.8 µg/ml. It 
exhibited MIC at 15.6  µg/ml for culture Klebshiella pneumoniae clinical isolate 1. 
For ASM 44, two cultures, Staphylococcus aureus ATCC 25923 and Bacillus 
subtilis ATCC 6633 were sensitive at 7.8 µg/ml. 
 
KUPO series was also active against several bacteria. Similarly, in KUPO series 
it was found in final screening, that for one culture Escherichia coli clinical isolate 
four compounds KUPO 3, KUPO 10, KUPO 12 and KUPO 13 were active with 
MIC at 7.8 µg/ml. 
 
Escherichia coli clinical isolate was inhibited at 7.8 µg/ml of KUPO 3 and KUPO 
10.Other cultures were not sensitive in higher dilution (15.6 µg/ml). KUPO 12 
and KUPO 13 have also inhibited Escherichia coli clinical isolate at 7.8 µg/ml 
and other cultures were not sensitive to their action in higher dilutions of final 
screening, In general, KUPO compounds were more active against Escherichia 
coli clinical isolate. 
 
The organic compounds shown in Table 5B were less active against the bacteria 
than Ciprofloxacin.  
 
In the performance of K series it was observed in secondary screening that all 
had antimicrobial action on all bacterial as well as fungal cultures at higher 
dilutions. Then after, during final screening, various categories were sorted out 
according to their capacity to act on microbes. They all were active at first 
dilution of final screening i.e. 7.8 µg/ml.  Out of all K compounds, less active was 
K1 as it could give antimicrobial action in first and second dilutions except in 
case of Proteus vulgaris lab culture (TABLE 5A). 
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Rest of the K compounds were less or more active exhibiting their antimicrobial 
potency with MIC at higher and higher dilutions. There was a compound K 8 
active against Staphylococcus aureus ATCC 25923 at 0.2 µg/ml.  
                
Fluconazole was taken as standard antifungal to find out exact MIC of Candida 
albicans cultures for the comparison of antifungal action of other organic 
molecules(TABLE 5C). 
 
K4, K8, K10 were active against Candida albicans ATCC 10231 (MIC-0.4 
µg/ml).whereas K3, K6, K7, K9 and K11 were also active for Candida albicans 
ATCC 10231at concentration 0.9 µg/ml. They showed comparatively less activity 
on Candida than their action on bacteria. Being very resistant Candida albicans 
clinical isolate exhibited more resistance than Candida albicans ATCC 10231. 
 
Candida albicans clinical isolate could not be inhibited in concentration less than 
0.9 µg/ml.K4,K6,K7,K8,K9,K10 and K 11 were active against Candida albicans 
clinical isolate at 0.9 µg/ml.The sensitivity of both the yeast cultures was similar 
for K 2 compound. 
 
In case of active biological compound Scinaia indica fatty acid extract giving 
antimicrobial effect on four cultures at 250 µg/ml proved to be ineffective. 
 
Finally, K 11 was the most potent out of entire K series and also among all 
screened compounds, as it has shown minimum MICs for all 19 microbial 
cultures. These synthetic molecules proved very promising to act on Gram 
Positive, Gram Negative bacteria as well as yeasts.  They need to be   further 
investigated for clinical trials and further pharmacological studies.
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TABLE 5A : MICs of potent organic compounds-Result of FINAL SCREENING (µg/ml) 
 
Microbial culture K1 K2 K3 K4 K5 K6 K7 K8 K9 K10 K11 
Escherichia coli ATCC 25922 3.9 3.9 0.9 0.9 0.9 1.9 0.9 0.9 0.4 0.4 0.4 
Escherichia coli 3.9 3.9 1.9 0.9 1.9 1.9 0.9 0.9 0.4 0.4 0.4 
Escherichia coli* 3.9 7.8 3.9 1.9 1.9 1.9 0.9 1.9 0.9 0.4 0.4 
Enterobacter aerogenes 3.9 1.9 0.4 1.9 0.4 0.4 1.9 0.4 0.9 0.9 0.9 
Proteus valgaris 1.9 3.9 0.4 0.9 1.9 0.4 0.9 0.9 0.4 0.4 0.4 
Proteus valgaris* 3.9 3.9 0.9 1.9 1.9 0.4 1.9 3.9 0.9 0.4 0.4 
Salmonella paratyphi B 7.8 1.9 0.9 3.9 0.2 0.9 0.9 0.9 0.4 0.9 0.9 
Salmonella paratyphi B* 7.8 1.9 0.9 3.9 0.9 0.9 1.9 0.9 0.9 0.9 0.9 
Pseudomonas aeruginosa ATCC 27853 7.8 0.9 3.9 0.9 1.9 1.9 1.9 0.4 0.9 0.4 0.4 
Pseudomonas aeruginosa 7.8 0.9 3.9 1.9 1.9 1.9 1.9 0.9 0.9 0.9 0.4 
Staphylococcus albus* 3.9 3.9 3.9 0.9 0.9 3.9 0.9 0.9 1.9 1.9 0.9 
Staphylococcus aureus ATCC 25923 3.9 1.9 3.9 0.4 0.9 3.9 0.9 0.2 0.4 0.9 0.4 
Staphylococcus citrus 3.9 1.9 1.9 0.4 0.9 1.9 0.9 0.9 0.4 0.9 0.4 
Staphylococcus citrus* 3.9 1.9 3.9 1.9 0.9 3.9 1.9 0.9 1.9 1.9 0.9 
Klebshiella pneumoniae* 1 7.8 1.9 1.9 3.9 1.9 1.9 1.9 3.9 0.9 0.9 0.4 
Bacillus subtilis ATCC 6633 15.6 3.9 1.9 0.9 0.4 1.9 0.4 0.9 0.4 1.9 0.4 
Klebshiella pneumoniae* 2 3.9 1.9 1.9 3.9 3.9 1.9 0.9 3.9 0.9 0.4 0.4 
 
Note: *Symbol indicates pathological isolates of Microorganisms
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TABLE 5B : MICs of potent organic compounds-Result of FINAL Screening(µg/ml) 
 
Microbial culture Ciprofloxacin CT1 ASM
8 
ASM
40 
ASM
44 
ASM 
47 
KUPO3 KUPO 
10 
KUPO1
2 
KUPO1
3 
Algal# 
Escherichia coli ATCC 25922 0.4 NA NA NA NA 15.6 15.6 15.6 15.6 15.6 250 
Escherichia coli 0.4 NA NA NA NA 15.6 15.6 NA 15.6 15.6 NA 
Escherichia coli* 3.9 NA NA NA NA NA 7.8 7.8 7.8 7.8 NA 
Enterobacter aerogenes 0.9 NA NA NA NA NA 15.6 NA 15.6 NA NA 
Proteus valgaris 0.9 NA 15.6 NA NA 15.6 15.6 15.6 15.6 NA NA 
Proteus valgaris* 7.8 NA NA NA NA NA 15.6 NA 15.6 NA NA 
Salmonella paratyphi B 1.9 NA NA NA NA NA 15.6 NA 15.6 NA NA 
Salmonella paratyphi B* 7.8 7.8 NA NA NA NA NA NA NA NA NA 
Pseudomonas aeruginosa ATCC 27853 3.9 7.8 NA NA NA NA NA NA NA NA 250 
Pseudomonas aeruginosa 3.9 NA NA NA NA NA NA NA NA NA NA 
Staphylococcus albus* 3.9 NA 15.6 NA NA NA NA NA NA NA 250 
Staphylococcus aureus ATCC 25923 1.9 NA 7.8 7.8 7.8 7.8 NA NA NA NA NA 
Staphylococcus citrus 0.9 NA 15.6 15.6 NA 7.8 NA NA NA NA NA 
Staphylococcus citrus* 3.9 NA NA NA NA NA NA NA NA NA NA 
Klebshiella pneumoniae* 1 7.8 NA NA 15.6 NA 15.6 NA NA NA NA 250 
Bacillus subtilis ATCC 6633 7.8 NA 7.8 7.8 7.8 7.8 NA NA NA NA NA 
Klebshiella pneumoniae* 2 15.6 NA NA NA NA NA NA NA NA NA NA 
 
Algal #-Scinaia indica fatty acid extract 
Note: *Symbol indicates pathological isolates of Microorganisms 
 
NA: not applicable 
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TABLE 5C: MICs of potent organic compounds-Result of FINAL SCREENING(µg/ml) 
 
 
Fungal culture Fluconazole K1 K2 K3 K4 K5 K6 K7 K8 K9 K10 K11 
Candida albicans ATCC 10231 0.4 15.6 3.9 0.9 0.4 1.9 0.9 0.9 0.4 0.9 0.4 0.9 
Candida albicans* 3.9 7.8 3.9 1.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 
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CHAPTER 6 
DISCUSSION 
Knowledge of Antimicrobial activity of newly synthesized organic compounds is 
necessary for combating resistance of resistant and virulent strains. Day by day 
resistance of commensals and pathogenic strains grow higher and higher.  
However, our knowledge is restricted to less than 1% of the facts about causes 
of resistant strains and their sensitivity. We were able to analyze the 
antimicrobial activity of Gram Negative, Gram Positive as well as fungi which can 
grow under normal laboratory conditions.  Still many other problematic resistant 
strains are to be screened for large number of synthetic compounds being 
synthesized every day.  Among them, several synthetic series and biological 
extracts have attracted considerable attention during the last several years.    
 
Antimicrobial activity of organic compounds is categorized into three categories 
high, moderate and poor. Loss of sensitivity of microorganism against 
antimicrobials may be due to many factors including change in their genetic 
makeup. The antimicrobial activity of any antimicrobial depends on many 
external and internal influences. The major part of their capacity to inhibit 
Prokaryotes depends on the major ring structure skeleton of the synthetic 
compound and the external moieties – additional groups attached to main 
skeleton.  The physical and chemical properties of synthetic compound are also 
detrimental factor in exhibiting their activity.  Many single synthetic compounds 
and / or a complete series of compounds have been successfully used for 
resistant strains in recent years. These synthetic compounds really worked 
miraculously for certain diseases which are difficult to cure. 
 
Considering all these aspects of antimicrobial agents, it becomes quite 
interesting to focus on analyzing their antimicrobial potential and to investigate 
the properties contributing to level of their antimicrobial action.  
 
The discovery of new groups of antimicrobials is necessary due to the increased 
incidence of multiple resistances among pathogenic microorganisms and 
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opportunistic microorganisms in immuno- suppressed or immune compromised 
patients against the drugs those are currently in clinical use (Burgess et al 1999). 
With the aim of finding new bioactive organic compounds from synthetic and 
biological organic compounds and to investigate the exact minimum inhibitory 
concentration of antimicrobials, we initiated to analyze the organic compounds 
with their antimicrobial activity and looked into the resistance of microorganisms 
and their sensitivity profile. 
 
The organic compounds were primarily screened on the basis of their effect at 
lower dilutions i.e. higher concentrations.  Many of them could be further 
differentiated or screened on the basis of their primary screening based applying 
higher dilutions and then finally with the help  of final screening with further high 
dilutions.  Each of the organic compounds under study has generated a typical 
antimicrobiogram, reflecting a significant diversity amongst them. 
 
Majority of the antimicrobials  dispersed from several synthetic origin series 
(differed) into the Mueller Hinton Agar medium when they were added into Petri 
dishes and killed the target organisms and shown no  growth at the site of 
inoculation.  Interestingly, in case of few organic compounds, they could not 
show inhibition of microbes and organisms could grow in the form of small 
colonies which could then be further investigated for the number of cells present.  
Another interesting trend was observed by some of the series of organic 
compounds that they did not produce antimicrobial effect on Gram positive 
bacteria, Gram negative bacteria as well as fungi. Especially, some series were 
effective for Gram Positive ones and some series were effective on Gram 
Negative ones and some had effects on both.  The reason was not so clear but it 
could be assumed that the capacity of these compounds was based on their 
structure- activity relationships. 
 
Generally, it has been established that several series possessing specific 
skeleton (centre ring) have comparatively greater killing effects on microbes. It 
has been proved in case of newer fluroquinolones.They have exhibited recently 
their potency against Gram Positive as well as Gram Negative bacteria within the 
range of 64 to 0.006 µg/ml MICs(O’Donnell,2004).  Similar explanation is for the 
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compounds having some additional groups leading to greater toxicity against 
microbial life. 
 
Another trend related to the antimicrobial activity of these compounds and its 
dependence on combination of above two facts. The results were recorded at 
the end of 24 hours to give complete growth cycle for a bacterium so that 
uniformity of growth could be maintained for all bacterial cultures.  Upon further 
incubation of the Mueller Hinton Agar plates, not a single cell of the bacterial 
culture could grow if once proved to be sensitive.  The possible reason for no 
growth might be the damages to vital cellular parts by the synthetic compounds. 
 
Some of the compounds proved active against other organisms did fail to give 
antimicrobial action against several microbial cultures or in some cases they 
could inhibit organisms.Coumarin derivatives proved more toxic and inhibited 
HIV strains but CT and QT series did not inhibited bacterial strains(Joshi et 
al,2006).  This behavior was observed in case of compounds like CDSB, KUQP 
series and extracts of red algae. 
 
Further studies such as finding their physicochemical basis at macromolecular 
level of the detection of the cause of their success and failure as antimicrobials, 
would be quite interesting. The similar approach of analysis could also be 
applied to fungal cultures. 
 
Concentration of antimicrobial agent has played a crucial role on sensitivity of 
the Gram Positive and/or Gram Negative bacteria as well as fungi. An interesting 
trend was found when concentration of organic compounds was studied with 
higher dilutions. 
 
In majority of the cases, the antimicrobial activity was found even with the 
decreasing compound concentrations and majority of the bacterial cultures were 
inhibited in the range of concentration of compound from 1000 to 250 µg/ml. 
 
Generally, this characteristic of exerting antimicrobial action was useful when it's 
applied in routine pathogens and resistant variants. If these organic compounds 
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can kill the pathogens as well as problematic resistant varieties of opportunists. 
We can use them for the production of antimicrobials for human healthcare and 
therefore, we studied the antimicrobial activity of the organic compounds from 
highly promising series.  Interesting results were observed when microbes were 
grown at different concentrations up to 0.2 µg /ml. 
 
Over the past few decades, marine organisms like red algae are the focus of a 
worldwide effort for the discovery of novel natural products. A small number of 
marine plants, animals and microbes have already yielded more than 12,000 
novel chemicals with hundreds of new compounds still being discovered every 
year (Donia and Hamann, 2003). The above studies have generated some 
valuable results, which can be used to study the antimicrobial activity of the 
antimicrobials, synthetic or biological origin. Nevertheless, antimicrobials 
synthesized by chemists or red algae have enormous clinical importance.  
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CHAPTER 7 
SUMMARY 
The present study deals with the antimicrobial activity of the organic 
compounds from synthetic and natural origin by using Agar Dilution method. 
 
The results are summarized as below; 
1) Clinical isolates of opportunist and pathogenic cultures of Gram 
Positive and Negative bacteria and fungi were obtained which were 
resistant to several antibiotics. 
2) Out of all organic compounds, a single series of organic compounds 
i.e. Ciprofloxacin series acted against all microbial cultures. 
3) With few exceptions, several series of organic compounds were 
effective at only 1000 µg/ml, while showed MIC at concentrations 
above 1000 µg/ml. They were substituted 3-[(2z)-3-phenyl-prop-2- 
enoyl]-2H–chromen-2-ones and 4-acetyl-3,5dimethyl-N"-[IE)-
substituted phenyl methylene]-IH-pyrrole-2- carbohydrazines.  
4) Specifically, 1-{2,4-dimethyl-5[(5-substituted phenyl-1,3,4-oxadiazol-2-
yl) carbonyl]-1H-pyrrol-3-yl} ethanones and 2-Amino-6 alkyl / alkylaryl-
5-oxo-4-substituted phenyl-5,6-dihydro-4H-pyrano[3,2-C] quinolone-3-
carbonitriles series proved effective against all bacteria in secondary 
screening i.e. at concentrations; 500 - 15.6 µg/ml. 
5) Several series were effective on certain group of bacteria. Such as, 4-
[(4-chlorophenyl) amino] 6-ethyl-2H-pyrono [3, 2, C] quinoline -2, 
5(6H)-diones series acted against Gram Positive bacteria. 
6) Ethyl-2-amino-6-methyl-5-oxo-4 substituted-5,6-dihydro-4H-pyrono[3,2-
C] quinine-3-carboxylates also acted on Gram Positive bacteria, such 
as Gram Positive cocci. 
7) Similarly, some series like N'-[(IE)-(3'chlorophenyl) methylene]-6-
methyl-2-oxo-2H-chromene-4-carbhydrazides were effective against 
Gram Positive cocci. 
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8) The most sensitive microbial cultures were Staphylococcus citrus 
clinical isolate, Staphylococcus aureus ATCC 25923, Pseudomonas 
aeruginosa ATCC 27853 and Proteus Valgaris clinical isolate. 
9) The most effective NCE (new chemical entity) out of all was K11.  
10) Several organic compounds, such as CT 1, ASM 40, ASM 44, ASM 47, 
MSB 1, KUPO 3, KUPO 10, KUPO 12, KUPO 13, CDSB 19, K1,K2, 
K3, K4, K5, K6, K7,K8,K9,K10,K11 and then after K11 reached into 
final screening level and were effective at higher dilutions with 15.6 
µg/ml or lower concentrations.  
11) In case of natural organic compounds, the inhibition of organisms was 
found at 250 µg/ml. 
12) For yeast, the most potent organic compounds were KUQP-14, KUPO-
8, K4, K8, K10 and K11. 
13) All microbial cultures showed characteristic pattern of their sensitivity 
for all synthetic as well as natural compounds. 
 
The organic compounds proved as most potent among each series were; 
 In Coumarin derivatives;CT 1 
 In Quinoline derivatives; QT 12 
 In Triazolo trianzino indoles; KUITT 21 
 In enecarboxylates; ASM 16  
 In Quinolone diones; ASM 47 
 In carbohydrazides; MSB 3 
 In ethanoles; KUPO 7 
 In carboxylates; CDQ 11 
 In carbohydrazines; CDSB 19 
 In carbonitriles; KUQP 6 
 In floroquinolones; K11  
 In natural extracts of Red Algae, fatty acid extract of Scinaia indica was 
most effective on microorganisms. 
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CHAPTER 8 
CONCLUSION 
The antimicrobial activity of the synthetic and Biological organic compounds was 
investigated by finding Minimum Inhibitory Concentrations of total 167 
compounds using NCCLs approved Agar Dilution Method. Most of the 
compounds could inhibit all strains of bacteria and yeast at 1000 µg/ml 
concentration. The reason behind the antimicrobial action may be the synergistic 
action of organic compounds with mildly effective solvent. 
 
The study revealed that 20 compounds were very effective in secondary 
screening and thus used in final screening. This might be due to the 
pharmacophore present in the active organo compounds. 
 
There were varying responses of microbes towards the action of total 12 series 
of organic compounds. Among the series of compounds, few were active for 
certain types of microbes. Potential of organic compounds to be actively 
antimicrobial is based on the structure of the compound. Final screening of 
organic compounds suggested that few could be developed as potential 
candidates for controlling potentially dangerous pathogenic organisms. 
 
CT 1 is active against two Gram Negative rods giving inhibition with 15.6 µg/ml. 
Among the compounds, ASM 8 was active against Gram Positive organisms. 
ASM 40 affected growth of Gram Positive as well as Klebshiela pneumoniae. 
ASM 44 is active against two organisms i.e. Staphylococcus aureus ATCC 
25923 and Bacillus subtilis ATCC 6633. ASM 47 was active against Gram 
Positive as well as Gram Negative organisms. In case of KUPO series, out of 
four compounds, KUPO 3, KUPO 10, KUPO 12 and KUPO 13 were more 
effective on Gram Negative small rods.  All of them were effective against 
Escherichia coli in general. 
 
The entire series of Floxacin derivatives was highly potential to kill all 
microorganisms at very high dilutions, as low as 0.2 µg /ml concentrations.  The 
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most effective compound was K11. In case of biological organic compounds, the 
fatty acid extract of Scinaia indica exhibited activity at 250 µg/ml.  The effect of 
CT 1 could be described in the simplicity and smaller size of molecule of C16 H12 
O3. Therefore, it might have facilitated the required dispersion and entry of CT 1 
into bacterial cell. Addition of Methyl groups in moderate amount would have 
enabled ASM 8, 40 and 44 as highly active. Moreover, chloride groups, additions 
of phenyl, napthyl, indolyl as well as the N2O3; N3O2, N3O3, N4O2 made the ASM 
as well as KUPO compounds as active antimicrobial agents. The variability in 
antimicrobial action among the compounds was attributed to the attachment of 
substitutional groups. 
 
In general, it appeared that ASM compounds were quite effective antimicrobial 
for Staphylococcus aureus ATCC 25923 and Bacillus subtilis ATCC 6633 , while 
KUPO series was useful against Escherichia coli clinical isolate. 
The more effective compounds were K8, K9, K10 and K11, where K11 appeared 
most effective. Therefore, K series compounds can be recommended for further 
pharmaceutical trials.    
 
Detailed account of physic-chemical properties of the organic compounds could 
be correlated with high antimicrobial activities.  Further studies on these aspects 
could focus on the DNA profiles of microorganisms. Understanding the genetic 
and biochemical basis of sensitivity and resistance of microbes would also be 
quite interesting to explore. 
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TABLE   4A 
MICs OF CT SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
Name of Micro Organisms 
CT 1 CT 2 CT 3 CT 4 CT 5 CT 6 CT7 CT8 CT9 CT10 
1 Escherichia coli ATCC 25922 1000 >1000 >1000 >1000 >1000 1000 >1000 >1000 >1000 >1000 
2 Escherichia coli  15.2 >1000 >1000 >1000 >1000 1000 >1000 >1000 >1000 >1000 
3 Escherichia coli* 1000 >1000 >1000 >1000 ND ND >1000 >1000 >1000 >1000 
4 Enterobacter aerogenes 500 250 1000 1000 >1000 1000 >1000 >1000 >1000 >1000 
5 Proteus valgaris >1000 250 >1000 1000 >1000 1000 >1000 >1000 >1000 >1000 
6 Proteus valgaris* >1000 >1000 >1000 >1000 ND ND >1000 >1000 >1000 >1000 
7 Salmonella paratyphi B >1000 >1000 >1000 >1000 >1000 1000 >1000 >1000 >1000 >1000 
8 Salmonella paratyphi B* 15.2 250 62.5 1000 >1000 ND >1000 >1000 >1000 >1000 
9 Pseudomonas aeruginosa ATCC 
27853 
15.2 >1000 15.2 ND >1000 1000 >1000 >1000 >1000 >1000 
10 Pseudomonas aeruginosa 1000 ND >1000 1000 >1000 1000 >1000 >1000 >1000 >1000 
11 Staphylococcus albus* >1000 ND >1000 >1000 >1000 ND >1000 >1000 >1000 >1000 
12 Staphylococcus aureus ATCC 25923 125 ND 62.5 ND ND >1000 >1000 >1000 >1000 >1000 
13 Staphylococcus citrus  ND ND ND ND ND ND >1000 >1000 >1000 >1000 
1 Staphylococcus citrus* ND ND ND ND ND 500 >1000 >1000 >1000 >1000 
15 Klebshiella pneumoniae* 1 ND ND ND ND ND >1000 >1000 >1000 >1000 >1000 
16 Bacillus subtilis ATCC 6633 ND ND ND ND ND >1000 >1000 >1000 >1000 >1000 
17 Klebshiella pneumoniae* 2  ND ND ND ND ND ND >1000 >1000 >1000 >1000 
TABLE  4B 
MICs OF QT SERIES:  RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 Name of Micro 
Organisms 
QT1 QT 2 QT 3 QT 4 QT 5 QT 6 QT 7 QT 8 QT 9 QT 10 QT 11 QT 12 QT 13 QT 14 QT 15 
1 
Escherichia coli ATCC 
25922 
1000 >1000 1000 1000 >1000 >1000 1000 1000 >1000 1000 1000 1000 500 1000 1000 
2 
Escherichia coli  
1000 >1000 1000 1000 >1000 >1000 1000 1000 >1000 1000 1000 1000 500 1000 1000 
3 
Escherichia coli* 
ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
4 
Enterobacter aerogenes 
1000 1000 1000 1000 >1000 >1000 >1000 1000 >1000 1000 >1000 1000 500 1000 1000 
5 
Proteus valgaris 
>1000 1000 >1000 1000 >1000 >1000 1000 1000 >1000 1000 1000 1000 >1000 >1000 >1000 
6 
Proteus valgaris* 
>1000 1000 >1000 500 >1000 >1000 ND ND ND ND ND ND ND ND ND 
7 
Salmonella paratyphi B 
ND 1000 >1000 1000 >1000 >1000 >1000 1000 >1000 1000 1000 1000 >1000 1000 1000 
8 
Salmonella paratyphi B* 
>1000 ND ND ND >1000 ND ND ND ND ND ND ND ND ND ND 
9 
Pseudomonas 
aeruginosa ATCC 27853 
>1000 125 >1000 1000 250 >1000 1000 31.2 >1000 1000 1000 125 500 1000 1000 
10 
Pseudomonas 
aeruginosa 
>1000 1000 >1000 1000 >1000 >1000 >1000 250 1000 1000 1000 250 500 1000 1000 
11 
Staphylococcus albus* 
ND ND ND ND ND >1000 ND ND ND ND ND ND ND ND ND 
12 
Staphylococcus aureus 
ATCC 25923 
500 1000 >1000 >1000 250 >1000 1000 >1000 1000 1000 1000 250 >1000 1000 1000 
13 
Staphylococcus citrus  
ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
14 
Staphylococcus citrus* 
500 1000 >1000 >1000 250 >1000 250 500 125 1000 1000 62.5 >1000 1000 1000 
15 
Klebshiella pneumoniae* 1 
>1000 >1000 >1000 1000 >1000 >1000 250 500 1000 >1000 1000 250 >1000 1000 1000 
16 
Bacillus subtilis ATCC 
6633 
>1000 >1000 >1000 >1000 >1000 >1000 >1000 1000 >1000 >1000 >1000 1000 1000 1000 1000 
17 
Klebshiella pneumoniae* 2  
 
ND >1000 >1000 1000 250 >1000 250 250 125 >1000 62.5 125 >1000 1000 1000 
TABLE 4C 
MICs OF CDQ SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
 
Name of Micro Organisms 
CDQ 
1 3 5 8 11 14 18 19 21 23 
1 Escherichia coli ATCC 25922 500 500 125 500 125 500 1000 1000 500 1000 
2 Escherichia coli  1000 1000 1000 1000 125 >1000 1000 1000 1000 1000 
3 Escherichia coli* 1000 1000 500 1000 125 >1000 1000 1000 1000 1000 
4 Enterobacter aerogenes 1000 500 125 1000 125 >1000 1000 1000 >1000 1000 
5 Proteus valgaris 500 500 125 500 62.5 500 1000 1000 >1000 1000 
6 Proteus valgaris* 500 500 125 1000 125 500 1000 1000 >1000 1000 
7 Salmonella paratyphi B 1000 1000 1000 1000 1000 >1000 500 500 >1000 1000 
8 Salmonella paratyphi B* 1000 1000 500 1000 1000 >1000 500 500 500 500 
9 Pseudomonas aeruginosa ATCC 27853 125 125 1000 1000 250 250 500 500 250 500 
10 Pseudomonas aeruginosa 1000 1000 500 500 1000 1000 500 500 1000 1000 
11 Staphylococcus albus* 62.5 250 125 500 125 500 500 500 500 500 
12 Staphylococcus aureus ATCC 25923 62.5 125 125 500 62.5 62.5 500 500 62.5 500 
13 Staphylococcus citrus  62.5 125 500 250 62.5 62.5 500 500 62.5 500 
14 Staphylococcus citrus* 62.5 125 500 250 62.5 62.5 500 500 62.5 250 
15 Klebshiella pneumoniae* 1 500 500 500 500 125 1000 1000 500 500 500 
16 Bacillus subtilis ATCC 6633 500 500 250 500 125 250 1000 1000 1000 500 
17 Klebshiella pneumoniae* 2  ND ND ND ND ND ND 1000 1000 ND 1000 
TABLE  4D 
MICs OF CDSB SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
Name of Micro Organisms 
CDSB 
1 3 4 6 7 10 11 15 19 20 21 
1 
Escherichia coli ATCC 25922 
1000 1000 1000 1000 1000 500 1000 500 1000 1000 250 
2 
Escherichia coli  
1000 1000 1000 1000 1000 500 1000 1000 500 1000 1000 
3 
Escherichia coli* 
1000 1000 1000 1000 1000 500 1000 1000 500 1000 1000 
4 
Enterobacter aerogenes 
1000 1000 1000 1000 1000 500 1000 500 1000 1000 250 
5 
Proteus valgaris 
1000 500 1000 1000 1000 500 1000 1000 1000 500 250 
6 
Proteus valgaris* 
1000 1000 1000 1000 1000 500 1000 500 125 1000 1000 
  7 
Salmonella paratyphi B 
1000 1000 1000 1000 1000 500 1000 1000 1000 1000 1000 
8 
Salmonella paratyphi B* 
1000 1000 1000 1000 1000 500 250 500 500 250 250 
9 
Pseudomonas aeruginosa 
ATCC 27853 
1000 500 1000 500 1000 250 500 125 500 250 500 
10 
Pseudomonas aeruginosa 
1000 1000 1000 1000 1000 250 1000 500 500 1000 1000 
11 
Staphylococcus albus* 
1000 1000 500 1000 1000 500 1000 250 500 250 250 
12 
Staphylococcus aureus ATCC 
25923 
1000 1000 500 1000 1000 250 250 250 15.6 250 250 
13 
Staphylococcus citrus  
500 250 500 500 500 250 1000 125 15.6 250 250 
14 
Staphylococcus citrus* 
500 250 500 500 500 500 500 125 125 250 250 
15 Klebshiella pneumoniae* 1 1000 1000 1000 1000 1000 500 1000 500 1000 1000 250 
16 Bacillus subtilis ATCC 6633 >1000 ND 1000 1000 1000 500 1000 500 1000 ND 250 
17 Klebshiella pneumoniae* 2  1000 1000 1000 1000 1000 500 1000 ND ND 1000 250 
TABLE 4H (a) 
 
ASM (i) SERIES:  RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
ASM(i) 
 Name of Micro Organisms 5 6 7 8 9 10 11 12 13 14 15 16 17 
1 Escherichia coli ATCC 25922 500 500 500 500 1000 125 500 1000 500 >1000 1000 62.5 1000 
2 Escherichia coli  500 500 500 500 1000 125 500 1000 500 >1000 1000 62.5 1000 
3 Escherichia coli* 500 500 500 1000 1000 125 500 1000 500 >1000 1000 62.5 1000 
4 Enterobacter aerogenes 500 500 500 1000 62.5 125 500 1000 500 >1000 1000 62.5 1000 
5 Proteus valgaris 500 500 500 15.6 1000 125 500 1000 250 >1000 250 62.5 >1000 
6 Proteus valgaris* 500 500 500 31.2 125 125 500 1000 250 >1000 250 62.5 >1000 
7 Salmonella paratyphi B 500 500 500 1000 250 125 500 1000 500 1000 250 62.5 1000 
8 Salmonella paratyphi B* 500 500 500 500 1000 125 500 1000 500 1000 250 62.5 1000 
9 Pseudomonas aeruginosa ATCC 27853 500 500 500 1000 1000 125 500 1000 500 >1000 250 62.5 1000 
10 Pseudomonas aeruginosa 500 500 500 1000 1000 125 500 1000 500 >1000 250 62.5 1000 
11 Staphylococcus albus* 500 500 500 15.6 1000 125 125 1000 250 500 62.5 125 1000 
12 Staphylococcus aureus ATCC 25923 500 500 500 15.6 62.5 125 125 1000 250 500 62.5 125 1000 
13 Staphylococcus citrus  500 500 500 15.6 62.5 125 125 1000 250 250 62.5 125 1000 
14 Staphylococcus citrus* 500 500 500 ND 62.5 125 125 1000 250 250 62.5 125 1000 
15 Klebshiella pneumoniae* 1 500 500 500 1000 62.5 125 500 1000 500 500 250 250 1000 
16 Bacillus subtilis ATCC 6633 500 500 500 15.6 62.5 125 1000 1000 500 500 ND 500 1000 
17 Klebshiella pneumoniae* 2  500 500 500 ND 62.5 125 500 1000 500 500 250 250 1000 
TABLE   4H (b) 
MICs OF ASM (i) SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 Name of Micro Organisms 18 19 20 21 22 23 24 25 26 
1 
Escherichia coli ATCC 25922 
31.2 1000 62.5 500 500 1000 >1000 500 1000 
2 
Escherichia coli  125 1000 >1000 500 250 250 1000 500 1000 
3 
Escherichia coli* 15.6 250 1000 250 
250 250 1000 500 1000 
4 
Enterobacter aerogenes 125 250 250 500 500 500 500 500 1000 
5 
Proteus valgaris 125 250 1000 1000 500 1000 500 62.5 1000 
6 
Proteus valgaris* 
15.6 250 62.5 1000 500 1000 500 62.5 125 
 7 
Salmonella paratyphi B 
31.2 250 1000 1000 1000 1000 1000 62.5 1000 
8 
Salmonella paratyphi B* 
125 250 1000 1000 1000 1000 1000 62.5 1000 
9 
Pseudomonas aeruginosa ATCC 
27853 
125 500 250 500 1000 500 500 500 1000 
10 
Pseudomonas aeruginosa 
15.6 500 62.5 500 1000 250 500 500 62.5 
11 
Staphylococcus albus* 
125 500 62.5 125 125 125 500 500 62.5 
12 
Staphylococcus aureus ATCC 25923 
125 500 62.5 125 125 125 500 62.5 62.5 
13 
Staphylococcus citrus  
31.2 500 ND 250 125 250 250 62.5 62.5 
14 
Staphylococcus citrus* 
15.6 500 62.5 250 250 250 250 62.5 62.5 
15 
Klebshiella pneumoniae* 1 
125 500 62.5 500 1000 500 1000 62.5 100 
16 
Bacillus subtilis ATCC 6633 
15.6 1000 62.5 1000 1000 1000 1000 62.5 ND 
17 
Klebshiella pneumoniae* 2  
31.2 500 ND 1000 500 500 1000 62.5 1000 
TABLE   4I (a) 
MICs OF ASM (ii) SERIES:  RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Name of Micro Organisms 30 31 32 33 34 35 36 37 38 39 40 
1 Escherichia coli ATCC 25922 125 500 125 125 250 500 1000 1000 250 250 250 
2 Escherichia coli  1000 500 500 500 250 500 1000 1000 250 250 500 
3 Escherichia coli* 500 500 500 ND 250 500 ND 1000 250 250 ND 
4 Enterobacter aerogenes 125 500 500 125 250 500 500 1000 250 250 1000 
5 Proteus valgaris 62.5 500 125 125 250 500 500 1000 250 250 500 
6 Proteus valgaris* 125 1000 250 ND 250 500 ND 1000 250 250 ND 
7 Salmonella paratyphi B 1000 500 125 1000 250 500 500 1000 250 250 1000 
8 Salmonella paratyphi B* 250 500 125 ND 250 500 ND 1000 250 250 ND 
9 Pseudomonas aeruginosa ATCC 27853 62.5 500 250 1000 250 500 500 1000 250 250 500 
10 Pseudomonas aeruginosa 125 500 250 500 250 500 500 1000 250 250 1000 
11 Staphylococcus albus* 62.5 1000 125 ND 250 500 ND 1000 250 250 ND 
12 
Staphylococcus aureus ATCC 25923 
62.5 1000 62.5 31.2 250 500 62.5 1000 250 250 15.6 
13 Staphylococcus citrus  62.5 1000 ND 31.2 250 500 62.5 1000 250 250 15.6 
14 Staphylococcus citrus* 62.5 1000 62.5 ND 250 500 ND 500 250 250 ND 
15 Klebshiella pneumoniae* 1 250 >1000 62.5 31.2 250 500 >1000 1000 250 250 62.5 
16 Bacillus subtilis ATCC 6633 62.5 >1000 125 250 250 500 31.2 >1000 250 250 15.6 
17 Klebshiella pneumoniae* 2  ND >1000 62.5 ND 250 500 ND 500 250 250 ND 
TABLE   4I (b) 
MICs OF ASM (ii) SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Name of Micro Organisms 41 42 43 44 45 46 47 48 49 50 
1 Escherichia coli ATCC 25922 125 1000 62.5. >1000 250 250 15.6 >1000 500 500 
2 Escherichia coli  250 1000 1000 500 250 250 15.6 >1000 500 500 
3 Escherichia coli* 125 1000 1000 ND 250 250 15.6 ND 500 ND 
4 Enterobacter aerogenes 250 1000 1000 >1000 250 250 ND >1000 500 500 
5 Proteus valgaris 250 1000 62.5 250 250 250 500 >1000 500 500 
6 Proteus valgaris* ND ND 62.5 ND 250 250 15.6 ND 500 ND 
7 Salmonella paratyphi B 250 1000 500 >1000 250 250 ND >1000 500 500 
8 Salmonella paratyphi B* ND ND 125 ND 250 250 500 ND 500 ND 
9 Pseudomonas aeruginosa ATCC 
27853 
250 1000 125 1000 250 250 ND >1000 500 500 
10 Pseudomonas aeruginosa 250 1000 250 1000 250 250 1000 >1000 500 500 
11 Staphylococcus albus* 250 ND 62.5 ND 250 250 ND ND 500 ND 
12 Staphylococcus aureus ATCC 25923 250 1000 62.5 15.6 250 250 ND 500 500 250 
13 Staphylococcus citrus  250 1000 62.5 31.2 250 250 15.6 500 500 250 
14 Staphylococcus citrus* ND ND 62.5 ND ND 250 15.6 ND 500 ND 
15 Klebshiella pneumoniae* 1 250 >1000 62.5 31.2 250 250 15.6 >1000 500 >1000 
16 Bacillus subtilis ATCC 6633 250 >1000 62.5 15.6 250 250 15.6 >1000 500 1000 
17 Klebshiella pneumoniae* 2  250 >1000 62.5 ND 250 250 ND >1000 500 >1000 
TABLE   4J 
MICs OF MSB SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 Name of Micro Organisms 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 Escherichia coli ATCC 25922 >1000 1000 62.5 1000 250 125 >1000 >1000 62.5 1000 500 >1000 >1000 >1000 1000 >1000 
2 Escherichia coli  15.6 1000 62.5 1000 250 125 >1000 125 1000 1000 >1000 125 >1000 250 1000 >1000 
3 Escherichia coli* ND 1000 62.5 1000 250 125 >1000 ND 500 1000 500 ND 500 ND 500 1000 
4 Enterobacter aerogenes 15.6 1000 62.5 1000 250 125 >1000 >1000 1000 >1000 500 1000 >1000 1000 1000 >1000 
5 Proteus valgaris >1000 62.5 62.5 1000 250 125 >1000 >1000 250 250 500 1000 >1000 1000 125 >1000 
6 Proteus valgaris* ND 62.5 62.5 1000 250 125 >1000 ND 1000 125 ND ND >1000 ND 1000 1000 
7 Salmonella paratyphi B >1000 500 62.5 1000 125 125 >1000 125 1000 >1000 >1000 125 >1000 250 1000 >1000 
8 Salmonella paratyphi B* ND 500 62.5 1000 250 125 >1000 >1000 62.5 500 ND ND >1000 ND 125 >1000 
9 Pseudomonas aeruginosa ATCC 27853 500 500 62.5 1000 125 125 >1000 125 62.5 250 1000 125 500 250 125 1000 
10 Pseudomonas aeruginosa >1000 250 62.5 1000 125 125 >1000 1000 62.5 62.5 1000 >1000 250 1000 125 250 
11 Staphylococcus albus* ND 500 62.5 1000 250 125 62.5 ND 62.5 62.5 ND ND 125 ND 125 125 
12 Staphylococcus aureus ATCC 25923 15.6 500 62.5 1000 125 125 62.5 125 62.5 62.5 31.2 >1000 125 1000 125 125 
13 Staphylococcus citrus  15.6 62.5 62.5 1000 250 125 62.5 62.5 62.5 62.5 31.2 31.2 62.5 62.5 125 62.5 
14 Staphylococcus citrus* ND 62.5 62.5 1000 250 125 62.5 ND 62.5 62.5 ND ND 62.5 ND 125 62.5 
15 Klebshiella pneumoniae* 1 >1000 62.5 62.5 1000 250 125 >1000 125 62.5 >1000 1000 31.2 1000 62.5 125 >1000 
16 Bacillus subtilis ATCC 6633 15.6 ND 62.5 1000 1000 125 ND 1000 62.5 ND 31.2 500 1000 1000 1000 >1000 
17 Klebshiella pneumoniae*2  ND 1000 62.5 1000 250 125 1000 1000 62.5 >1000 31.2 500 ND 1000 ND ND 
 
TABLE   4E (a) 
MICs OF KUITT SERIES:  RESULT OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
 
 
 
 
 
 
 Name of Micro Organisms KUITT 
1 2 3 4 5 6 7 8 9 10 
1 Escherichia coli ATCC 25922 250 500 500 1000 500 125 125 250 250 500 
2 Escherichia coli  500 1000 1000 1000 500 125 125 250 250 500 
3 Escherichia coli* 125 125 500 1000 500 125 125 250 250 500 
4 Enterobacter aerogenes 1000 1000 125 500 500 125 125 250 250 500 
5 Proteus valgaris 62.5 62.5 250 500 500 125 125 500 500 500 
6 Proteus valgaris*   62.5 62.5 125 500 500 1000 125 250 250 500 
    7 Salmonella paratyphi B  62.5 62.5 1000 500 500 1000 1000 500 500 500 
8 Salmonella paratyphi B* 62.5 62.5 500 500 500 125 250 250 250 62.5 
9 Pseudomonas aeruginosa ATCC 27853 125 125 125 500 500 125 1000 500 500 62.5 
10 Pseudomonas aeruginosa 125 125 125 1000 500 125 500 250 250 500 
11 Staphylococcus albus*  62.5 62.5 1000 1000 500 1000 1000 500 500 62.5 
12 Staphylococcus aureus ATCC 25923 62.5 62.5 1000 1000 500 1000 1000 250 250 62.5 
13 Staphylococcus citrus  ND  ND 500 500 500 ND 1000 1000 ND  ND  
14 Staphylococcus citrus* 62.5 62.5 125 1000 500 1000 1000 500 500 62.5 
15 Klebshiella pneumoniae* 1   250 500 125 500 500 1000 1000 250 250 62.5 
16 Bacillus subtilis ATCC 6633 >1000 1000 1000 1000 500 250 500 1000 500 1000 
17 Klebshiella pneumoniae* 2  ND ND ND 1000 ND   ND 1000 1000  ND ND  
TABLE   4E (b) 
MICs OF KUITT SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
 
 
 
Name of Micro Organisms 
KUITT 
11 12 13 14 15 16 17 18 19 20 21 
1 Escherichia coli ATCC 25922 1000 62.5 500 500 125 62.5 62.5 500 ND 62.5 62.5 
2 Escherichia coli  1000 500 >1000 500 500 62.5 62.5 500 ND 62.5 62.5 
3 Escherichia coli* 500 500 1000 500 500 62.5 62.5 500 500 31.2 62.5 
4 Enterobacter aerogenes 250 500 62.5 62.5 125 62.5 62.5 500 500 62.5 62.5 
5 Proteus valgaris 1000 500 62.5 62.5 250 62.5 500 500 62.5 62.5 62.5 
6 Proteus valgaris* 250 500 62.5 62.5 125 62.5 500 500 62.5 31.2 31.2 
7 Salmonella paratyphi B 1000 1000 1000 1000 1000 125 250 500 62.5 62.5 62.5 
8 Salmonella paratyphi B* 1000 62.5 500 500 62.5 62.5 62.5 500 250 62.5 62.5 
9 Pseudomonas aeruginosa ATCC 27853 500 500 250 500 125 125 62.5 500 62.5 31.2 31.2 
10 Pseudomonas aeruginosa 500 500 1000 500 500 62.5 250 500 125 31.2 62.5 
11 Staphylococcus albus* 500 125 >1000 1000 250 62.5 1000 500 62.5 31.2 31.2 
12 Staphylococcus aureus ATCC 25923 62.5 62.5 62.5 62.5 125 62.5 62.5 250 62.5 62.5 62.5 
13 Staphylococcus citrus  125 ND 62.5 62.5 ND 62.5 62.5 250 62.5 62.5 62.5 
14 Staphylococcus citrus* 62.5 ND 62.5 62.5 125 62.5 62.5 250 62.5 62.5 62.5 
15 Klebshiella pneumoniae* 1 62.5 >1000 62.5 62.5 125 250 62.5 500 62.5 62.5 62.5 
16 Bacillus subtilis ATCC 6633 1000 250 500 62.5 >1000 500 500 500 500 31.2 62.5 
17 Klebshiella pneumoniae* 2  
 
62.5 ND 62.5 62.5 ND ND ND ND ND ND 62.5 
TABLE   4F 
MICs OF KUPO SERIES: RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 
KUPO 
 Name of Micro Organisms 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 Escherichia coli ATCC 
25922 
250 500 15.6 500 500 250 31.2 250 250 15.6 125 15.6 15.6 62.5 125 62.5 
2 Escherichia coli  500 500 15.6 500 250 250 31.2 250 250 31.2 125 15.6 15.6 125 125 62.5 
3 Escherichia coli* 250 500 15.6 500 250 250 31.2 250 250 15.6 125 15.6 15.6 62.5 125 62.5 
4 Enterobacter aerogenes 125 500 15.6 500 250 250 31.2 250 250 31.2 125 15.6 250 125 125 62.5 
5 Proteus valgaris 125 500 15.6 500 500 250 31.2 250 250 15.6 125 15.6 250 125 125 62.5 
6 Proteus valgaris*   500 500 15.6 500 500 250 31.2 250 250 500 125 15.6 250 125 125 62.5 
7 Salmonella paratyphi B 125 500 15.6 500 250 250 31.2 250 250 500 125 15.6 250 125 125 62.5 
8 Salmonella paratyphi B* 125 500 31.2 500 250 250 31.2 250 250 500 125 125 250 62.5 125 62.5 
9 Pseudomonas aeruginosa 
ATCC 27853 
125 500 500 500 500 250 31.2 250 250 500 125 125 250 125 125 62.5 
10 Pseudomonas aeruginosa 125 500 500 500 250 125 31.2 250 125 500 62.5 125 250 62.5 62.5 62.5 
11 Staphylococcus albus* 125 500 500 500 250 125 31.2 250 125 500 62.5 125 250 62.5 62.5 125 
12 Staphylococcus aureus 
ATCC 25923 
125 500 500 500 250 125 31.2 250 125 500 62.5 125 250 62.5 62.5 125 
13 Staphylococcus citrus  125 500 500 500 250 125 31.2 250 125 500 62.5 125 250 62.5 62.5 125 
14 Staphylococcus citrus* 500 500 500 500 500 125 31.2 250 125 500 62.5 125 250 125 62.5 125 
15 Klebshiella pneumoniae* 1 250 500 500 500 500 125 31.2 250 125 500 62.5 125 250 125 62.5 125 
16 Bacillus subtilis ATCC 6633   250 500 500 500 500 250 31.2 250 250 500 125 125 250 125 125 125 
17 Klebshiella pneumoniae* 2  250 500 500 500 500 250 31.2 250 250 500 125 125 250 125 125 125 
TABLE 4G 
 MICs OF KUQP SERIES:  RESULTS OF PRIMARY AND SECONDARY SCREENING (in µg/ml) 
 KUQP 
 Name of Micro Organisms 1 2 3 4 5 6 7 8 9 10 11 12 13 15 16 
1 Escherichia coli ATCC 25922 500 250 500 500 250 500 250 250 250 250 500 62.5 125 125 250 
2 Escherichia coli  500 250 500 500 250 500 250 500 250 250 500 62.5 250 125 250 
3 Escherichia coli* 500 250 500 500 250 500 250 500 250 250 500 62.5 250 125 250 
4 Enterobacter aerogenes 500 250 500 500 250 250 250 500 250 250 500 62.5 250 125 250 
5 Proteus valgaris 500 250 500 500 250 500 250 500 250 250 500 62.5 250 125 250 
6 Proteus valgaris* 500 500 500 500 250 500 250 500 250 250 500 500 125 125 250 
7 Salmonella paratyphi B 500 500 250 500 250 500 125 500 250 250 500 500 250 125 250 
8 Salmonella paratyphi B* 500 500 250 500 250 500 125 500 250 250 250 500 125 125 250 
9 Pseudomonas aeruginosa 
ATCC 27853 
500 500 250 500 250 31.2 125 500 250 250 250 500 125 125 250 
10 Pseudomonas aeruginosa 500 500 500 500 250 31.2 125 500 250 250 250 500 250 125 250 
11 Staphylococcus albus* 500 500 500 125 250 250 250 500 250 250 250 500 250 125 250 
12 Staphylococcus aureus 
ATCC 25923 
500 500 500 125 250 500 250 500 250 250 500 500 250 125 250 
13 Staphylococcus citrus  500 500 500 125 250 500 250 500 250 250 500 500 250 125 250 
14 Staphylococcus citrus* 500 500 500 500 250 500 250 250 250 250 500 500 250 125 250 
15 Klebshiella pneumoniae* 1 500 500 500 500 250 250 250 250 250 250 500 500 250 125 250 
16 Bacillus subtilis ATCC 6633 1000 500 500 500 250 250 250 500 250 250 500 500 250 125 250 
17 Klebshiella pneumoniae* 2  1000 500 500 500 250 250 250 500 250 250 500 500 250 125 250 
 
